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A B S T R A C T
Cancer is a leading cause of death worldwide. Development of new
cancer drugs is increasingly costly and time-consuming. By exploi-
ting massive amounts of biological data, computational repositioning
proposes new uses for old drugs to reduce these development hurdles.
A promising approach is the systematic analysis of structural data for
identification of shared binding pockets and modes of action.
In this thesis, I developed the Protein-Ligand Interaction Profiler
(PLIP), which characterizes and indexes protein-ligand interactions
to enable comparative analyses and searching in all available struc-
tures. Following, I applied PLIP to identify new treatment options
in cancer: the heat shock protein Hsp27 confers resistance to drugs
in cancer cells and is therefore an attractive target with a postulated
drug binding site. Starting from Hsp27, I used PLIP to define an in-
teraction profile to screen all structures from the Protein Data Bank
(PDB). The top prediction was experimentally validated in vitro. It
inhibits Hsp27 and significantly reduces resistance of multiple mye-
loma cells against the chemotherapeutic agent bortezomib.
Besides computational repositioning, PLIP is used in docking, bin-
ding mode analysis, quantification of interactions and many other ap-
plications as evidenced by over 12,000 users so far. PLIP is provided
to the community online and as open source.
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1
I N T R O D U C T I O N
1.1 motivation
new drugs for cancer treatment Cancer is one of the lead-
ing causes of death worldwide with 14.1 million new annual incid-
ents in 2012 [35]. This number is expected to almost double until the
year 2030 [35]. Due to the complexity of the disease, innovative ap-
proaches are required to find new treatments. Costs, time-consuming
studies [290] and high failure rates [151] are major barriers in drug
development. Drug repositioning can be a valuable alternative: by re-
assessing natural compounds, shelved, or approved compounds for
new indications, it provides shortcuts for development and in the
case of drugs lowers costs due to existing safety profiles [290]. Today,
drug repositioning already accounts for up to 30 % of newly Food
and Drug Administration (FDA)-approved drugs [117]. Many findings
from in vitro and in vivo activity-based screening of approved drugs
from diverse compound classes and original indications have already
led to new applications as anti-cancer treatment [232]. However, such
efforts require the availability of comprehensive compound libraries
and resources for experimental testing.
Figure 1: Brivudine (BVDU) is a remarkable repositioning example: The ap-
proved virostatic can bind to both its original target, a thymidine
kinase in Herpes (green, left) and a small heat shock protein rel-
evant for cancer (blue, right). The proteins have similar binding
environments and allow to bind BVDU via a sandwich π-stacking
(Sπ, alignment view in the middle). A complete picture on BVDU’s
binding characteristics requires a systematic analysis.
1
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use case : bvdu A remarkable example for drug repositioning is
the small-molecule drug (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU),
which is marketed as an antiviral for Herpes infections but has gained
attention in recent years due to its role as a modulator of the Heat
shock protein 27 (Hsp27) [99]. The reason why BVDU can bind both to
its original target, a Thymidine Kinase (TK) in the virus, and the heat
shock protein, results from highly similar binding environments in
both proteins as illustrated in Figure 1: while the global structures of
TK (green) and Hsp27 (blue) are vastly different, a few key residues in
their binding pockets (see Figure 1, alignment view in the middle) are
spatially arranged in a similar manner. Most strikingly, both proteins
can bind BVDU via a so-called sandwich π-stacking (Sπ, colored part),
which allows for tight binding of the ligand. Systematic investigation
of BVDU’s binding characteristics could lead to identification of more
approved drugs and natural products which bind to Hsp27. As this
heat shock protein is a key player in cancer and is strongly connected
to induction of chemoresistance to a multitude of standard cytotoxic
drugs [100], finding new Hsp27 inhibitors could also meet a large un-
met medical need and thus would have a high socioeconomic impact.
computational drug-target prediction With the fast growth
of biological data [243, 50], an increasing number of computational
methods tries to predict secondary drug targets for a compound of
interest or new binders for a query target [117, 207]. This enables to
foresee repositioning opportunities at an early stage [207] and vastly
reduces the drug-target space to be explored. Established approaches
exploit diverse datasources, ranging from scientific literature (text
mining), over omics data in network analyses to structural data for
similarity detection of ligand binding environments [97, 117]. The
Protein Data Bank (PDB) is an excellent resource for drug target pre-
diction: as the largest publicly available database for structural data
it lists 124,000 protein structures (as of December 2016), most of them
with bound ligands and is estimated to cover the majority of known
drug targets [96]. Assuming that compounds can bind to targets with
similar binding environments, many established methods aim to un-
ravel these similarities using geometrical or chemical features [115,
217]. Only recently have interactions between proteins and ligands
come into focus. As independence from both ligand and protein struc-
tures can be reached, comparison of interaction patterns is especially
promising for detection of similarities between proteins with distinct
global structure (target hopping) [217] and ligands from different che-
mical classes (ligand hopping).
protein-ligand interactions To provide features for com-
parison, contacts between proteins and ligands need to be reliably
detected. To this end, existing algorithms and databases lack compre-
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hensiveness or sufficient level of detail [217]: crystal structure data
of protein-ligand complexes as the basis for detection algorithms re-
quires consideration of all biologically relevant interaction types, wa-
ter molecules and ions the binding site, as well as assessment of fa-
vorable geometries for different contact types [218]. Even with small
molecules (e.g. most drugs), molecular recognition by proteins can
already lead to very complex interaction patterns which need to be
described on atom level in order to capture phenomena such as back-
bone hydrogen interactions [217]. As of today, interaction data in the
PDB is still largely untouched for drug repositioning. Exhaustive min-
ing of protein-ligand interaction data from the known structural pro-
teome may lead to substantial improvements in this area, but also in
other applications such as docking postprocessing or binding mode
discrimination. While knowledge-based approaches are preferred for
focused target prediction efforts, fully automatic design for mining
similar interaction patterns are the basis for generic high-throughput
repositioning platforms.
3d interaction profiling A focus on interaction data fades
out protein amino acids or ligand moieties not involved in binding
and therefore enables to capture the essence of molecular recognition.
For large datasets, the method of choice is the encoding of complex
3D interaction data into simpler profiles or fingerprints [217].
However, almost all existent methods are either protein- or ligand-
focused, making it hard to find hits with different ligand scaffolds
or unrelated protein classes [217]. Furthermore, what is typically in-
vestigated in this context are pharmacophores, i.e. an arrangement of
steric and electronic features relevant for potential binding [166], but
not the predicted interactions themselves. To enable specific detection
of conserved interaction patterns among distantly related proteins,
a special viewpoint is required: interaction patterns need to be de-
scribed and compared in a structure-invariant way and restricted to
predicted interactions, not pharmacophores. This is especially import-
ant for drugs which are known to have a high fraction of unmatched
functional atoms [103], leading to a disparity between potential bin-
ding features and preferences for contacts. Binding preferences are
also reflected by multiple possibilities of functional groups to be de-
tected by the binding partner, e.g. in the case of aromatic rings. Thus,
a reliable method for interaction pattern matching can identify new
targets for drugs and vice versa based on similar binding behaviour
derived from structural evidence.
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1.2 aim
Interaction patterns are a unique and largely untouched data source
for drug repositioning. With cancer as one the focus areas of this
research area, the overarching aim of this thesis is:
Aim: Finding new cancer drugs.
To exploit 3D interaction patterns for the prediction of new drug-
target combinations in cancer, two important problems need to be
solved: the characterization of protein-ligand interactions in 3D struc-
tures (Open Problem I) and the development of an reliable screening
for similar binding behaviour (Open Problem II).
Open Problem I
How can protein-ligand interactions be characterized?
Figure 2: Interactions between proteins and ligands can be derived from
crystal structure data. However, specialized tools are needed to
detect non-covalent interactions such as π-stacking (green) or hy-
drogen bonds (blue) with high reliability.
Ligands recognize their host proteins using complex spatial ar-
rangements of non-covalent interactions (Figure 2). Due to the multi-
tude of different interaction types found in biological structures and
the huge space of possibilities for binding, this problem requires con-
sideration of both biological and computational aspects.
biological aspects Biologically relevant interactions need to
be selected, requiring a profound understanding of the mechanisms
at atomic level. The underlying attractional forces between proteins
and ligands have to be translated into a simple set of rules for binding
which can be detected by a machine in a rule-based fashion.
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computational aspects The growing amount of structural data
poses computational problems, especially due to handling of diverse
molecular structures. Furthermore, fast and reliable processing of all
structures and deposition into machine-readable formats for further
processing is required. A toolbox for detection of protein-ligand in-
teractions can thus provide highly relevant data not only for reposi-
tioning, but also ligand design, binding mode identification, docking,
and virtual screening.
Open Problem II
How can similar binding behaviour be reliably detected?
Figure 3: Key binding characteristics can be shared between different lig-
ands or proteins: for an automated comparison, similar three-
dimensional patterns (I-IV) need to be rapidly identified to score
similarity between two complexes.
As the 3D interaction patterns between ligands and their host pro-
teins reflect molecular recognition, one can expect a compound be-
ing able to bind to proteins with interaction patterns similar to their
primary target. In order to capture key similarities and differences
between molecular complexes (Figure 3), methods for encoding of
patterns and similarity scoring need to be developed, again taking
both biological and computational viewpoints.
biological aspects Complex spatial interaction patterns as ob-
served in biological complexes have to be reduced to a simple rep-
resentation without loss of essential information. This requires the
manual or automatic description of relevant interaction patterns. To
enable similarity detection between complexes with structurally un-
related targets and ligands, this description needs to be independent
from molecular structures and focus on interaction patterns.
computational aspects Three-dimensional arrangements of in-
teraction vectors have to be encoded into simpler feature vectors (fin-
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gerprints) for efficient storage and high-throughput comparison. Fur-
thermore, the design of the encoding and comparison algorithms has
to be optimized for discrimination of similar and dissimilar protein-
ligand complexes.
1.3 outline
background The first background chapter 2 will explain why re-
positioning is seen as a solution to stagnant development pipelines
and how computational approaches can assist in the selection of po-
tential drug-target pairings. To lay a foundation to the understanding
of interaction data, chapter 3 characterizes biologically relevant inter-
actions between proteins and ligands. chapter 4 will give an overview
on the established methods for profiling interaction patterns. Further-
more, major conceptual differences to geometrical and pharmacolo-
gical approaches as well as limitations will be shown.
results : algorithms and applications The Protein-Ligand
Interaction Profiler (PLIP) offers a comprehensive solution for detec-
tion of inter-molecular contacts. The underlying algorithm, its valida-
tion as well as main features will be presented in chapter 5.
As a central application, the known structural proteome was screened
for compounds with similar binding behaviour to a known cancer
drug. This workflow for 3D interaction profiling and validation of
hit compounds is presented in chapter 6. Furthermore, the PLIP inter-
action data allowed for studies in other domains as well, including
a repositioning study in Chagas disease (see chapter 7). Finally, a
proof-of-concept analysis with a novel fingerprint design for auto-
mated high-throughput screening for similar interaction profiles will
be demonstrated in chapter 8.
Part I
B A C K G R O U N D

2
D R U G R E P O S I T I O N I N G
This chapter contains material from the publication Computational
Drug Repositioning by Target Hopping: A Use Case in Chagas
Disease by Haupt et al. [98] published 2016 in Current Pharmaceuti-
cal Design [98]. For detailed information on author contributions see
the publication list on page v.
As already discussed in section 1.1, the antiviral drug BVDU and
its activity against the cancer target Hsp27 is a remarkable example of
repositioning. While BVDU was brought from Herpes to cancer, there
is a vast space of unexplored compounds from other indications to
be screened. Such a systematic search for new Hsp27 binders in silico
needs understanding why compounds can seemingly hop from one
target to the other. Next to an introduction on repositioning and its re-
quirements on the molecular level, this chapter will assess untapped
data sources and approaches which form the basis for identification
of novel Hsp27 binders with 3D interaction profiling in chapter 6.
2.1 overview
The need for innovative and cost-effective solutions for approving
drugs for the market puts an increasing pressure on big pharma [10].
While global sales totaled to $1,1 trillion in 2015 [257], companies still
have to recover from an all-time low of successfully launched new mo-
lecular entities (NME) in 2006-2013. According to the latest study of
the Tufts Center [263], development costs for an approved drug have
rocketed to $2.6 billion. Major factors are long development times of
often more than a decade, high failure rates, and increasingly com-
plex clinical trials [263].
old drugs One promising solution to this problem is to re-evaluate
already approved, shelved, or abandoned drugs and dietary sup-
plements for new indications. This approach, called drug repositio-
ning or drug repurposing, aims to address all the major factors dri-
ving costs in modern drug development. Since most considered com-
pounds have already undergone safety and efficacy assessments, both
time and costs for further development are dramatically decreased. It
is estimated that as of today, already 30 % of new FDA-approved
compounds stem from repositioning efforts, generating more than a
quarter of the annual revenues for the pharma industry [184].
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success stories In the past, there have been several success stor-
ies in drug repositioning: one is eflornithine, originally developed as
an anti-cancer drug, and now marketed for sleeping sickness and as
facial hair removal creme. Its targets are both a human and a trypa-
nosomal decarboxylase [198]. Another example is celecoxib, which
inhibits a cyclooxygenase (the aspirin target) and carbonic anhydrase,
a drug target in glaucoma [274].
Often, repositioning cases result from low throughput screening:
the drug tamoxifen, previously used as an anti-estrogen, was found
in such a screen to be an effective anti-protozoal against Leishmania
amazonensis [172]. Similarly, glybenclamide, an antidiabetic, was shown
to also have an anti-thrombotic activity in mouse models [258].
With compounds successfully marketed for a different indication,
Lilly Pharma has reached annual revenues of more than $1 billion with
just two drugs: the first one, gemzar (gemcitabine) was originally de-
veloped as an antiviral but is now used as a medicine against various
cancers. Evista (raloxifene) has made the transition from an osteo-
porosis drug to a treatment for invasive breast cancer, with relaunch
in 2007 [184].
However, the best known repositioning case is still Viagra by Pfizer Inc.
During clinical trails on angina treatment, the serendipitious observa-
tion of side effects led to efforts to market this compound as a pill
against erectile dysfunction [84]. Viagra is a true blockbuster drug,
with sales beyond $2 billion a year.
diseases in focus In drug repositioning, two focal areas of re-
search have developed in the last decade: cancer and neglected dis-
eases. The number of cancer diagnoses are growing each year, with an
rise of now 14.1 million (2012) to an estimated annual number of 23.6
million new cases by 2030 [35]. Due to the complexity of cancer there
is need for innovative approaches, giving rise to repositioning efforts
of diverse compound sets [144]. According to Cancer Research UK
[35], more than 4 of 10 cancers diagnosed worldwide occur in coun-
tries with a short life expectancy, poor education, and a low standard
of living. Lacking infrastructure for advertisement and distribution
as well as illiquid patients give no incentives for big pharma to de-
velop de novo drugs. With dramatically reduced investment in time
and money, repositioning poses a unique chance to provide afford-
able medication. This is also true for the diverse class of neglected –
often tropical – diseases. Here, special non-profit organization such
as the Center for World Health & Medicine (CWHM) or Cure Within
Reach (CWR) focus on the development of compounds for these dis-
eases and specifically pursue repositioning projects [184] to make the
best use of publicly and privately raised money.
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2.2 drug promiscuity
The reason why repositioning can be successfully applied lies in the
binding behaviour of (small) molecules: While early studies on protein-
ligand binding were shaped by Emil Fischer’s model of lock and
key [78], reality has taught a different lesson over time: it is not un-
common that one ligand can bind to multiple different proteins, i.e.
that it shows promiscuous binding behaviour. Haupt, Daminelli and
Schroeder [96] studied promiscuity on a comprehensive set of bioact-
ive compounds and found that more than a third of them bind to
more than one protein target. This behaviour can lead to unwanted
side effects [236], but also opens up repositioning opportunities [97],
such as in the case of Viagra [62].
local similarities are key There are many reasons why com-
pounds may act at different locations in the cell or in the body. Non-
specific action can explain the promiscuous behaviour of some com-
pounds. One example is the diverse class of anaesthesia, where many
members are thought to interact with bilayer lipids or cause allosteric
changes to proteins by weak interaction [161]. Often, however, it can
be observed that a compound may bind specifically to the binding
pockets of two or more unrelated. Some ligands do so by adaption:
they undergo conformational changes or use different chemical moi-
eties for binding, i.e. show different binding modes [246]. More often,
however, the microenvironment in the ligand binding sites has a ma-
jor influence on whether a compound can bind. Shape and chemical
similarity are two important factors guiding this molecular recogni-
tion [200]. Sufficient similarity of the environments of two binding
pockets thus allows a ligand to bind both targets as in the case of cele-
coxib which binds to both a cyclooxygenase and a carbonic anhydrase
[200]. Identifying such cases in a systematic manner for repositioning
is the aim of computational drug target prediction.
2.3 computational drug target prediction
Prediction of target binding for compounds of interest in silico can be
addressed with mining different data sources: With over 26 million
item in PubMed1, scientific literature is a rich resource to mine repor-
ted drug effects or known modes of action. This way, also previously
unknown relationships between drugs and targets can be inferred
(e.g. in its simplest form with Swanson’s ABC model [254]) and hy-
potheses for repositioning generated. Text mining usually generates
many low-confidence predictions, taking a lot of time to sift through
manually.
1 ncbi.nlm.nih.gov/pubmed
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Figure 4: Target Hopping describes the process of repositioning drugs to an-
other target structurally unrelated from the primary one. Binding
sites of known (A, green square) and structurally unrelated target
proteins (B, blue circle) are characterized (I). A comparison of bin-
ding environments is performed (II). If the similarity is sufficiently
high, one can assume that the drug dA originally binding target A
may bind target B and vice versa, i.e. dB may bind target A.
With the rise of high-throughput omics methods [53, 117], data from
gene regulatory, metabolic, or protein-protein interaction networks
has also been explored [65] next to data from purely computational
approaches such as chemical similarity or ontology mining [151, 282].
They key here is to discover non-obvious relationships, e.g. effects of
drugs on single proteins or subnetworks. Basic approaches to find
signals in network analyze properties such as shortest paths between
two nodes or connectivity distributions. Resulting from a network
analysis by Zhao et al. [298], the drugs sunitinib and dasatinib, used
for the treatment of renal cell carcinoma and chronic myelogenous
leukemia respectively, were shown to also reduce brain metastases
derived from breast cancer [298].
While all these methods can give useful hints at commonalities
between drugs and targets, only structural approaches can provide
definite insights into molecular recognition and predict binding with
high confidence.
structural approaches In computational drug target predic-
tion, structural approaches usually deal with the study of similarities
between binding environments (binding sites) of proteins. Figure 4
demonstrates the underlying assumption: Drug dA is known to bind
protein A and drug dB is known to bind protein B. If the proteins A
and B share a binding site, it can be assumed that drug dA will bind
to protein B (and vice versa for drug dB to protein A). So-called target
hopping can be achieved by identifying shared binding sites between
structurally unrelated targets. Analogously, scaffold hopping describes
the discovery of such as relationship between two compounds which
are from different chemical classes.
The Protein Data Bank (PDB) [22] as the main public data source for
protein structures2 currently holds more than 124,000 protein struc-
tures and 22,000 distinct compounds (e.g. drugs), making it an ex-
2 A PDB structure refers to a 3D model from X-ray crystallography, NMR studies or
in silico modeling deposited in the PDB [22]. They usually describe the structure of
a protein, often in complex with ligands, i.e. one or multiple organic or anorganic
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cellent resource for large-scale approaches. Additionally, the space
of known drugs targets in PDB is almost complete: estimations for
the coverage range from 80 % [285] to 92 % [193]. The fact that ap-
proximately 3 out of 4 structures are complexed with another com-
pound (PDB, 2016/12) enables comparative approaches of interactions
between proteins and their bound ligands. According to the BioLiP
database [291], data on more than 600 biologically relevant protein-
ligand complexes are added each week: for comparative approaches,
this results in tens of millions of new pairings to be analyzed weekly.
To explore this vast space for repositioning, both fast and reliable
methods for binding site comparison are required, which will be dis-
cussed in the following paragraphs.
binding site comparison methods Algorithms to compare
the binding sites of proteins can be divided by their computational
approaches into alignment-based and alignment-free methods. An-
other classification can be done by their representation of binding
sites, e.g. by geometrical [134, 226, 284] and/or chemical features [233,
33]. In this short overview, the former classification by computational
approaches will be used. For a detailed comparison of algorithms by
binding site representation, please refer to the reviews by Jalencas
and Mestres [115] and Haupt and Schroeder [97].
Alignment-based methods usually apply rigid-body transforma-
tion of atoms groups in the binding sites to find the best possible
alignment [114]. The resulting structural alignment can then be scored
directly, e.g. with Z-scores against a random background (see e.g.
ProBis [134]) or reassessed (e.g. LigandRMSD [96]).
Widely used algorithms to align structures locally on the binding
site include SMAP [283], ProBiS [134], PocketMatch [292], MolLoc [6],
and Multibind [233].
SMAP is specifically designed to compare binding pockets between
proteins independent of the sequence order of the residues lining the
binding sites. It uses a Cα representation of the protein structure,
characterizing each atom by a geometric potential to reflect the dis-
tance to the surface and neighboring atoms [283]. Two binding sites
are aligned by computing the maximum weighted common subgraph
of the graphs built from a tessellation of Cα atoms.
ProBis works similar in the sense that it also translates the protein
surface residues to graphs. Nodes in the graph, however, are func-
tional groups here and the two resulting graphs are combined to a
product graph, wherein ProBiS searches the maximum clique [134].
More binding site alignment algorithms are described elsewhere
[127, 68, 97, 200, 211, 285, 137, 135] and specialized tools for more fine-
small molecules, ions, nucleotides, peptides or other polymers. One structure can
contain multiple such complexes.
14 drug repositioning
grained subenvironment comparison are listed by Bartolowits and
Davisson [17].
Co-crystallized ligands in structures can provide an additional level
of information to be exploited. The LigandRMSD by Haupt, Dam-
inelli and Schroeder [96] for example measures how well two bound
ligands of the compared binding sites are aligned by the superposi-
tion of the binding sites themselves. Similar measures have been ap-
plied in protein-protein docking [267], drug target identification [123]
and binding site similarity assessment [181, 284].
However, the computational expenses of pairwise alignments and
associated scoring methods have given rise to so-called alignment-free
methods. Prominent approaches use geometric hashing to represent
geometries and chemical features of binding sites in a feature vec-
tor (e.g. in PocketMatch [292]). Results from alignment-free methods,
however, have the severe disadvantage of being hard to interpret. Con-
sequently, they are often used in combination with alignment-based
methods.
discovering remote similarities All binding site compar-
ison methods aim at being able to discover local similarities even
between structurally or functionally unrelated proteins. Such cases
are of particular interest for drug repositioning [255] since they are
not reflected by chemical similarity of ligands or global structures of
proteins. However, detection of similarities in exactly these cases is
especially difficult.
In binding site comparison algorithms, structural properties of the
pockets are used as features. This can lead to a tendency to stay
within a limited scope of structurally or functionally related proteins,
i.e. a target hopping can’t be achieved.
Integration of protein-ligand interaction profiles has come into re-
search focus recently and may offer a solution to this problem: they
can grasp the essence of binding sites, ignore amino acids not in-
volved in binding, and take a viewpoint which is more uncoupled
from the chemical structures of proteins and ligands. Therefore, ex-
ploitation of interaction data promises to allow for better identifica-
tion of similarities between unrelated proteins. Encoding this data
into simpler profiles (fingerprints) for easier comparison has been es-
tablished first with the SIFt method by Deng, Chuaqui and Singh
[57]. From then on, different concepts for interaction fingerprint-
ing have been explored. Since fingerprinting interactions of proteins
and ligands for repositioning requires profound understanding of the
mechanisms of molecular recognition, the next chapter 3 will intro-
duce important concepts of ligand binding and discuss biologically
relevant interaction types. Following, state-of-the-art strategies for ab-
straction, encoding and comparison of interaction patterns will be
discussed in chapter 4.
3
P R O T E I N - L I G A N D I N T E R A C T I O N S
This chapter is based on the publication Polypharmacology Rescored:
Protein-Ligand Interaction Profiles for Remote Binding Site
Similarity Assessment by Salentin et al. [217] published 2014 in
Progress in Biophysics and Molecular Biology [217]. For detailed
information on author contributions see the publication list on
page v.
Proteins can recognize and bind their ligands via specific arrange-
ments of reversible (non-covalent), weak contacts (see section 3.1).
Even for small-molecule drugs such as BVDU, a multitude of diffe-
rent interaction types may be involved. To identify more key inter-
actions next to the characteristic sandwich stacking (see section 1.1),
a profound understanding on the nature and geometries of different
contact types is necessary (see section 3.2). Furthermore, the concept
of binding modes will discussed in more detail (section 3.3) to outline
how ligands can adapt to different targets and what this means for
similarity searching with interaction patterns as applied in chapter 6
and chapter 8. Finally, current approaches to detect contacts will be
discussed in section 3.4 and evaluated if they have the capability to
perform proteome-wide screenings such as the search for potential
binders of Hsp27 with similar binding patterns as BVDU (see chapter 6).
3.1 small molecule binding
Small molecules are usually defined as compounds with a molecular
weight below 900 g/mol [163] and thus comprise most drugs and
drug-like molecules. Binding sites for this class of compounds are
+
-
+
Protein
Ligand
Contact
often pockets on the protein surface. Typically, they are about 40 %
larger [3] than the ligand they accomodate. Binding sites are special
regions: they display a high degree of sequence conservation [36] and
often contain unusual amino acids with pivotal roles for catalysis or
ligand recognition [119]. For computational methods, they are often
defined as the set of all protein amino acids in close proximity to the
ligand (e.g. 4 A) and can also include conserved water molecules or
cofactors (e.g. ions).
receptor and ligand flexibility For molecular recognition,
conformational changes in the protein binding site domains or single
side chains[182] are sometimes required to allow binding of the lig-
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and [16]. This mechanism is called induced fit. In other cases, conform-
ational selection takes place, where a fitting pose from an ensemble of
possible ligand conformers is selected [16]. Regardless of the theore-
tical number of conformers a ligand can take [89] or the number of
targets it can bind to [96], the number of actually observed bound
ligand conformers is low, suggesting that adaption and flexibility is
coming mainly from the protein binding site.
3.2 interaction types
From a high-level view, a good fit between a protein and its bound
ligand is often expressed in complementarity of both shape and elec-
trostatic properties [119]. A closer look reveals that molecular recogni-
tion is mainly governed by a specific 3D arrangement of reversible, so-
called non-covalent interactions. Reversibility is a major trait of most
biologically relevant contacts, allowing ligands to unbind from the
receptor. However, there are some well-known exceptions showing
covalent, i.e. non-reversible interactions, such as the suicide inhibit-
ors penicillin and aspirin [209]. Although contributions of single non-
covalent interactions (see Figure 5) are small in comparison to cova-
lent bonds, which can easily exceed 100 kJ/mol, additive and syner-
gistic effects result in average interaction energies of 10-80 kJ/mol for
a protein-ligand complex [131]. Next to non-covalent interactions, in-
direct forces such as water-mediated interactions, solvent or entropic
effects can fundamentally influence binding behavior [16]. About two
thirds of all ligand atoms take part in physically favorable interac-
tions, whereas the rest is supposedly used for scaffolding and tuning
of binding properties. Major differences can be found between syn-
thetic compounds and natural products [103, 82]: the former, inclu-
ding many drugs, have more unmatched functional atoms [103].
Exhaustive analyses of protein-ligand structures in the PDB have
gathered information on preferred interaction types, their propensit-
ies and distribution of geometries [125, 42, 196]. In the majority ofA new large-scale
statistics on
interaction types in
the PDB is presented
in section 6.2
protein-ligand complexes, both polar and nonpolar interactions are
present [42, 103], although there are cases where almost exclusively
hydrophobic interactions (e.g. in steroid binding [246]) or polar inter-
actions (as cation-π interactions in choline-binding proteins [66]) are
used. A previous analysis [217] on a representative set of promiscu-
ous drugs by Haupt, Daminelli and Schroeder [96] showed that the
most abundant interaction types are hydrophobic contacts and hy-
drogen bonds, followed by salt bridges and π-stacking [217]. In this
context, Kasahara, Shirota and Kinoshita [125] found that the majority
of interactions is universal for all protein families.
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Figure 5: Non-covalent interaction types, their typical distances and approx-
imate energy contributions to protein-ligand binding[15, 31, 38, 83,
108, 235, 237, 242]. The abscissa shows the energy contribution in
a relative order, beginning with the lowest on the bottom. Open-
ings of the boxes indicate more permissive distance constraints for
upper or lower boundaries.
It has to be noted, however, that the preferences vary among dif-
ferent types of ligands [103]. Although some interaction types are
rare (see section 6.2), they should not be neglected since ligand in-
teractions with important drug targets might be underestimated, e.g.
cation-π interactions in G Protein-coupled receptors [294]. Following,
the biologically most relevant interaction types (shown in Figure 6
and Figure 7) will be briefly discussed.
hydrophobic contacts This first interaction takes a special place
since it does not result from attractive forces between unpolar mo-
lecules, but the tendency of water to displace them. The effect can
be observed in the aggregation of hydrophobic molecules or che-
mical groups in aqueous solution: they thereby reduce their water-
accessible surface area and release water molecules into the bulk,
where they can form hydrogen bonds. This process is accompanied
by an entropic gain [179]. Thus, hydrophobic contacts are no bonds,
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but long-range attractive interactions with energies depending on the
area of the contacting surfaces [110]. In protein-ligand binding, spa-
tial pairings of hydrophobic amino acids and unpolar ligand groups
(see Figure 6a1 ) are governed by this effect.
hydrogen bonds Hydrogen bonding (Figure 6b) is considered
the most important of all directed non-covalent interactions between
biomolecules [242]: supposably, it increases binding affinity of a lig-
and one order of magnitude with each additional hydrogen bond
(H-Bond) [131]. Typical values for bonding energies range from 10
to 40 kJ/mol [108]. They are formed between a donor group (D-H),
which provides a positive end in form of a hydrogen atom due to
a polar covalent bond, and an acceptor group (A) of high electron
density. Observed geometries fall within a narrow range with dis-
tances between donor and acceptor groups ranging from 1.7 to 2.4
A as well as angles from 130 to 170◦ at the proton and 150◦ at the
acceptor side [108]. These constraints in directionality and distance
are less predominant for weak H-bonds of the type C-H· · ·O [242].
However, regardless of their strength and selectivity [108], H-Bonds
are not essential for high affinity binding [131].
water-mediated interactions It is increasingly acknowledged
that indirect hydrogen bonds via water molecules (Figure 6c) have to
be considered to understand molecular recognition [16], as it was
already shown for the characterization of protein-protein interactions
[256]. Water enhances the adaptability in binding as it can serve as
both hydrogen bond donor and acceptor and induces only minimal
steric hindrance. This way, water molecules can serve as bridges for hy-
drogen bonding. The energetic gain from additional hydrogen bonds
involving a buried water molecule can exceed the entropic loss from
keeping the water molecule isolated from bulk liquid [146], therefore
making this type of interaction favorable.
salt bridges Salt bridges (ionic interactions, Figure 6d) play a
key role in molecular recognition and are crucial for conferring spe-
cificity [288]. They are formed between charged amino acids not more
than 4 A away from a ligand atom of opposite charge. Salt bridges
have typical binding energies between 3 and 13 kJ/mol [15].
π-stacking Interactions between aromatic rings (π-stacking, Fig-
ure 7a) are governed by an interplay of electrostatic and hydrophobic
interactions [273]. Stable arrangements of aromatic rings are found
either in parallel (sandwich) or in a perpendicular (T-shaped) orient-
1 To avoid ambiguity, protein-ligand complexes in the figure and throughout the
document are reported with a unique ID (UID) by concatenation of PDB ID, chain
ID, HET ID, and assigned residue of the ligand in the chain with colons.
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(a) Hydrophobic (1M7W:DAO:A:700). (b) H-Bonds (3BBH:SFG:A:206).
(c) Water bridges (2ATI:IHU:H:848). (d) Salt bridges (4MWW:G39:A:513).
Figure 6: Non-covalent interaction types (I). All visualizations show exem-
plary complexes of proteins (blue) and ligands (orange) from
the PDB after analysis with PLIP. Interactions are visualized with
colored lines: hydrophobic contacts (grey, dashed), hydrogen
bonds (blue, solid), water bridges (light blue, solid), and salt
bridges (yellow, dashed). See chapter 5 for details.
ation [179]. Preferred distances for stacking range from 4.5 and 7 A
with angles between 30 and 90◦ [31]. Interaction energies are estim-
ated to be 8 kJ/mol for the sandwich configuration and 11 kJ/mol for
T-stacking [235].
cation-π interactions Cation-π interactions (Figure 7b) have
been increasingly acknowledged as an important non-covalent bond
for molecular recognition [83] and are especially relevant for binding
by G Protein-coupled receptors [294]. This interaction type is formed
between a positive charge and an aromatic ring (due to its negative
charged layer of delocalized π electrons) and has average binding
energy ranges from 12 to 14 kJ/mol [83].
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halogen bonds Halogen bonding (Figure 7c) resembles hydro-
gen bonding in some aspects, with the main difference that a halogen
atom is shared between an acceptor and donor instead of a hydrogen
[203]. Many drugs have donor groups for this interaction type [237]
and halogenated ligands are present in over 1000 PDB structures [159].
The preferred orientation is linear with an interaction energy, depend-
ing on the halogen atom (I>Br>Cl>F), from 1.97 to 14.2 kJ/mol [237].
metal complexes Often encountered in binding sites of enzymes,
metal ions serve as catalysts for biological reactions, e.g. in metallo-
proteases or carbonic anhydrases. Metals can also maintain protein
structure [92]. Usually, the protein takes the role of a so-called mul-
tidentate ligand in the complex, represented by the partaking amino
acids [94] or conserved water molecules. This arrangement forms a
cage around the ligand ion with a specific coordination geometry [92]
(see also Figure 7d).
(a) π-stacking (1XDN:ATP:A:501). (b) π-cation (2REG:CHT:A:1).
(c) Halogen bonds (1VSN:NFT:A:283). (d) Metal complex (2PVB:CA:A:110).
Figure 7: Non-covalent interaction types (II). All visualizations show exem-
plary complexes of proteins (blue) and ligands (orange) from
the PDB after analysis with PLIP. Interactions are visualized
with colored lines: π-stacking (green, dashed), π-cation (orange,
dashed), halogen bonds (cyan, solid), and metal complexation
(pink, dashed). See chapter 5 for details.
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entropy and strain energy The non-covalent interactions as
discussed above do not give the full picture on molecular recognition [173]:
additional important aspects are entropy and strain. Entropy captures
the degrees of freedom for a ligand (three translational and one ro-
tational degree of freedom). This freedom of movement is partly lost
upon binding, especially when the ligand is tightly bound [173]. This
happens as the protein-ligand complex moves toward the lowest pos-
sible energy state, leading to deformation of both partaking partners.
Entropic and enthalpic forces (i.e. non-covalent interactions) can be
in the same order of magnitude [173]. For binding, this means that
both entropic loss and strain energy due to deformation have to be
compensated by other terms [16], e.g. non-covalent interactions.
While entropy, strain and other factors may play pivotal roles in
molecular recognition, non-covalent interactions offer unique possib-
ilities for description of complexes since their properties and geomet-
ries can be easily formalized in rule sets (see also section 5.2). Finally,
more interaction types than described here are known to have biolo-
gical relevance, but may occur rarely or only in specific contexts. For
an in-depth discussion on further molecular interactions with biolo-
gical relevance, see the excellent review by Bissantz, Kuhn and Stahl
[26].
3.3 ligand binding behaviour
A single ligand can bind to multiple proteins with identical or diffe-
rent recognition strategies, i.e. show one or more binding modes. In
many cases, this results from functional groups in the ligand which
can recognize different counterparts in the protein, e.g. a ligand aro-
matic ring binding to another ring via π-stacking or to a charged
amino acid via a π-cation interactions. Furthermore, water molecules
or the protein backbone can take the role of hydrogen bond acceptors
or donors and thus enable recognition in different binding environ-
ments. Finally, not all functional ligand atoms may be used for bin-
ding in a complex, resulting in seemingly unused ligand substructures
in complexes. Thus, in some cases no apparent similarity between in-
teraction patterns can be observed for the same ligand binding to
different proteins.
extreme binding mode switches With both natural products
and synthetic compounds there are known cases of extreme binding
mode switches. One case reported in literature are two known bin-
ding modes of the anti-inflammatory flufenamic acid [14], shown in
Figure 8: the binding modes differ vastly between D2 11-ketoreductase (A),
a protein involved in gastrointestinal tumors [158], and an androgen
receptor (B), equally important in prostate cancer [72]. While flufe-
namic acid shows many polar contacts (including salt bridges and
22 protein-ligand interactions
hydrogen bonds) in the first case, it uses almost exclusively hydro-
phobic contacts in the second. Despite the differences, the drug is
biologically active in both targets in the micromolar range [14].
(a) Complex with ketoreductase. (b) Complex with androgen receptor.
Figure 8: Extreme binding mode switch of flufenamic acid. While the D2
11-ketoreductase complex (A, PDB ID: 1S2C) has mostly polar con-
tacts, the androgen receptor complex (B, PDB ID: 2PIX) is of very
hydrophobic nature. Images were generated with PLIP.
Another example is the natural flavone chrysin which can switch
between very apolar and polar binding modes in different proteins
[219]. Finally, there are cases where a binding mode switch happens
between structurally similar binding sites as the example reported by
De Moliner, Brown and Johnson [56] demonstrates: they describe the
inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) which can bind to the
conserved ATP binding site of several kinases. Surprisingly, it shows
two distinct binding modes depending on the protein it binds to, ex-
ploiting other interaction patterns and even binding to different por-
tions of the binding site [56]. Here, the binding mode switch between
the analyzed kinase targets CK2 and CDK2 is reflected by a 10-fold
difference in affinity [56].
All these different cases demonstrate that binding mode switches
can occur between similar or different binding environments and can
have an unexpected impact on affinity. Predicting such behaviour on
a large scale is very challenging and currently an unsolved problem.
promiscuous binding behaviour The ability to switch between
different binding modes is also one factor leading to promiscuous
binding behaviour, i.e. the binding to many unrelated targets. Physi-
cochemical properties, among them binding preferences, have also
been discussed as deciding indicators.
While hydrophobic contacts were for a long time considered to be
the main cause of promiscuous binding, many contradictory results
have emerged over time and it is now thought that hydrophobicity
doesn’t necessarily lead to promiscuity [96]. This becomes clear when
looking at prominent examples of promiscuous drugs, which are very
diverse in their binding characteristics, such as (fluor)ibuprofen and
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sinefungin: While the first has a distinct hydrophobic character as
well as only few contact points, the latter shows a pronounced hydro-
philic character and complex hydrogen bonding patterns [246]. Al-
though the observed binding behaviour of sinefungin is completely
opposed to the long-established focus on promiscuous hydrophobic
ligands, a large hydrogen bonding potential of a ligand allows it
to bind in a promiscuous fashion to diverse environments. Other
examples between these extremes are seemingly independent from
physicochemical properties: quercetin, for example, often shows a
high number of hydrophobic contacts inspite of the potential for
many hydrogen bonds [246].
As of now, it is still unclear to which degree the actual binding be-
haviour is coupled to physicochemical properties. Korkuć and Walther
[140] already pointed out that no monotonic relationship between any
compound properties and promiscuity can be observed, but rather
one or more so-called sweet spot regions (e.g. both very low and very
high hydrogen bond acceptor counts). Other studies indicate that the
proteins may play a more prominent role due to shared binding sites
[96].
Furthermore, the purpose and origin of promiscuity are still un-
clear. It is theorized that promiscuous ligand could belong to clusters
of ligand hubs which are metabolically most important, ancient, or fre-
quent and therefore need to be recognized by many different protein
groups [246]. Also, the existence of similar structures (binding sites
features, compound subgroups, interactions) in different functional
context may serve as a driver for evolvability and help organisms to
adapt to environmental changes while keeping an overall robust sys-
tem [276]. Contrary, many examples of measurable promiscuity may
heavily depend on available data [106] and thus simply be a result of
research bias.
biological relevance Especially in drug development, in silico
analysis of interactions and predictions of binding affinity are an im-
portant part in many pipelines, but conclusions on biological relev-
ance may be very limited: studies indicate that therapeutic efficacy is
not necessarily associated with high binding affinity as the example
of two anti-melanoma drugs shows [286]. One of them, sorafenib, was
shown to be a potential nanomolar inhibitor of the protein B-Raf, but
failed during clinical trials due to low anti-melanoma efficacy. The
other compound, PLX4720, showed only moderate micromolar inhib-
ition, but was found to be a potent inhibitor of downstream signaling
in cells with B-Raf. Most remarkably, it is estimated that more than
80 percent of interactions in cellular networks for metabolism, gene
regulation and signal transduction are weak [286] and thus similar to
the second case. For studies of protein-ligand interactions and their
energy contributions, this means that a good predicted binder won’t
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make a good drug by default. More importantly, the presence of key
interactions may be a better indicator if a modulation of protein func-
tion will take place. To this end, a small proof-of-concept analysis
section 7.4 looks at the possibility to use such knowledge-based ap-
proaches in docking, where scores are usually completely based on
predicted binding affinities.
3.4 in silico detection of contacts
Due to the immense complexity of interactions that can arise in bio-
logical systems, the models to describe the contacts require a sim-
plification, usually guided by a tradeoff between speed and physical
accuracy [173]: on the one side, there is a large class of energetic mod-
els – heavily used in docking – which rely on force fields to describe
the energy landscape of a molecular complex. Equations for this ap-
plication contain simplified terms for internal strain as well as electro-
statics and hydrophobicity to describe inter-atomic forces [164]. While
computations can be very demanding depending on the considered
terms and the number of simulated objects, their predictive quality
for binding energies remains low [74]. For large-scale analyses and
comparative studies, so-called rule-based approaches can be a valu-
able alternative: in contrast to data-driven, unsupervised approaches
[125], they assume predefined classes of interactions. The underlying
algorithms thus exploit knowledge on interaction geometry by screen-
ing for allowed distances, angles, and orientations as well as suitable
pairs of functional groups, fragment, or atoms to form different con-
tact types [218]. Rule-based approaches are more straightforward, but
their performance depends on the quality of the ruleset and settings
for detection thresholds.
available tools and algorithms Table 1 presents an over-
view on selected tools and resources for protein-ligand interactions.
Many specialized software such as HBPLUS by McDonald and Thornton
[170] and plugins [87] for detection of contacts focus on hydrogen
bonds, which are generally considered the biologically most relevant
type. In a more general approach, but with a clear focus on visualiza-
tion, tools such as PoseView [244], LigPlot+ [147], and LeView [32] are
specialized in generating 2D interaction diagrams. To enable a com-
prehensive detection of non-covalent interactions with rule sets, Dur-
rant and McCammon [66] developed the BINding ANAlyzer (BIN-
ANA), which can detect five of the eight previously discussed inter-
action types (see Table 1 and section 3.2).
Most free 3D protein visualization software such as RasMOL [225],
Chimera [201], and PyMOL [229] offer at least some functionality to
detect and visualize relevant interactions, e.g. hydrogen bonding. In
contrast, commercial software from the drug discovery and chemoin-
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formatics domain can usually detect a wide range of interactions. Ex-
amples include MOE [41] and Proasis [60]. Finally, precalculated data
on protein-ligand contacts on atom-level can be found in the CREDO
database [228]).
However, as Table 1 shows, none of the listed tools can offer func-
tionality for both visualization and generation of parseable result files
with the complete information on interactions and their geometries.
Furthermore, many of them require extensive structure preparation
or are restricted to a small set of interaction types. This severely li-
mits their usage for PDB-wide screening on interaction patterns (see
chapter 6). How these limitations can be overcome to enable a com-
prehensive characterization of contacts in the structural proteome is
discussed in chapter 5.
pharmacophores vs . interactions Pharmacophores are an
long-standing concept extensively used in drug discovery for the de-
scription of binding properties and can be defined according to Gund
[88] as ‘a set of structural features in a molecule that is recognized at a
receptor site and is responsible for that molecule’s biological activity’.
This definition can be applied as well to the binding site of a protein
to describe features for potential formation of interactions.
It is important to note that the concept of interaction analysis fo-
cused on in this thesis is different from pharmacophores in one im-
portant aspect: whereas the former describe observable contacts, phar-
macophores captures potential for contacts. This is pivotal as the
interactions in a complex depend on many additional factors, such
as the environment, and flexibility of protein and ligand. Next to un-
matched ligand or proteins atoms [103] and multiple possible recog-
nition modes of functional groups, backbone hydrogen bonds are an-
other factor of uncertainty: while binding site pharmacophores may
consider amino acid side chain properties, hydrogen bonds to the
backbone of amino acids is often neglected, although they make up
for almost half of all hydrogen bonds between proteins and ligands
(see the analysis in section 6.2). Concluding, these aspects show why
a transition from potential to observable contacts is key to capture
binding preferences in different contexts.
For the computational analysis of binding behaviour, interaction
preferences, and promiscuity, reliable abstractions of the complex 3D
patterns are necessary. The next chapter 4 will therefore introduce
state-of-the-art concepts for encoding and storing data on interaction
patterns.
4
C O M P U TAT I O N A L A N A LY S I S O F I N T E R A C T I O N
P R O F I L E S
This chapter is based on the publication Polypharmacology Rescored:
Protein-Ligand Interaction Profiles for Remote Binding Site
Similarity Assessment by Salentin et al. [217] published 2014 in
Progress in Biophysics and Molecular Biology [217]. For detailed
information on author contributions see the publication list on
page v.
Large-scale interaction data from protein-ligand complexes allows
to screen for similar interaction patterns. This approach is also used
to find ligands with similar binding behaviour to BVDU and thus po-
tential inhibitors of the cancer target Hsp27 (see section 1.1). However,
the large amount of data in the PDB with several 100,000 single inter-
actions makes it impossible to perform exhaustive comparisons visu-
ally. To this end, the complex 3D interaction data needs to be encoded
into simpler representations, so-called fingerprints, which can then
be compared and ranked automatically. Current approaches for inter-
action fingerprinting (section 4.1), their comparison (section 4.2), and
their value for proteome-wide screenings such as for Hsp27 binders
(see chapter 6 and chapter 8) will be discussed in this chapter.
representations To generate simplified representations (profiles),
data has to be reduced in complexity, often accompanied by dimen-
sional reduction. In previous approaches, 3D interaction data has
been encoded in graphs [59], matrices [59], and – most importantly –
one-dimensional feature vectors, so-called fingerprints [46, 250, 47,
199, 268]. These structures have gained most attention in the last years
due to their fast processing and comparison as well as low memory
consumption. Fingerprint-based comparison has a long-standing his-
tory in text mining (e.g. for plagiarism analysis or screening for simi-
lar items in a database [241]) and chemoinformatics [280, 279].
principle The comparison of protein-ligand complexes with fin-
gerprints is illustrated in Figure 9. Two proteins with bound ligands,
I
II
III
IV
V
VI
>_
I II III IV V VI
1 11 100
but low global similarity are to be compared (Figure 9A). To focus
on the binding environment, only the ligand and its surrounding bin-
ding site residues are considered (Figure 9B) and interactions extrac-
ted with an appropriate tool such as PLIP (Figure 9C). In the final step
(Figure 9D), the raw interaction data is encoded into fingerprints (fea-
27
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ture vectors) to enable automatic and objective scoring of binding
features.
4.1 overview on interaction fingerprinting
Starting in 2004, interaction fingerprinting has explored many dif-
ferent concepts for encoding and comparing the complex patterns
from biological complexes. For this comprehensive overview on inter-
action fingerprinting design, descriptors will be classified according
to the entities they focus on, namely ligand-based, target-based, and
fused perspective fingerprints (see also Desaphy et al. [59]). Table 2
shows an overview according to this classification on published fin-
gerprint designs, their features and areas of application. Addition-
ally, Figure 10 groups fingerprints by entities and shows relationships
between similar designs.
4.1.1 Binding Site Focus
Binding site-focused fingerprints map detected interaction features to
receptor atoms and are limited to the analysis of cases with identical
or highly similar proteins (e.g. kinase subfamilies).
the sift family The first developed interaction fingerprint, Struc-
tural Interaction Fingerprint (SIFt, [57]) was formulated to overcome
the limitations of traditional approaches to compare protein-ligand
interactions, which heavily relied on generation of interaction dia-
grams with tools such as LIGPLOT1 and required visual inspection
[57]. The SIFt approach of Deng, Chuaqui and Singh [57] includes
the detection of non-covalent interactions and H-Bonds separately
with ready-usable tools and subsequent assignment of properties to
each interacting binding site residue. The presence of interactions is
stored in a seven-bit string for each residue and the single bit strings
concatenated in fixed order to yield the final fingerprint [57]. Deng,
Chuaqui and Singh [57] successfully applied SIFt in docking pose
analysis, grouping of ligand binding modes, and virtual screening of
compound libraries [57]. In the following years, the SIFt fingerprint
was refined for various special applications: p-SIFt [46] enables clus-
tering of SIFt fingerprints by encoding conserved interactions in a set
of complexes. The more recent r-SIFt design [58] was developed to
apply SIFt to larger combinatorial libraries in virtual screening: it en-
codes whether residues interact with the core or the side groups of a
ligand [58] and therefore uses a fundamentally different interaction
concept with regard to the original SIFt as only a distance threshold is
applied to decide whether a contact is formed or not [58]. The r-SIFt
fingerprint enabled a significant enrichment of dockable molecules
1 ebi.ac.uk/thornton-srv/software/LIGPLOT
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from a large combinatorial library and outperformed the established
scoring functions PMF [177] and ChemScore [69]. The latest major ad-
dition to the SIFt family is w-SIFt by Nandigam et al. [183], which in-
troduces a weighting scheme based on a set of complexes with known
IC50 values [183]. Hydrogen bonds, salt bridges and hydrophobic in-
teractions with three binned distances are considered as features in
this fingerprint [183]. An approach to automate SIFt fingerprints for
multi-conformer ensembles of ligands and receptors was published
by Mordalski et al. [175].
other designs The Expanded Interaction Fingerprint method by
Kelly and Mancera [129] was published shortly after the original SIFt
publication. It also uses a fixed-length binary fingerprint assigned
to binding site atoms [129]. This fingerprint, however, focuses solely
on hydrogen bonding and encodes the hydrogen-bonding specific ac-
cessibility of a residue as well as the bond strength, estimated by
observed distances and angles [129]. It also features a simple weight-
ing scheme and clustering of site points for an improved discrimin-
ation of similar binding modes [129]. In order to have a more gen-
eral interaction-based fingerprinting scheme for docking purposes,
Mpamhanga et al. [176] developed the Knowledge-based Interaction
Fingerprint, which encodes only hydrophobic interactions and hy-
drogen bonds into bit strings for each heavy atom in the binding site
[176]. This fingerprint was used to score similarity of docked poses
with native reference poses from estrogen receptor antagonists and
retrieved up to 2-fold enrichment compared to the standard GOLD
[269] fitness score [176]. Additionally, Mpamhanga et al. [176] demon-
strated how to combine interaction fingerprinting with principal com-
ponent analysis to identify and separate binding modes [176].
Another residue-based method is the Protein-Ligand Interaction
Fingerprint or PLIF [49]. It features hydrogen bonds, ionic interac-
tions and surface contacts [224] and discriminates between backbone
and side chain as well as strong and weak interactions, resulting in
12 bits per residue [224]. The Molecular Interaction Fingerprint by
Marcou and Rognan [165] is based on PLIF and capable of detect-
ing strong and weak hydrogen bonds, ionic and hydrophobic inter-
actions, π-stacking as well as π-cation interactions and metal com-
plexes [165]. The authors could demonstrate that the Molecular IFP
performs superior to the scoring functions Goldscore and Chemscore
[269]. A Python implementation of an IFP based on PLIF and Mo-
lecular IFP has been published by Radifar, Yuniarti and Istyastono
[206] under the name PyPLIF and has been extended by Xie et al.
[287] into Fs-IFP, a 80× 7 bit fingerprint for kinase binding site com-
parison [287]. The most recent addition to binding site-focused meth-
ods is SIRILID (Simple Ligand-Receptor Interaction Descriptor) by
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Chupakhin et al. [48], which is as well based on IFP and merges fin-
gerprints of the amino acids to yield a fixed-length fingerprint.
4.1.2 Ligand Focus
While binding site-focused approaches map features onto binding
site residues, the interaction data in ligand-focused fingerprints is
usually mapped on ligand atoms or fragments. Exceptions are pharmacophore-
based approaches such as LigandScout by Wolber and Langer [281],
which encode interactions (hydrogen bonds and analogues, hydro-
phobic and charge-transfer interactions) into a 3-dimensional model
with abstract representation of the ligand and its interactions. Mul-
tiple pharmacophores can then be combined by performing a 3D
alignment and calculating averaged points [281].
enrichment of chemical fingerprints As mentioned above,
most ligand-focused fingerprints do not generate de novo profiles, but
use existing 2D ligand structures and enrich them with interaction
data, such as the Interaction Annotated Structural Features (IASF) by
Crisman, Sisay and Bajorath [52]. Interactions and predicted energies
are assigned to ligand fragments using a conventional Extended Con-
nectivity Fingerprint ECFP4 [52]. This design allows to screen existing
compound libraries for potential leads with higher specificity [52].
enrichment of fragments Another approach to incorporate
interactions into 2D molecular fingerprints was published by Tan,
Lounkine and Bajorath [251] which reduces the molecular fingerprints
data to fragments in contact with the receptor [251]. The authors
demonstrated that the recovery rate of active compounds with their
method is superior to those considering complete structural finger-
prints [251]. This approach is an example for an indirect encoding
of interactions by reducing structural fingerprint to bins relevant for
binding rather than enriching a full ligand descriptor with interaction
information as done by Crisman, Sisay and Bajorath [52].
The concept of interacting fragments was expanded by the same
group with the IF transfer fingerprints in 2009 [249]. The authors
describe an approach for combining MACCS keys with keys for in-
teracting fragments [249], which was later extended for encoding in-
formation from ensembles of one receptor with multiple inhibitors
(3D-IFS-TP) [252]. The IF fingerprints [251] and its two modified ver-
sions, IF-TFP [249] and 3D-IFS-TP [252], all rely on the use of pre-
defined fragment dictionaries, in this case MACCS keys.
With the Atom-centered Interacting Fragments (AIF) fingerprint
Batista, Tan and Bajorath [18] demonstrated how to overcome this
limitation. Protein-ligand interactions are detected in the same way as
for IF-TFP [18]. Fragment libraries are then generated by storing frag-
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ments with interacting ligand atoms in SMARTS strings [18]. They
can be used for similarity searching in compound libraries and have
been shown to perform better than standard structural keys [18].
Another approach is the Pharmacophore-based interaction finger-
print (Pharm-IF) by [224], designed for virtual screening with dock-
ing. The detection of interactions is based on PLIF [49] and involves
an integer fingerprint that encodes how often a certain interaction
pair occurs, considering types and distances. In combination with ma-
chine learning methods, Sato, Honma and Yokoyama [224] achieved a
higher performance in screening than with GLIDE score [79] or PLIF
[49].
4.1.3 Fused Perspective
Protein-ligand fingerprints have proven useful for ligand and target
prediction [211] but were limited to homologous targets or similar
ligand classes. For a most flexible and universal approach, interaction
patterns have to be encoded without mapping them onto atoms, frag-
ments, or residues in the ligand or protein. Such fused-perspective
fingerprints represent interaction data independent of specific ligand
and receptor atom positions, e.g. by using pseudo atoms to demark in-
teractions in space. Being a very recent design, only two fingerprints
of this type have been published as of today: APIF and TIFP, which
will be discussed below.
first design : apif As the first of its kind, the Atom-pairs-based
Interaction Fingerprint (APIF) by Pérez-Nueno et al. [199] labels atoms
according to their affiliation (protein or ligand) their type (hydro-
phobic, hydrogen-bond acceptor or donor) [199]. Not single, but pairs
of interactions in a complex are then fingerprinted together with the
distances between them [199]. As seven binned distances and six in-
teraction types are considered, the resulting fingerprint length is fixed
to 6× 72 = 294 bits [199]. In their docking study, they could demon-
strate that APIF performs equally well to the binding site-focused
Knowledge-based IFP by Mpamhanga et al. [176] and could improve
results in virtual screening and post processing [199].
state-of-the-art : tifp fingerprints Desaphy et al. [59] de-
veloped the 210 integer fingerprint TIFP by using pseudo atoms placed
mid-distance between the interacting atoms of receptor and ligand for
each specific contact. Special about their fused-perspective strategy
is that the interaction features are neither located at a interacting re-
ceptor nor ligand atoms, but between them. Pseudo atoms are labeled
according to the interaction type and merged if neighboring atoms
have the same label, e.g. pseudo atoms for hydrophobic interactions
[59]. To retrieve a fixed-length structure-invariant fingerprint (inde-
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pendent of the site or ligand geometry), triplets of atoms are binned
(as shown in Figure 11).
Figure 11: An exemplary procedure to generate fixed-length structure-
invariant fingerprints. Distances between all pairs of features
with labels for hydrophobic interactions or H-Bonds are com-
puted and binned according to the ranges (a to d, top right). The
pair-wise spatial orientation of features is captured in triangles,
resulting in three labels each (starting clockwise from the left).
Labels of triangles are sorted to reduce the fingerprint length and
mapped to specific positions of the fingerprint to increase the bin
value.
Due to the limited number of bins and interaction features, the fin-
gerprint has a fixed size. In the given example (Figure 11), two pseudo
atoms in a distance of 4 A would be put into a distance range bin c
with 4 ⩽ c < 6 A. Combining the distances and interaction features
for three adjacent pseudo atoms yields a specific string after sorting,
which can be assigned to an exact position in the fingerprint (see Fig-
ure 11). Since the number of bins in the fingerprint corresponds to the
number of theoretically possible triplets (> 74, 000), the authors per-
formed several steps to reduce the number of bins, ending up with a
fingerprint of 210 integers [59].
The TIFP design is independent of both the binding site and the
ligand structure and therefore allows to detect similar interaction pat-
terns in remotely related complexes. The implementation of Desaphy
et al. [59] allowed for the output of structural alignments based on in-
teraction patterns and was successfully applied to re-scoring of dock-
ing poses and binding site alignments.
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Two new fused-perspective designs are presented in this thesis,
including a 3D profiling feature vector to encode key interactions
from an ensemble of complexes (chapter 6) and a novel structure-
independent fingerprint design for large-throughput comparison on
proteome scale in chapter 8.
4.2 comparison of profiles
Interaction fingerprint as binary or integer features vectors can be
compared using standard distance and similarity measures such as
the (modified) Tanimoto coefficient [129], Euclidean distance [176], or
simple matching [176]. However, the choice of a measure can heavily
influence score distributions and thus interpretation of datasets.
example : cosine similarity vs . euclidean distance Euc-
lidean distance and cosine similarity are two of the best-known meas-
ures and have long been used in other domains, e.g. text mining. The
first one measures the distance between points defined by two vec-
tors, whereas the second measures the angle of feature vectors with
respect to the origin. This leads to different behaviour: Cosine simil-
arity tends to cluster vectors by direction, Euclidean distance by mag-
nitude (i.e. by L2-norm). When searching for the most similar items in
a ranked fashion (i.e. k-nearest neighbors), the order is fixed no mat-
ter if Euclidean or cosine similarity is used since the transformation
from one to the other is monotonic [138].
high-dimensional sparse data Features in interaction finger-
prints are high-dimensional representations of data and often sparse.
Distance and similarity measures can often show counter-intuitive
behaviours when moving to higher dimensions [2]. In both chemoin-
formatics and text mining, researchers have long worked with high-
dimensional and sparse feature vectors, so their experience can help
to pick an appropriate measure for interaction fingerprint compar-
ison. In the chemoinformatics domain, cosine similarity and Tanimoto
coefficient are established as equally reliable measures [13]. Also in
text mining, there is often similar performance of different similarity
measures for high-dimensional sparse data [107].
For specific research questions, more specialized measures can be
used. One of them is the Tversky index [264], which is a directional
(asymmetric) similarity and does not measure similarity between items,
but between a prototype and a variant. This measure is already estab-
lished in chemoinformatics and has advantages when searching quer-
ies against a database [45]. For an overview and additional references
on other (binary) similarity and distance measures, see the review by
Seung-Seok, Sung-Hyuk and Tappert [231].
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P L I P : T H E P R O T E I N - L I G A N D I N T E R A C T I O N
P R O F I L E R
This chapter is based on the publication PLIP: fully automated
protein-ligand interaction profiler by Salentin et al. [218]
published 2015 in Nucleic Acids Research [218]. Furthermore, it
contains material from Discovery of Mycobacterium tuberculosis
InhA Inhibitors by Binding Sites Comparison and Ligands
Prediction by Stular et al. [245] published 2016 in the Journal
of Medicinal Chemistry [245]. For detailed information on author
contributions see the publication list on page v.
The Protein-Ligand Interaction Profiler (PLIP) addresses the limita-
tions of currently available tools (see Table 1 in chapter 3) and of-
fers rich functionality for detection of interactions. Thus, it is the pre-
requisite to understand the binding preferences of the small-molecule
drug BVDU (see section 1.1) and enable for proteome-wide screening
for novel Hsp27 binders (chapter 6) and a wide range of other ap-
plications with interaction data (see chapter 7). A detailed discussion
of the underlying algorithm is given in section 5.2 and specific im-
plementations presented in section 5.3. The validation of PLIP on a
diverse set of complexes from the PDB is described in section 5.4.
5.1 materials and methods
Since this chapter describes PLIP as a software tool, methodological
aspects will be discussed throughout the chapter. For technical de-
tails on the implementation, see the supplementary information in
Appendix A.
plip validation set For the validation of the PLIP algorithm, a
set of 30 diverse protein-ligand complexes with non-covalent interac-
tions described in literature was composed (Table 13 in Appendix A).
Additionally, complexes with binding site mutants, symmetrical bin-
ding, and coordination of different metal ions were added as test
cases (see Table 14 in Appendix A). Only interaction types listed
in the corresponding publications were considered for each complex.
The basic validation cases (Table 13) cover all interaction types detect-
able with PLIP and structures with different resolutions (1.2 to 3.3
Å). Implemented as Python unit tests, the set of interacting residues
for a specific interaction type was compared against the set PLIP de-
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tects for the given complex. Contact both reported in literature and
detected with PLIP are listed as true positives. Additional contacts
detected by PLIP, but not listed in the publication are labeled as false
positives.
5.2 the plip algorithm
This section describes the PLIP detection algorithm in detail. Further-
more, section 5.3 documents how PLIP was made available as a com-
mand line tool, web service, a PyMOL plugin and via a REST API
to enable access for a broad range of users. For more information on
dependencies and license information of the published code, please
refer to Appendix A. For a full list of parameters and their default
values, please refer to Table 12.
PLIP uses a rule-based system for detection of non-covalent inter-
actions between protein residues and ligands: knowledge on chemi-
cal groups able to participate in a specific interaction (e.g. hydro-
gen bond donors) and interaction geometries (e.g. distance and angle
thresholds) from literature are used to characterize non-covalent inter-
actions between protein and ligand. Overall, the detection algorithm
can be divided into four sequential steps (Figure 12A-D). In the first
preparation step, relevant binding complexes are automatically ex-
tracted and errors in input files corrected. For each binding site, the
algorithm then annotates functional atoms or groups in the protein
and ligand which can partner in specific interactions. Subsequently,
geometric rules are applied to match groups in protein and ligand
forming an observable interaction. In the last step, interactions are
filtered to report only the most relevant contacts to the user.
The analysis is exemplified by Bacillus subtilis DegV protein binding
palmitic acid (PDB ID 3FYS).
Step 1: Structure Preparation
structure initialization Depending on the user input, PDB
files are read from files or downloaded from the RCSB server using
the file services at files.rcsb.org if a valid PDB ID is provided.
Each PDB structure file is checked for integrity and frequently occu-
ring errors in the file format such as missing or non-standard iden-
tifiers, inconsistent numbering or invalid atom types automatically
fixed. Additionally, information on covalent linkages and alternate
atom locations are parsed from the file. OpenBabel [189] is used for
core functionalities related to molecular structure information. Since
this library uses different internal atom numbering for atoms, map-
pings for ATOM indexes are created which are later used to restore
the original numbering as seen in the PDB file. Polar hydrogens are
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added to the structure and alternative conformations, models, and
positions removed by default.
detection and filtering of ligands PDB structures can con-
tain a multitude of crystallization artifacts or unspecific binders which
are all deposited as ligands (HETATM entries) in the files. Due to
the diversity of ligand classes, it is often hard to distinguish these
compounds from relevant binders. To avoid arbitrary filtering with
blacklists, information from the BioLiP database [291] on compounds
known as unspecific binders1 was used. If a ligand from a structure
is present in this list, the user gets a warning for a potential arti-
fact. Ligands in this list appearing more than 15 times in one struc-
ture (adapted from Yang, Roy and Zhang [291]) are excluded com-
pletely. Biologically relevant metal cations from a manually curated
list (see Appendix A) are retained, while the frequent anions chloride
(CL), iodide (IOD) and bromium (BR) as well as molybdenum (MO),
rhenium (RE), and holmium (HO) are excluded. For the latter sets,
no interactions are currently defined. Previous to the detection step
for the interactions, PLIP extracts all ligands and their binding sites
contained in the structure. Modified amino acids are identified and
excluded using MODRES entries of the PDB files.In the example,
only palmitic acid is
kept as a relevant
ligand (Figure 12A).
Due to the previously parsed information from covalent linkages,
multi-part ligands such as polysaccharides or peptides can be treated
as single entities. Depending on the ligand size and composition,
class labels2 are automatically assigned to each ligand. Larger ligands
such as RNA or even complete protein chains can processed the same
way as small molecule ligands.
binding site atoms The binding site distance cutoff is determ-
ined by adding up 6.0 A to the maximum extent to the ligand (max-
imum distance of a ligand atom to the ligand centroid). As the un-
derlying data is a point cloud, the centroid c for a point cloud of size
N can be easily calculated as shown in Equation 1. All protein atoms
within this distance cutoff to any binding site atom are considered as
part of the binding site.
c = (x̄, ȳ, z̄) = (
∑N
n=0 anx
N
,
∑N
n=0 any
N
,
∑N
n=0 anz
N
) (1)
This initial set of residues is then used to annotate potentially bin-
ding functional groups in the second step of the pipeline.
1 Downloaded from zhanglab.ccmb.med.umich.edu/BioLiP/ligand_list (2014/07)
2 SMALLMOLECULE, SMALLMOLECULE+ION, POLYMER, ION, DNA,
DNA+ION, RNA, RNA+ION
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Step 2: Feature Annotation
Prior to detection of contacts between ligands and proteins, functional
groups in both entities must be identified. Annotating the structures
with potentially interacting groups enables fast matching in the next
step. Due to the diversity of features, a different rule set is required
for each one. For each of the following rules, ligand and binding site
atoms are iterated separately.
aromatic ring detection The detection of aromatic rings in
ligands and proteins is done in two steps. First, the provided Smallest
Set of Smallest Rings (SSSR)3 perception system from OpenBabel is
used. While being reliable in most cases, the system runs into limi-
tations with condensed ring structures (e.g. ethidium, PDB HET ID
ET in PDB structure 2zoz) and similar constructs. To enable a prac-
tical solution to this problem, all cases where rings are reported as
not aromatic are checked again with a planarity criterion [141]. To
this end, the normals of each atom in the ring to its neighbors is cal-
culated. The angle between each pair of normals has to be less than
aromaticPlanarity. If this holds true, the ring is also considered as
aromatic.
hydrophobic atoms An atom is classified as hydrophobic if it is
a carbon and has only carbon or hydrogen atoms as neighbours.
hydrogen bond donors and acceptors OpenBabel [189] is
used to identify hydrogen bond donor and acceptor atoms. Atoms
from aromatic rings (see above) are excluded from this selection. The
same is true for halogen atoms, which are treated separately (see
further below).
charged groups The detection of charged groups is only ex-
haustive for the binding site, not the ligands. For proteins, positive In the example case
of DegV with
palmitic acid,
charges can be
assigned to two
amino acids as well
as the ligand
carboxyl group
(Figure 12B).
charges are attributed to the side chain nitrogens of the amino acids
arginine, histidine and lysine using rule sets. Negative charges are
assigned to the carboxyl groups in aspartic acid and glutamic acid. In
ligands, positive charges are assigned to quaterny ammonium groups,
tertiary amines (assuming the nitrogen could pick up a hydrogen and
thus get charged), sulfonium and guanidine groups. Negative charges
are reported for phosphate, sulfonate, sulfonic acid and carboxylate.
halogen bond donors and acceptors Assuming that halo-
gen atoms are not present in proteins (unless they are artificially mod-
ified), halogen bond donors are searched for only in ligands. All flu-
3 Basically, it searches for any set of rings sharing no more than a certain number of
atoms with other rings.
44 plip : the protein-ligand interaction profiler
orine, chlorine, bromide or iodine atoms connected to a carbon atom
qualify as donors. Halogen bond acceptors in proteins are all carbon,
phosphor or sulphur atoms connected to oxygen, phosphor, nitrogen
or sulfur.
water Water atoms are assigned to a ligand-binding site complex
if their oxygen atoms are within a certain cutoff to the ligand which is
determined by adding up bsDistMax to the maximum extent4 to the
ligand. This means the farthest distance of a ligand to a water atom
is bsDistMax.
Step 3: Detection of Interactions
With the annotated functional groups in both protein and ligand, PLIP
can start to match potentially interacting groups and apply geometric
thresholds from literature-derived rule sets. PLIP can detect eight bio-
logically relevant interaction types, including hydrophobic contacts,
hydrogen bonds, water bridges, salt bridges, π-stacking, π-cation in-
teractions, halogen bonds, and metal complexes. Figure 6 and Fig-
ure 7 in chapter 3 show examples for each of the interaction types
supported in PLIP. For standard values of geometric thresholds used
in the description, see the information in Table 12 (Appendix A).
hydrophobic interactions As hydrophobic interactions res-
ult from entropic changes rather than attractive forces between atoms,
there are no clear geometries of hydrophobic association. However,
the observed attraction between hydrophobic atoms decays exponen-
tially with the distance between them [110].
A generous cutoff was chosen, identifying a prime set of hydro-
phobic interactions between all pairs of hydrophobic atoms within a
distance of hydrophDistMax.
hydrogen bonds A hydrogen bond between a hydrogen bond
donor and acceptor is reported if several geometric requirements are
fulfilled. The distance has to be below hbondDistMax and the angle at
the donor group (D-H. . . A) above hbondDonAngleMin.
As a general rule, a hydrogen bond donor can take part in only one
hydrogen bond, while acceptor atoms can be partners in multiple hy-
drogen bonds (e.g. bifurcated hydrogen bonds). For multiple possible
hydrogen bonds from one donor, only the potentially strongest con-
tact, i.e. the one with a donor angle closest to 180 °is kept.
aromatic stacking π-Stacking for two aromatic rings is repor-
ted whenever their centers are within a distance of pistackDistMax
4 maximum distance of a ligand atom to ligand centroid, see also Equation 1
5.2 the plip algorithm 45
and the angle deviates no more than pistackAngDev from the optimal
angle of 90 ° for T-stacking or 180 ° for P-stacking.
Additionally, each ring center is projected onto the opposite ring
plane. The distance between the other ring center and the projected
point (i.e. the offset) has to be less than pistackOffsetMax. This value
corresponds approximately to the radius of benzene + 0.6 A.
pi-cation interactions π-Cation interactions are reported for
each pairing of a positive charge and an aromatic ring if the distance
between the charge center and the aromatic ring center is less than
picationDistMax. In the case of a putative π-cation interaction with
a tertiary amine of the ligand, an additional angle criterion is applied
(see PLIP source code for details).
In the example case,
the distances
between atoms in
positive and
negative charges in
the protein and
palmitic acid are
measured to decide
whether to report a
salt bridge
(Figure 12C).
salt bridges Whenever two centers of opposite charges come
within a distance of saltbridgeDistMax, a salt bridge is reported
without applying additional geometric restrictions.
water-bridged hydrogen bonds While residues can be bridged
by more than one water molecule, for the prediction in PLIP the only
case considered is one water molecule bridging ligand and protein
atoms via hydrogen bonding.
The water molecule has to be positioned between hydrogen bond
donor/acceptor pairs of ligand and protein with distances of the wa-
ter oxygen within waterBridgeMindist and waterBridgeMaxdist to
the corresponding polar atoms of the donor or acceptor groups. If a
constellation with a water atom fulfills these requirements, two angles
are checked. The angle omega between the acceptor atom, the water
oxygen and donor hydrogen has to be within waterBridgeOmegaMin
and waterBridgeOmegaMax. Additionally, the angle theta between the
water oxygen, the donor hydrogen and the donor atom has to be lar-
ger than waterBridgeThetaMin.
Similar to standard hydrogen bonds, a water molecule is only al-
lowed to participate as donor in two hydrogen bonds (two hydrogen
atoms as donors). In the case of more than two possible hydrogen
bonds for a water molecule as donor, only the two contacts with a
water angle closest to 110 °are kept.
halogen bonds Halogen bonds are reported for each pairing of
halogen bond acceptor and donor group having a distance of less
than halogenDistMax and angles at the donor and acceptor group of
halogenDonAngle and halogenAccAngle with a deviation of no more
than halogenAngDev.
metal coordination For metal complexes, PLIP considers metal
ions from a set of more than 50 species (see Appendix A for details).
46 plip : the protein-ligand interaction profiler
Possible interacting groups in the protein are sidechains of cysteine
(sulfur), histidine (nitrogen), asparagine, glutamic acid, serine, threon-
ine, and tyrosine (oxygen), as well as all main chain oxygens.
In ligands, following groups are considered for metal complexation:
alcohols, phenolates, carboxylates, phosphoryls, thiolates, imidazoles,
pyrroles, and the iron-sulfur cluster as a special constellation. For
metal ions, all groups with a maximum distance of metalDistMax to
the ligand are considered for the complex.
After assigning all target groups to one metal ion, the resulting set
of angles of the complex is compared with known sets of angles from
common coordination geometries (linear [2], trigonal planar [3], tri-
gonal pyramidal [3], tetrahedral [4], square planar [4], trigonal bipyr-
amidal [5], square pyramidal [5], and octahedral [6]). The best fit with
the least difference in observed targets is chosen as an estimated geo-
metry and targets superfluous to the constellation are removed.
Step 4: Postprocessing
To avoid clutter in the visualization and report only relevant inter-
actions, several additional filtering and clustering steps are applied.
They all aim at reducing the number of reported contacts to a small
set of highly relevant interactions.
reduction of hydrophobic contacts Since the number of
hydrophobic interactions with a one-step approach as sketched above
can easily surpass all other interaction types combined, it may strongly
influence subsequent evaluation [59]. To overcome this problem, the
number of hydrophobic interactions is reduced in several steps. First,
hydrophobic interactions between rings interacting via π-stacking are
removed. This is done because stacking already involves hydrophobic
traits [273].
Second, two clustering steps are applied. If a ligand atom interacts
with several binding site atoms in the same residue, only the inter-
action with the closest distance is kept. Subsequently, the set of hy-Figure 12D
demonstrates the
reduction of
hydrophobic
contacts with
clustering.
drophobic interactions is checked from the opposite perspective: if a
protein atom interacts with several neighboring ligand atoms, just the
interaction with the closest distance is kept. Together, these reduction
steps help to report only the most representative hydrophobic inter-
actions.
reduction of hydrogen bonds Since salt bridges involve purely
electrostatic interactions as well as hydrogen bonds, it is not meaning-
ful to report both interaction types between the same groups. Thus,
hydrogen bonds between atoms are removed if they belong to groups
that already form a salt bridge to that atom.
5.3 command line tool , web server , and plugins 47
output files After going through all four steps of the detection
algorithm, the final set of contacts is then reported to the user. To
this end, both XML and human-readable markdown-style files can
be generated. For a full description of the formats, see Appendix A.
These files contains information on all contacts, details on particip-
ating atoms and geometries. Additionally, images are rendered from
PyMOL sessions and the session files itself are saved as well.
3D Visualization of Interaction Patterns
To generate images5, the interaction data is prepared for visualiza-
tion in Chimera [201] or PyMOL [229]. By default, PyMOL is used
and multiple visualizations can be generated in parallel. The ligand
and its surrounding binding site residues are shown as sticks and
the interactions as dashed or solid lines. Charge or ring centroids are
visualized as semi-transparent pseudoatoms. Color coding is used
to discriminate different interaction types. Various selections are cre-
ated for the user, providing toggles for displaying different interac-
tion types, representations and atom groups of interest, such as un-
paired hydrogen bond acceptors. Figure 13 shows an example of a
visualization generated with PLIP: although the observable binding
pattern is quite complex, the clear visualization lets the user focus on
key interactions.
automatic viewpoint Setting a good viewpoint automatically
is not a trivial task due to the diversity of ligand and binding site
shapes. Most random viewpoints will face the side or back of the
bindingsite, not enabling a clear view into the pocket and on the rel-
evant contacts. To solve this problem, the view is first centered on the
ligand molecule. Then, the camera (the viewpoint) is rotated so that
the longest axis of the ligand molecule is aligned with the horizontal
axis of the view. Following, the camera rotates 110 °around the ho-
rizontal axis. This is important for flat molecules, where the rotated
view is now on the upper or lower side of central ring structures, not
on their sides. Finally, the camera zooms out to bring all binding site
residues into view.
5.3 command line tool , web server , and plugins
During this project, the PLIP detection module has been published as
an open-source command line tool, a web service, a PyMOL plugin,
and via a REST API.
5 All images in this thesis were generated with PLIP v.1.3.3 and PyMOL v1.7 on
Ubuntu 14.04 LTS.
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Protein Ligand
Salt Bridge H-Bond Water Bridge Hydrophobic Contactpi-Stacking
ChargeWater
Figure 13: Example of an interaction diagram generated with PLIP: Vari-
cella zoster virus thymidine kinase (1OSN) binding the anti-herpes
drug brivudine-monophosphate. The binding is dominated by a
double π-stacking and polar interactions at the terminal regions
of the ligand.
command line tool The PLIP command line tool offers the
highest degree of flexibility for analysis with access to all paramet-
ers. It has been published together with the publication in Nucleic
Acids Research [218]. For details on implementation and usage, see
Appendix A.
web server PLIP is available as a web service to offer analysis of
protein-ligand complexes in the browser. The algorithm works as de-
scribed above for the command line tool, although advanced settings
such as changing thresholds is not available to users. In contrast, the
service aims at easy one-click processing without further setup.
The service is available at:
plip.biotec.tu-dresden.de
The web application is implemented in the Java-based framework
Grails [210] and runs on a Tomcat server. All data is saved in a MySQL
database. An local copy of the PDB archive (rcsb.org[22]) is main-
tained using the RCSB FTP services at ftp://ftp.wwpdb.org. For the
full-text search, Apache Lucene [8] is used. The website offers search
by PDB ID, structure title, PDB HET ID, compound name, and en-
zyme EC number [186].
The BioLiP database is used to offer an annotation on biological rel-
evance for each protein-ligand complex. To this end, the Perl script6
6 zhanglab.ccmb.med.umich.edu/BioLiP/download/download_all_sets.pl
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Table 3: Resources for the PLIP REST API. With <BASEURL> = projects.
biotec.tu-dresden.de/plip-rest. <PDBID> has to be a valid PDB
identifier. <FORMAT> can be either xml or txt.
Resource Method
<BASEURL>/pdb/<PDBID>?format=<FORMAT> GET
<BASEURL>/new?format=<FORMAT> POST
<BASEURL>/plugin POST
provided by Yang, Roy and Zhang [291] is used to retrieve weekly
updates from the database.
rest api A Representational State Transfer (REST) API [76] allows
users to send remote queries to the PLIP server and retrieve interac-
tion data. The PLIP REST API is available on several URLs (Table 3)
to retrieve precalculated results by PDB ID, post structure files for
analysis, or use PLIP in plugins (see below).
pymol and chimera plugins PLIP has been integrated into
the ProBiS plugin for the PyMOL Molecular Graphics [229] and UCSF
Chimera [201], available at insilab.org/probis-plugin [245].
Given a protein structure as input, it allows prediction of its bin-
ding sites and potential ligands for repositioning. Users can view the
predicted binding sites and for each site, its associated family of pre-
dicted ligands in 3D representation. The plugin allows live computa- Predictions on
novel inhibitors for a
validated drug
target from
Mycobacterium
tuberculosis from
this software were
experimentally
validated. For more
details, see Stular
et al. [245]
tion of binding sites using the ProBiS algorithm [136] on a specially
prepared database of all known binding sites and their corresponding
ligands from PDB, which is performed on the client computer from
the plugin itself. In this plugin, PLIP allows visualization between
query proteins and putative binders found by binding site alignments.
The plugin remotely queries a special REST resource (see Table 3) to
retrieve a serialized python object7 with the visualization data. The
display of potential intermolecular contacts in this context provides
an important visual control on potential binding of ligands to the
query protein. Non-covalent contacts from the query protein to one
selected ligand are visualized and listed within the GUI.
5.4 validation of plip
During testing, initial thresholds from literature (see Table 12) have
been modified (in the case of distance thresholds max. ± 1.5 A and
angles max. 20 °) in order to prevent false negative results. At the
same time, the number of false positive was kept as low as possible.
For the total of 41 manually curated validation cases, a number of
7 using the pickle module
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244 (positive, P) specifically interacting residues together with the
interaction types were reported in the selected publications. With 237
correct (TP), 50 false positive (FP) and 7 false negative (FN) reports,
PLIP reaches a recall (true positive rate, TPR) of TPP =
237
244 ≈ 97% at a
precision of TPTP+FP =
237
237+50 ≈ 83%.
5.5 discussion
In this chapter, the Protein-Ligand Interaction Profiler (PLIP) was presen-
ted as a comprehensive algorithm to detect biologically relevant in-
teractions from structural complexes. The 8 considered interaction
types cover all so-called canonical interactions, e.g. hydrophobic
contacts, hydrogen bonds, salt bridges, and π-stacking, which are
considered most important for molecular recognition in literature.
Furthermore, also non-canonical types such as metal coordination,
water-bridged hydrogen bonds, π-cation interactions, and halogen
bonds are considered, which together with the more frequent types
can accurately model binding between proteins and their ligands.
comparison to state-of-the-art algorithms As discussed
in section 3.4, other available tools and resources for protein-ligand
interactions have either limitations in their coverage of interaction
types, their potential for usage in high-throughput screenings, or are
commercial (see also Table 1). With its comprehensive detection al-
gorithm and the amount of considered interaction types, PLIP is on
par with commercial software in this area [41, 60] and state-of-the-art
among freely available tools. Furthermore, it makes no compromise
between visualization and generating parseable data: both completely
prepared PyMOL session files and XML files with full information on
contacts and their geometry are given as an output. Unlike any other
tools (see Table 1), this allows for both manual and interactive inspec-
tion of contacts as well as further processing of interaction data in an
analysis pipeline. Other major advantages are that no structure pre-
paration is necessary and any input structures in PDB format can be
processed via the command line in batch mode, making PLIP stand
out as a truly fully automated tool. Finally, PLIP goes beyond inter-
actions of proteins and typical ligands with its options to analyze
contacts between proteins and DNA/RNA or cofactor binding.
Since the publication of PLIP [218], three more tools and web servers
have been made available and will be briefly discussed: Hermosilla
et al. [102] present a new approach to analyze protein-ligand interac-
tions mainly from trajectories (docking paths or molecular dynamics
simulations). Its analysis of interactions is energy-based with heavy
usage on GPU computations. Although the authors compare directly
to PLIP in their publication [102] and discuss the lack of interactive
exploration of time series as a drawback of PLIP, it has to be noted
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that both tools pursue vastly different purposes: While the tool by
[102] focuses on visual exploration, PLIP offers both visualization and
machine-readable report files for further processing. An automatic
analysis of trajectories is therefore possible with PLIP data by gener-
ating reports for each frame and then analyzing the time-dependent
change in patterns. A proof-of-concept example for docking analysis
is presented in section 7.4.
MANORAA (Mapping Analogous Nuclei Onto Residue And Af-
finity) by Tanramluk et al. [253] is a web server solution to detect
7 types of non-covalent interactions of ligand fragments to multiple
proteins. It is specialized on linking observable interactions to bin-
ding site affinities. Therefore, the server is dependent on external
databases (CREDO, Binding MODAD, KEGG, UniProt, and SAMUL
[253]) and is thus rather an data aggregation service for comparative
analysis. Again, PLIP has no disadvantage here since it offers compar-
able data as used CREDO, which is used by MANORAA, and even
has the option to include further models, e.g. from docking.
Finally, the Arpeggio server by Jubb et al. [118] comes closest to PLIP
with its concept of a Python-based detection tool and an extensive set
of contact types. The server allows for submission of entries from PDB,
but also custom structure files and offers – just as PLIP – interactive
visualization in the browser and download of PyMOL session files.
However, only counts of interactions are listed on the webpage and
textual result files don’t contain any information on interaction geo-
metries, making Arpeggio primarily a tool for visualization. In direct
comparison, PLIP generates by default more focused 3D diagrams and
rendered images which can directly be used in publications without
further preparation and has result files with all relevant distances and
angles listed for each contact.
Concluding, the uniqueness of the PLIP feature set with compre-
hensive detection of interactions, visualization, parseable output, fully
automated processing of any structures and its availability to the
community still holds true and meets all requirements for extensive
characterization and exploitation of contacts in the complete PDB as
demonstrated in chapter 6.
performance and computational complexity PLIP is using
OpenBabel [189] for internal representation of molecular structures.
After reading the input structure, the complete molecule is loaded
into memory for the subsequent analyses, resulting in a constant
memory usage. Since classes are instantiated for each atom and its as-
sociated information, the space complexity for the data space grows
linear with O(a), where a is the total number of atoms in an input
structure.
The bottleneck in terms of computation time for larger structures
may result from the calculation of pairwise distances between ligand
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and protein atoms. This calculation is necessary in the first step (Fig-
ure 12A) of the PLIP algorithm to annotate binding site residues for
each ligand. First, a preselection of binding site residues is made by
approximate distance calculations between the ligand centroid and
residue centroids. In the worst case, all protein residues for each of
the n ligands are selected for the following pairwise distance calcu-
lation. This makes it necessary to consider all combinations of al lig-
and and ap protein atoms and yields a cubic time complexity with
O(n ∗ al ∗ ap).
However, the preselection step usually vastly reduces the search
space and selects on average 19 out of 800 residues from a typical pro-
tein. With approximately 19 atoms (sic!) in an average protein amino
acid and 19 atoms (sic!) in typical ligand, this gives a constant and
low number of comparisons c = 193 ≈ 7000 for each ligand, resulting
in a linear complexity O(n) for the average case.
In practice, some routines by OpenBabel may add more computa-
tion time than considered above: one example is the recursive Kekule
valence bond function also used in PLIP. It is applied once for each
of the n ligands in a structure to determine which rings are aromatic
and has exponential complexity [189]. To this end, it is stopped after
15 seconds or 30 recursions [189] and may only add overhead for
ligands with very complex ring structures.
In a practical test with a sample dataset of 20,000 PDB structures,
the median processing time was 3.1 s, meaning that the complete
PDB with currently more than 120,000 structures can be processed
overnight on a small-sized cluster. Weekly updates from the PDB with
approx. 200 new structures each 8 can thus be processed in 10 minutes.
Most importantly, this processing step does not need to be repeated
for following comparative analyses, e.g. virtual screening ( chapter 6
and chapter 8).
plip evaluation The systematic evaluation of the PLIP algorithm
is a unique feature among freely available interaction tools. Users can
download the representative test suite with complexes covering all
supported interaction types, different resolutions, binding site muta-
tions, and symmetrical complexes from a public repository. With a
high precision (83 %) at almost perfect recall (93 %), these results
show that PLIP can indeed be universally applied to structural data
and detects all relevant interactions.
A larger benchmark set would enable to test for even more con-
stellations, but the main limitation here is availability of publications
with detailed descriptions of interactions in structures. Also, negative
evidence is missing (e.g. that no hydrogen bonds can be formed at
8 Information derived from rcsb.org/pdb/statistics/contentGrowthChart.do?
content=total. Basis for the calculation is the yearly growth in 2016.
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a possible constellation), which would enable a better fine-tuning of
thresholds.
False negative results have been checked manually and often re-
vealed that reported interactions in literature may also depend on
the specific binding context or experience from crystallographic ex-
perts, e.g. for decision between salt bridges and hydrogen bonds. This
means that generic rules as used in PLIP might always miss out in
some specific cases.
limitations Although the rule-based PLIP algorithm can process
nearly all available PDB structures (> 96%) efficiently and precisely
report relevant interaction types (see above), several limitations arise
from such a design: rule sets enable transparent screening for mo-
lecular contacts, but have to be carefully constructed. Since usually
many geometric thresholds are involved for each interaction type
(see section 5.2), small changes can have significant impact on large-
scale statistics of interactions. Furthermore, all thresholds are subject
to a tradeoff between high recall, leading to cluttered visualizations,
and precision (with the chance of missing out on contacts in low-
resolution structures). PLIP thresholds were kept as tightly as possible
while at the same time aiming to detect all interactions deemed rel-
evant by crystallographic experts. The benchmark set (see section 5.4)
shows this focus on recall, with a true positive rate of 97 % at a preci-
sion of 83 %.
Another limiting factor is that some subroutines of PLIP are not ex-
haustive for detection of potentially interacting groups, e.g. charge de-
tection in ligands due to dependency on pre-defined candidate lists,
or annotation of aromatic rings. These problems may not occur that
often in energy-based models, where usually no pre-defined func-
tional annotations are needed. The same is true for the abstraction
of hydrophobic interactions, which do not result from an attractive
interaction (see section 3.2) and therefore can be better depicted with
energy landscapes than with vectors.
conclusion The PLIP algorithm enables fast and reliable charac-
terization of the complex three dimensional binding patterns arising
from protein-ligand binding. With its universal availability and unique
combination of comprehensive detection, visualization, and atomic-
level reports on contacts and their geometries, PLIP is the current
state-of-the-art tool for detection of non-covalent interactions. With
access to largely untouched data on almost 4 million contacts from
the structural proteome, PLIP can enable improved virtual screening
for repositioning candidates as well as improve docking and ligand
design routines, as demonstrated in chapter 6 and chapter 7.

6
N O V E L C A N C E R D R U G S W I T H 3 D I N T E R A C T I O N
P R O F I L I N G
This chapter is based on the publication Honey as cancer
treatment? Interaction patterns identify chrysin as
suppressor of cancer chemoresistance by Salentin et al. [219]
(revised manuscript under review in PLOS Computational Biology)
For detailed information on author contributions see the publication
list on page v.
As a main application in this thesis, PDB-wide interaction data from
PLIP (see chapter 5) was used to screen the known structural pro-
teome for novel binders to Hsp27, a priority target in cancer due to its
involvement in apoptosis and formation of chemoresistance. Prior to
the analysis, preferred interactions of small molecules were analyzed
on a representative set (section 6.2) to sketch the contact landscape
and identify potential pitfalls for an interaction-based analysis. The
3D interaction profiling workflow for screening novel Hsp27 binders
is presented in section 6.3: as a knowledge-based approach, it uses
information on binding preferences derived with PLIP (see chapter 5)
of the known inhibitor BVDU to identify other compounds with simi-
lar interaction patterns. Technical details on in silico and lab protocols
are documented in Appendix B.
6.1 materials and methods
Datasets
representative sets of protein-small-molecule complexes
PDB-wide quantitative studies require non-redundant sets to avoid
bias from overrepresented groups. Since the atomic units in this con-
text are protein-ligand complexes, bias from both the protein and
ligand space needs to be removed. A unique complex in this context
should represent a unique combination of a protein family and a spe-
cific chemical compound. To achieve such a grouping, a PDB snapshot
with 122,985 entries was downloaded (2016/10/14). All structures
were analyzed with PLIP v1.3.2 using standard settings (Table 12) to
yield an expanded set of 440,024 protein-ligand complexes. PLIP was
able to process 118,280 (96.17 %) of the input files.
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Complexes in the set were filtered with the BioLiP1 database [291],
which provides a semi-manually curated whitelist of biologically rel-
evant complexes in the PDB. This step enables to exclude unspecific
additives such as choline while keeping them in complexes where
they are specifically binding (e.g. in an ABC transporter, PDB ID
2REG). The step retained only 190,537 items (45.30 % of the input set).
Second, items without interactions were discarded, leaving 184,212
complexes. The last step removed non-small-molecule ligands and
composite (i.e. multi-part) ligands. This finally yielded the redundant
protein-small-molecule (PSM) set with 100,611 complexes. It contains
28.22 % of the original dataset.
Each complex in the dataset already contained a canonical Simplified
Molecular Input Line Entry Specification (SMILES)2 for the ligand from
the PLIP analysis. Additionally, each protein-ligand complex was an-
notated with the Pfam[77]3 family of the participating protein. There-
for, a Pfam family is assigned to each interacting binding site residue.
The majority Pfam family is then assigned to the complex. Each unique
combination of Pfam family and SMILES is then enumerated to yield
the group IDs. 6,819 items could not be mapped due to missing Pfam
or missing SMILES, 93,792 (93.22 % of final redundant PSM set) were
mapped successfully. The resulting non-redundant protein-small-molecule
(nrPSM) set contains only unique groups (32,081) with regards to lig-
and structure and protein family. For each group, a cluster repres-
entative is chosen which has the most contacts between protein and
ligand.
screening set for 3d interaction profiling Crystal struc-
ture data was downloaded from the PDB FTP Archive on 8th of April,
2015. The containing 107,663 structure files were analyzed using PLIPIn contrast to the
PSM and nrPSM sets,
this dataset contains
complexes between
proteins and
different types of
ligands.
v1.1.1 with default settings to detect relevant interactions. Processing
with PLIP was successful for 106,577 structures (99 %). Result files
were deposited in XML format for further evaluation. In the sub-
sequent steps of the analysis, only biologically relevant complexes
were considered. To achieve this, the set of binding sites was filtered
with BioLiP [291], yielding 170,219 complexes in 55,597 PDB struc-
tures (52 % of processed structures). This final screening set con-
tains complexes from 16,460 unique targets (Uniprot IDs) and 13,704
unique ligands (PubChem IDs).
1 zhanglab.ccmb.med.umich.edu/BioLiP/download.html, 2016/08/13
2 opensmiles.org/opensmiles.html
3 ftp://ftp.ebi.ac.uk/pub/databases/Pfam/current_release/pdbmap.gz, retrieved on
2016/10/14
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3D Interaction Profiling Workflow
Characterization of the BVDU interaction pattern
In order to construct a search pattern for the following virtual screen-
ing step, observed interactions and their spatial orientations in BVDU
complexes were analyzed and encoded into a consensus or meta-pattern
(Figure 14B). To expand the available data, complexes with its mono-
phosphated form BVDU-MP were integrated as well, considering only
the BVDU core (i.e. ignoring contacts to the monophosphate moiety).
Fourteen complexes in the PDB contain either BVDU (PDB HET ID:
BVD) or its monophosphated form BVDU-MP (PDB HET ID: BVP).
A full list of identifiers is given in Table 5. All these complexes were
characterized with PLIP and characteristic subpatterns occuring in at
least one of the structures were formally described and listed with
a unique letter. A subpattern in this context is a single, specific non-
covalent interaction or an arrangement of up to two of these interac-
tions and their geometric constraints in the complex ensemble. Geo-
metric constraints included in this analysis are observed distance
ranges and angles between atoms or bonds. The patterns were thus
manually defined as indicated in Table 4.
Together, all patterns form the BVDU metapattern, i.e. a superset
of all observed characteristic interactions in the 14 complexes (see
Figure 14B). This way, the metapattern is not biased by the different
number of complexes for each structure (Table 5), but only a qualitat-
ive description.
BVDU interaction pattern matching
To identify compounds with interaction patterns similar to the known
Hsp27 binder BVDU, a virtual screening using interaction pattern
matching was performed (Figure 14C). A custom script was used to
find interaction patterns in protein-ligand complexes using PLIP data.
For each complex, the information on presence of subpatterns was
stored in a simple 10-bin boolean fingerprint, with each bin repres-
enting the presence (1) or absence (0) of a subpattern.
All complexes with 6 or more of the subpatterns present (951 com-
plexes from 600 different PDB structures) were selected in a virtual
screening step (shown in Figure 14C) and redundant entries for com-
pounds discarded to remove redundancy.
Out of this set with 248 different ligands, just the complexes with
ligands annotated as drugs (experimental, clinical study, or approved
status) were considered for the subsequent prioritization step. The
drug classification was performed using our in-house database Com-
prot [54, 96], which contains a advanced classification for compounds
based on the Therapeutic Target Database (TTD) [44].
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Finally, this procedure yielded the candidate set of 58 drugs to be
further evaluated.
Compound Prioritization
In order to select a compound to be tested in lab experiments, a
two-step prioritization of candidate compounds was performed (Fig-
ure 14D): first, they were manually grouped and this classification re-
evaluated with a chemical similarity fingerprint (Chemical Grouping
and Similarity). Following, selected compounds were docked against
viral TK and an Hsp27 model (Docking).
Chemical Grouping and Similarity
The chemical grouping of compounds was performed manually ac-
cording to the observed scaffolds in the molecules. Compounds with
no clear group membership were labelled as singletons. To re-evaluate
the manual grouping with a chemical fingerprint similarity meas-
ure, structures of chemicals were downloaded from PubChem in SDF
format and similarity between them calculated using the PubChem
Score Matrix Service. A chemical heatmap was generated with hier-
archical clustering using average linkage. Compounds on the axes
were grouped according to the manual classification by scaffold and
ordered within each group by chemical similarity using hierarchical
clustering on average distances, enabling to visually check the corres-
pondence between manual grouping and chemical fingerprint simil-
arity.
docking AutoDock 4.2 with rigid body docking was used to re-
dock BVDU (Figure 14D) into the known binding site of viral TK (PDB
ID: 1OSN) [25] and into the putative binding site of a structural model
of Hsp27 [99]. For a detailed docking protocol, see Appendix B. The
top hit compound according to predicted affinities in Hsp27 and TK
was selected for experimental validation.
Experimental validation of lead compound
After pattern matching and docking analysis, the top candidate com-
pound chrysin was tested in two assays in comparison to the known
Hsp27 inhibitor BVDU (see Figure 14E) to demonstrate its inhibitory
effect on Hsp27 (Biochemical Assay) and reduction of chemoresist-
ance in multiple myeloma cells (Resistance Assay).
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Figure 14: 3D interaction profiling workflow. A Interaction data for all
protein-ligand complexes from the PDB were calculated with PLIP
and complexes filtered for biological relevance using the BioLiP
database. B Patterns A-J were manually annotated in 14 com-
plexes of BVDU(-MP) and defined in a structure-invariant man-
ner. C The dataset was screened for complexes with BVDU-like
binding patterns. Top matches were selected by using a cutoff
of six or more patterns. The final set was selected by docking to
Hsp27 and TK with subsequent filtering for ligands with higher
predicted affinities than BVDU in a redocking experiment, yield-
ing the final candidate set. D The top compound was tested for
Hsp27 inhibition in a biochemical assay and a chemoresistance
assay for validation.
biochemical assay A compound is tested in an in vitro assay to
investigate its effect on Hsp27 function (Figure 14E). Hsp27 is known
to act in vitro as a chaperone [113] for citrate synthase (CS), which
misfolds at temperatures above 43 ◦C. In presence of Hsp27, the
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misfolding is reduced. Inhibitor binding to Hsp27 impairs its chape-
rone function, leading to accumulation of denatured citrate synthase,
which serves as a measure for inhibitory effectiveness of a compound.
BVDU, controls, or the candidate compound were incubated with cit-
rate synthase. Aggregated CS was precipitated at 3 time points (30,
60, 90 min) and quantified using capillary electrophoresis. The rela-
tive inhibitory values were calculated by measuring the amount of
misfolded client protein and subtracting the value for the blank run
with DMSO buffer and all values divided by the value for BVDU and
normalized for the used concentration of added substance.
resistance assay A multiple myeloma cell line was seeded in
logarithmic growth phase and incubated with bortezomib. Addition-
ally, potential Hsp27 inhibitors were added. No cytotoxic was added
for the control run. Bortezomib was added in increasing dosages in
three passages while a medium with bortezomib and BVDU was used
as a positive control. For details on both experimental protocols, see
Appendix B.
Repositioning Matrix
In addition to validation of the top hit compound, known and pre-
dicted relations for all targets and drugs in the candidate set were
retrieved from PDB, STITCH, and ChEMBL (Data Mining). The data
was annotated with protein superfamilies as well as compound classes
for the drugs (Target and Compound Annotations) and visualized
(Matrix Visualization) to enable a high-level view on the presented
workflow and further repositioning opportunities.
data mining Known and predicted targets for the 43 proteins in
the candidate set was retrieved from STITCH (2017/02/20). Protein
identifiers were mapped into Uniprot identifiers using a mapping
file provided by STRING in the Download section, using which 39 of
43 proteins were successfully mapped. ChEMBL data on measured
affinities was manually retrieved for all entries (2016/08/28).
target and compound annotations To achieve a less fine-
grained view on compound-target relations, targets were annotated
with their SCOPe superfamilies and compounds with chemical classes
according to the MeSH classification. Simple MeSH classifications
in the Chemicals and Drugs category for all compounds were down-
loaded from PubChem (2016/10/03) via the web application pro-
gramming interface (API). The superfamily classification for proteins
was taken from the SCOPe database v2.06. For the structural evidence,
all drug-target pairs appearing as hit complexes from the virtual
screening step were considered. For technical details, see Appendix B.
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matrix visualization Binding evidence from PDB (structural
evidence) and relations from STITCH and ChEMBL (other evidence)
was color-coded and represented in a matrix for each combination
of target and compound in the candidate set. Relations are shown
between compounds groups (according to MeSH classification, ab-
scissa) and protein superfamilies (according to SCOPe classification,
ordinate). A colored rectangle was drawn for each evidence from
either PDB (green) or STITCH and ChEMBL (orange). If both struc-
tural evidence and other evidence was available for a combination,
only the structural evidence was visualized. Entries on both axes
were clustered by the number of shared targets for the compounds
axis and number of shared compounds for the targets axis.
6.2 interactions in the pdb
cluster distribution The PDB nrPSM set was analyzed to get an
overview on binding behaviour of small molecules. Figure 15 shows
the distribution of cluster sizes in the dataset on a double logarithmic
scale.
Figure 15: Distribution of clusters in the nrPSM dataset. The frequency of
cluster sizes is shown on a log-log scale.
The dataset contains 93,792 small-molecule-protein complexes in
32,081 clusters, with > 18 % (17,533 complexes) being singletons. The
frequency for clusters steadily declines with an increasing cluster size
(Figure 15). The largest clusters contain complexes of heme with dif-
ferent protein families, led by globin (513 complexes) and nitric ox-
ide synthase (357 complexes). Sulfate (SO4) and phosphate (PO4) are
present in most clusters with 268 and 256 memberships. Other fre-
quent ligands include adenosine phosphates (e.g. ADP, AMP) and
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glycerol (GOL) with more than 100 different clusters each. Proteins
with most cluster memberships are protein kinase domains with 1613
different clusters, followed by trypsin, tyrosine kinase, hormone re-
ceptor, and aspartate protease with over 500 memberships each.
protein-ligand contacts Next, only cluster representatives
from the nrPSM set were considered in order to avoid bias from fre-
quent ligands and protein families. First, the total number of contacts
between a small molecule and its host protein in the dataset was ana-
lyzed. This number comprises all counts from PLIP interaction types
(see chapter 5). For this analysis, the dataset was collapsed by tak-
ing the average for each unique ligand. As shown in Figure 37 (Ap-
pendix B), the molecular weight shows a modest correlation (r2 =
0.41) with the total number of contacts. Considering this observation,
the distribution of contacts numbers was normalized by the molecu-
lar weight of the ligand and visualized in a histogram (see Figure 16).
The distribution has a median number of 3 contacts per 100 g/mol
molecular weight.
Figure 16: Weight-normalized number of contacts. Shown is the frequency
for the number of contacts normalized with the ligand molecular
weight. The dashed blue line indicates the median.
With a median weight of 372.4 g/mol for a small molecule in the
nrPSM dataset, around 11 interactions can be expected for a typical
ligand. There are no noticeable differences in the distributions between
drugs and non-drugs (data not shown).
In total, the dataset lists 394,303 contacts between small molecules
and proteins. The most abundant fraction is made of hydrogen bonds
with approx. 43 % (see Figure 17). Other frequent interaction types are
hydrophobic contacts (26 %), water bridges (14 %), and salt bridges
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(7 %). The co-occurrence of interaction types in complexes was also
analyzed (results in Table B, Figure 38). While there is a tendency of
polar interaction (hydrogen bonds, water bridges, salt bridges) types
to co-occur, no strict couplings between types was detected.
Figure 17: Frequency of interaction types in the nrPSM dataset. The ordinate
shows the share of each interaction type on the number of all
contacts (N=394,303).
hydrogen bonds As indicated above, hydrogen bonds are the
by far most prominent group among all analyzed interaction types.
This bond can be formed to both sidechain and backbone portions
of the binding site amino acids. Of all 169,370 hydrogen bonds in
the dataset, almost 48 % (80,887) are formed to the protein backbone.
While the majority of complexes with multiple hydrogen bonds (5
or more) has a mixture of backbone and sidechain contacts of this
type (see Figure 39 in Table B), there are some complexes which use
exclusively backbone or sidechain hydrogen bonds. The second case
is less prominent, with just 232 complexes in the dataset.
π − Stacking The interaction between two aromatic rings, also
called π-stacking, is present in more than 28 % (9,046) of all complexes
in the dataset. This corresponds to 7,100 different ligands and more
than 1,000 protein families. Approximately 13 % (4,174) even show
two or more stackings between the ligand and its host protein.
unpaired atoms When atoms are functional, i.e. could poten-
tially take part in a specific interaction, but are not used, they are
called unpaired. For halogen atoms, this is often the case: of 4,751
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complexes with ligands having halogen groups, they remain com-
pletely unused in 73.2 % of all cases. For hydrogen bond acceptors
(HBAs) (31,202 complexes) and hydrogen bond donors (HBDs) (29,394
complexes) this is true for just 3.4 and 6.8 %. In many cases (accept-
ors: 20.0 %, donors: 50.0 %), all of the present functional atoms are
used to form hydrogen bonds. For HBDs, in average approx. 78 % of
all donors of a ligand are used for this specific interaction type.
Figure 18: Patterns found in complexes with BVDU(-MP) with the ligand
BVDU (orange) and the interacting target residues (blue). Letters
indicate the patterns: A Base pattern - aromatic ring in ligand,
B Double π-stacking to base ring, C Double π-stacking to base
ring on opposite sites, D Parallel double π-stacking to base ring, E
Double hydrogen bonds to base ring, F Double hydrogen bonds
to the same residue, G Parallel double hydrogen bonds, H Distal
hydrophobic contact, I Distal hydrogen bond and J Distal halo-
gen bond.
6.3 3d interaction profiling
The rationale of the analysis was to identify FDA-approved drugs
or dietary supplements with a similar preferred arrangement of non-
covalent contacts as observed in complexes of the known Hsp27 in-
hibitor BVDU and to validate their ability to inhibit Hsp27 activity and
overcome chemoresistance in cell lines.
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6.3.1 Screening for Heat Shock Protein Inhibitors
bvdu key interactions BVDU uses different interaction types
(hydrogen bonds, π-stacking, halogen bonds, and hydrophobic con-
tacts) for binding using its central nucleobase ring, the deoxyribose
moiety, and the bromovinyl residue. In total, then different patterns
A-J between different complexes with BVDU were defined (see Fig-
ure 18). A formal definition for each pattern is listed in Table 4: while
an aromatic ring in the ligand served as a base pattern (A), all other
patterns were defined in relation to this anchor. Figure 19 shows the
variation of these predefined patterns between different complexes
with BVDU.
Figure 19: Variation of patterns A-J in 14 BVDU complexes. Blue fields in-
dicate presence of pattern, empty fields indicate absence.
BVDU displays a limited set of 10 patterns (A-J), which are used in
varying combinations to bind to different protein targets: while all
complexes have at least one π-stacking interaction to the central aro-
matic ring (base pattern A), the double stacking (pattern B) is present
at least once in three of five structures. Next to a distal hydrophobic
contact (pattern H), which is visible in all complexes, the two paral-
lel hydrogen bonds to the base aromatic ring in the nucleobase part
(patterns EFG) are most predominant in the ensemble with presence
in all but one structure (2JAW). While a single hydrogen bond in the
sugar residue (pattern I) appears in all complexes of three structures
(1KI8, 1OSN, 2W0S), the distal halogen bond (pattern J) is predom-
inant in the complexes with the proteins from D. melanogaster and
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Vaccinia virus. The sandwich stacking (patterns BCD) is only visible in
the Varicella zoster thymidine kinase complexes (PDB ID 1OSN).
Key interaction patterns within a crystallographic structure are mostly
consistent. One remarkable example of conserved interactions despite
dissimilar arrangement of binding site residues is the halogen bond of
the bromovinyl group: in two structures from D. melanogaster (2VQS)
and Vaccinia virus (2W0S), it is formed with different backbone amino
acids (Ser106 in 2VQS and Asn65 in 2W0S).
Differences can be observed for example in the low resolution4
D. melanogaster multisubstrate deoxyribonucleoside kinase (PDB ID:
2VQS), where an additional π-stacking (patterns BC) is observable in
chain D due to a different orientation of the Phe80 residue in the bin-
ding site. In another case, the absence of a typical hydrogen bond to
the sugar moiety (pattern I) in the Vaccinia virus thymidylate kinase
(PDB ID: 2W0S) arises from a longer distance between the ligand to
a binding site tyrosine residue (Ty101).
virtual screening finds bvdu-like patterns After defini-
tion of the patterns (see Table 4), the 3D interaction profiling work-
flow was tested against the original 14 BVDU(-MP) complexes and
was able to recover all previously manually annotated patterns A-J
with 100 % accuracy. Next, a virtual screening step was performed
to screen for the characteristic BVDU subpattern in the complete PDB
(see section 6.1). For each complex, the number of BVDU patterns
was annotated. As some compounds appear in many structural com-
plexes in the PDB (with more than 20 compounds each appearing in
over 100 complexes), redundancy was avoided by considering only
the best-matching complex for each unique compound, resulting in a
set of 15,712 non-redundant complexes. Figure 20 shows the distribu-
tion of the number of non-redundant hit complexes for each number
of patterns.
Whereas most complexes in the set show just one pattern (remotely
similar binding behaviour, see Figure 20, left), the number stead-
ily decreases, with only 6 complexes in the dataset showing almost
the complete BVDU metapattern (identical binding patterns, right). A
threshold of 6 as the median5 pattern count of the original BVDU
complexes was chosen.
4 2.9 A with an R factor of 0.242
5 More specifically, it is the median of the medians for each PDB structure with BVDU
complexes, yielding a typical number of present patterns needed for binding
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Figure 20: Distribution of patterns in the screening dataset. The group with
two or more patterns comprises 531 unique drugs and 3,823 other
compounds. With increasing number of patterns, this number
decreases and leaves just 2 drugs and 4 other compounds dis-
playing almost the complete metapattern of BVDU (9 of 10 pat-
terns). Three examples are shown to demonstrate the presence of
patterns: benzoic acid has three matching patterns (ABC), chrysin
shows 6 matches (ABCDEH), and inosicic acid has 8 BVDU-like pat-
terns (ABCDEFGI). A cutoff of 6 patterns was determined to build
a candidate set for experimental validation.
Subsequently, all complexes with ⩾ 6 or more matching patterns
(951 complexes from 600 different PDB structures) were selected for
further analysis. Out of this set with 248 different ligands, all non-
drugs were removed as the aim was to identify potential candid-
ates for drug repositioning. The remaining compounds (12 approved
drugs, one in clinical trials, and 45 marked as experimental) were
considered for further analysis.
6.3.2 Honey against Cancer?
chemical grouping and similarity The candidate set com-
prises 58 unique drugs in complexes with 43 unique targets. The
compounds can be manually grouped into nucleobases, pyranoses,
aminopteridones, and flavones (Figure 21A). Pyranoses and flavones
are the smallest groups with two compounds each. Seven compounds
with diverse scaffolds remain as singletons. The average pairwise che-
mical similarity between the compounds in this set is relatively low at
41 % and distinct similarity clusters (Figure 21B, red color) are visible
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in the heatmap, which are mostly consistent with the manual group-
ing by chemical scaffold (Figure 21A): the observed similarity within
most groups (marked with black lines) is higher (red clusters) then
between them. One noticeable exception are the aminopteridones,
which have more diverse chemical structures. Other cases of simil-
arities between compounds from different groups (thin red lines) are
often caused by shared sidegroups such as multiphosphate moiet-
ies. As a special case, the nucleobase-containing group forms distinct
clusters for pyrimidine and purine scaffolds and also shows some
diversity within each subgroup (lower right corners of the boxes).
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Figure 21: Chemical grouping of candidate compounds (A) and pairwise
chemical similarity (Tanimoto score) in a heatmap with hierarch-
ical clustering (B). Nucleobases (blue) are the largest group in the
set (40 members). They form two distinct clusters in the heatmap,
separated by pyrimidine and purine scaffolds. Aminopteridones
(red) with two six-membered rings in the core group (7 mem-
bers) are more diverse and show a lower similarity within the
group. Pyranoses (green), six-membered ring carbohydrates and
flavones (yellow), a subclass of flavonoids, (2 members each) are
very similar within each group (lower right corner). Singletons
(7 members) are not shown as a group in A and do not form a
consistent cluster.
To select the most promising compound for experimental valida-
tion as an inhibitors of Hsp27, a two-step prioritization process was
performed. First, chemical groups with high potential were selected,
paying particular attention to the potential for further improvement
of compounds by chemical modification and the novelty of the scaf-
fold for Hsp27 inhibition: nucleotide analogues as the largest group
in the set are already established as antiviral drugs and can repress
viral reproduction by competing with natural (d)NTP substrates [234].
BVDU also falls in this group, showing that 3D interaction profiling
can recover compounds from well-characterized groups. Since the
aim was to find compounds with novel scaffolds for Hsp27 inhibition,
this group was discarded. Some aminopteridones are already paten-
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ted as inhibitors for other heat shock proteins (e.g. WO2015123456A1
for Hsp90) [248] or approved drugs (e.g. sapropterin against phenylketon-
uria [149]). Flavones are a potential source of anticancer drugs [154]
and although no extensive toxicology data exists [81], many mem-
bers are already marketed as dietary supplements and generally con-
sidered safe for consumption. These two groups were retained for
further analysis. Carbohydrate are an emerging source of lead com-
pounds [71], but the pyranoses found in the candidate set were too
small and poorly diverse to serve as glycomimetics building blocks
and were discarded. From the group of singletons, only three com-
pounds were kept while the remaining ones were discarded as they
had known cytotoxicity, potential for DNA intercalation, were unsuit-
able for building chemical derivatives or violated Lipinski’s rule of
five.
docking The retained compounds and BVDU as a standard were
tested in docking experiments against the two known targets of BVDU:
Hsp27 and viral TK. In comparison the known binder BVDU, 6 (TK)
and 8 (Hsp27) candidates ranked higher in docking, not including any
members from the class of aminopteridones. Among the compounds
showing consistently better predicted affinities to both proteins in
comparison to BVDU, chrysin (6 pattern matches) was ranked first
in the set with predicted affinities twice as high as the known binder.
In the top-scoring docking pose in TK (Hsp27), the ligand binds via 7
(5) of the BVDU subpatterns: a sandwich π-stacking interaction, hydro-
gen bonds with its hydroxyl groups and a distal hydrophobic inter-
action. In Hsp27, a second π-stacking interaction to Hsp27 is possible
when allowing the binding site residue Phe33 to bend towards the
ligand.
Currently, there are two crystal structures of complexes with chrysin
(PDB HET ID: 57D) available in PDB, one with human transthyretin
(PDB ID: 4DES) and one with rabbit glycogen phoshorylase (PDB ID:
3EBO). In the transport protein transthyretin, chrysin binds with low
affinity [260] using almost exclusively hydrophobic contacts and just
one hydrogen bond to a lysine at the binding site entrance. In con-
trast, the complex of chrysin with the phosphorylase is dominated by
a sandwich π-stacking [261] and stabilized via additional hydrogen
bonds and water bridges and is thus very similar to the docking bin-
ding poses: in both Hsp27 and TK, chrysin binds via sandwich (TK)
or combined face-to-face and face-to-edge (Hsp27) π-stacking and is
stabilized via hydrophobic interactions at the B-ring (see Figure 21A
for ring annotations) as well as hydrogen bonds at the A-ring.
6.3 3d interaction profiling 71
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10 12 14 16 18 20
bortezomib only
bortezomib + 30 µM BVDU
bortezomib + 1 µM chrysin
0.2 ng/mL 0.3 ng/mL 0.4 ng/mL bortezomib
C
e
ll 
C
o
u
n
t 
(m
io
/m
L
)
Days of treatment
Control
Bortezomib Treatment
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
C
e
ll 
C
o
u
n
t 
(m
io
/m
L
)
Days of treatment
untreated
30 µM BVDU
1 µM chrysin
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A
B
Figure 22: Reduction of drug resistance by chrysin. A In the control run,
there is no difference in the growth of cells treated with or
without test compounds, BVDU or chrysin (without bortezomib).
B With increasing doses of bortezomib over three passages, there
is a clear difference in growth between treatment with bortezomib
only or addition of BVDU or chrysin. While BVDU visibly re-
duces cell count at 30 µM concentration, addition of chrysin at
1/30th of this dose is more effective than BVDU.
chrysin as an hsp27 inhibitor and chemoresistance blocker
In the biochemical aggregation assay for Hsp27 inhibition (see sec-
tion 6.1), chrysin was found to be > 70 times more active than the
known binder BVDU. This potency of inhibition is similar to the com-
pounds identified in a previous study (49 to 80 times stronger) which
identified candidates by exploring structural similarity of targets in
PDB [100].
Figure 22 shows the experimental results of treatment of the mul-
tiple myeloma cell line RPMI-8226 with bortezomib and chrysin. In
the control run, cells were allowed to grow without addition of the
cytotoxic drug (Figure 22A) and there was no difference in growth
between untreated cells and cultures treated with BVDU or chrysin
alone. Upon treatment with bortezomib (Figure 22B), the cells de-
velop resistance to the increasing amounts of the cytotoxic drug. While
cells treated with bortezomib achieve a cell count of 800,000 after 19
days, chrysin-treated cells are reduced to 440,000 (55 %). Chrysin at a
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concentration of 1 µM is remarkably more potent than 30 µM BVDU
to suppress the development of chemoresistance.
6.3.3 Recovering Known Drug-Target Pairs
With Chrysin, a prioritized compound from the candidate set was suc-
cessfully confirmed in experiments as an inhibitor of Hsp27 and to
reduce drug resistance. However, also the remaining 59 compounds
and 43 targets in this set are potentially interesting as they all share
similar interaction patterns. It is therefore expected that within this
pool more compounds could possibly bind one or several targets. To
check whether any relations are already known, a matrix was gen-
erated (Figure 23) which contains evidence from crystal structures
(green) and from other sources (text mining, biological assays, and
pathway information from STITCH and ChEMBL, orange) for all com-
binations of annotated drug chemical classes and protein superfamil-
ies.
Figure 23: Drug-target relations from the candidate set with external evi-
dence. Ligands are grouped according to their MeSH classifica-
tion and proteins according to the SCOPe superfamily annotation.
Some relations are known through structural evidence (green), or
data from binding assays, text mining and pathways (orange).
The MeSH annotation for compounds yielded 19 groups (inclu-
ding the Singletons group for those where annotation was missing or
failed) and the SCOPe superfamily annotation resulted in 23 target
groups (including the Undefined group for targets where the super-
family is unknown, see Figure 23). In the latter case, proteins annota-
tion was unsuccessful for 4 out of 43 proteins in the candidate set due
to failed mapping of STITCH target IDs to Uniprot IDs.
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From all 437 possible combinations of proteins and compounds
(Figure 23), 41 (9.4 %) are already confirmed by structural evidence
(green). For 81 (18.5 %) other drug-target pairings, there is evidence
from text mining, bioassays, screening or pathway data (from STITCH
and ChEMBL, orange) for binding. Taken together, both sources provide
evidence for 27.9 % of all combinations. Due to the arrangement of
data points by the number of shared targets (for compounds) and
the number of shared ligands (for targets), clusters are visible in the
matrix. They indicate protein and ligand ensembles for which evi-
dence is available that they almost all could bind to each other: one
smaller distinct cluster (lower right corner) is formed by dUTPase-
like proteins, UDP-Glycosyltransferases, HAD like protein, Nudix,
and (Trans)glycosidases with nucleosides, nucleotides and singletons
with both structural and other evidence. A large cluster is visible in
the top right of the matrix with 6 compound and 7 protein groups.
Interestingly, this cluster also contains the chemical group of the hit
compound chrysin and the superfamily of TK (both marked in red
font). As for compounds, evidence for binding with the most target
superfamilies (17) is available for nucleosides, while the P-loop con-
taining nucleoside triphosphate hydrolases are known to bind most
(12) of the chemical classes from the set.
6.4 discussion
Interactions in PDB
frequent complexes With interaction data on more than 93,000
biologically relevant small-molecule complexes, it is the first time that
such a large representative dataset was analyzed for interaction pref-
erences. The distribution of cluster sizes from complexes of unique
ligands and protein families (Figure 15) follows a straight line a the
log-log plot and therefore probably adheres to a power law: while
there are many singleton clusters, only a few larger clusters appear.
It is intuitive that complexes with heme are the most frequent since
this ligand is present in nearly 4000 PDB entries, which corresponds
to > 3% of all deposited structures. Although BioLiP was used for fil-
tering, many clusters with ligands like sulfate or phosphate remain. It
is important to note that these remaining ligands are no artifacts, but
specifically binding ligands. The most frequent proteins such as pro-
tein kinase domain or trypsin are well studies and therefore overrep-
resented. The clustering reduced this bias, while still leaving many
clusters with the same protein and different ligands, e.g. inhibitors.
binding preferences As expected, ligands make more contacts
with increased weight due to a higher amount of functional atoms.
The number of 11 contacts for a typical small molecule results in com-
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plicated three-dimensional patterns: consider again Figure 18 show-
ing the BVDU subpatterns, which comprise just 7 contacts. This im-
plies that for large-scale comparisons as done with 3D interaction pro-
filing in this work, the observed complex patterns need to be encoded
into a simpler representation (e.g. the 10-bit fingerprint with BVDU
features). While the given number of contacts for a typical small mo-
lecule gives a good estimate due to the large non-redundant dataset,
it is possibly a slight overestimation resulting from the cluster repres-
entatives, which were selected as those complexes with most contacts
to the protein.
Figure 24: Example complex with an extreme usage of backbone hydrogen
bonds. Shown is CySG, a methyltransferase, in complex with
NAD cofactor (1PJS:NAD:A:502). The complex uses only back-
bone hydrogen bonds for binding and uses many amino acids
which otherwise can not form hydrogen bonds with their side-
chain (marked in red).
The distribution of interaction types among all contacts (Figure 17)
shows that while hydrogen bonds are predominant, small molecules
bind with a diverse set of interactions: one remarkable observation
is that water bridges rank third, although there are often neglected
in analysis of structural complexes. Halogen bonds occur only rarely
since halogen atoms are usually artificially introduced into ligands,
e.g. drug candidates and remain in most cases completely unused in
complexes with proteins (see section 6.2). Since the statistics demon-
strate that even hydrogen bond donors and acceptors are not always
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paired, interaction pattern analysis has an advantage over pharmaco-
phores since such binding preferences are considered.
In the nrPSM set, hydrogen bonds to the protein backbone consti-
tute almost 50 % of total H-bonds and therefore more than 20 % of
all contacts. This finding is highly relevant for the analysis of bin-
ding from structural complexes: as already considered in the PLIP
algorithm, contacts need to be analyzed on atom, not an residue level.
Opposed to this result, many previous methods focused on side chain
properties. In comparison to another study, the determined number
for backbone hydrogen bonds is on the high side: Gallina, Bork and
Bordo [82] report a fraction of 25 %. It has to be noted, however, that
the current study considers almost a magnitude more (9998) unique
ligands. Figure 24 shows an extreme example of backbone H-Bond
usage from the analyzed set: in a complex (1PJS:NAD:A:502) with a
methyltransferase, NAD binds exclusively with such backbone bonds.
Most interestingly, this involves amino acids which can not form this
type of contact with their sidechain (marked in red: valine, alanine,
glycine, leucine, and phenylalanine6, which form 7 of the 10 observed
bonds).
The presented results demonstrate the potential of PLIP data for
general characterization of binding preferences and reveal that pre-
viously underestimated factors such as backbone hydrogen bonding
are major factors in molecular recognition of small molecules.
Virtual Screening with 3D Interaction Profiling
pattern similarity links chrysin to herpes and cancer
Chrysin as the top-scoring compound was experimentally confirmed
to inhibit Hsp27 chaperone function and reduce chemoresistance in
multiple myeloma cells (see subsection 6.3.2). Here, the question arises
whether the result can explain the anti-herpetic and anti-tumor activ-
ities reported in many studies.
Chrysin (5,7-dihydroxyflavone) belongs to the flavone subgroup of
flavonoids [295]. Found in all plants as secondary metabolites [271],
they play an important role in development, reproduction, and growth
[271]. One of the best-studied members is quercetin which has been
a research focus for some time due to its proposed activity in mul-
tiple conditions, including inflammation and obesity [5]. Both quer-
cetin and chrysin contain a catechol group, which has been previ-
ously identified as an indicator for possible promiscuous binding
behaviour [12].
Chrysin is especially concentrated in various members of the Pas-
siflora genus [61], the oyster mushroom Pleurotus ostreatus [4], and in
honeycomb [75]. As the inhibitory effect of flavones on human aro-
6 Phenylalanine can form so-called aromatic hydrogen bonds, but not the usual
type
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matases is well documented [128], chrysin is widely used as a die-
tary supplement for athletes, hoping to reduce estrogen levels [167]7.
Additionally, numerous studies have linked chrysin to anti-allergic,
antiviral, and anti-inflammatory effects [126].
Some types of honey, such as the New Zealand manuka [275], can
contain very high flavonoid concentrations, up to 1.16 mg/100 g with
chrysin as one of the principal components [39]. Antiviral activity of
extracts as well as isolated chrysin was demonstrated against Herpes
simplex virus [162, 227, 143], Varicella zoster [112], and human Enter-
ovirus 71 [272] without any noticeable cytotoxic effects.
Beneficial effects of chrysin and a number of derivates have been
shown in several cancer cell lines [126], including HeLa cells [297],
human colorectal cancer cells [213], and lung cancer metastatic colon-
ies [153]. The mechanism is not yet fully established here and many
potential targets have been proposed [213], e.g. induction of apop-
tosis [297, 247, 220, 213]. Other studies hint at a role for chrysin in
the inhibition of hypoxia-inducible factor-1α, a critical protein for an-
giogenesis in prostate cancer [80]. Micromolar concentrations were
required to elicit significant effects on cell viability [220], induction
of apoptosis [247], or inhibition of interaction between Hsp90 and
HIF-1alpha in cells [80]. A more detailed discussion on the roles of
flavonoids and chrysin in cancer is available by Kasala et al. [126].
BVDU can effectively target both Hsp27 and viral thymidine kinase
due a remarkable similarity of residue placement in the binding sites
of the proteins as shown by Heinrich et al. [99]. Given this connec-
tion between both targets and the rich evidence from literature on
the dual activity of chrysin against cancer cell lines and Herpes virus,
the results in this study provide further evidence to explain the mech-
anism of chrysin in both scenarios. Firstly, the poses and interaction
patterns observed in the top-scoring complexes from docking to TK
and Hsp27 show the same key interactions as found in the crystal
structure of glycogen phosphorylase with BVDU. Secondly, inhibition
of Hsp27 chaperone activity was demonstrated experimentally. Given
the weight of evidence for binding of chrysin to Hsp27, a binding to
TK is also likely. Finally, the targeting of Hsp27 by chrysin agrees well
with activities reported in the literature: many of the studies cited
above connect chrysin with induction of apopotosis and it is pro-
posed that Hsp27 protects cancer cell against apoptosis by interact-
ing with pro-apoptotic proteins such as STAT3 or CASP3 and Hsp27
inhibition leads to a reinduction of apoptosis in cells [100]. The anti-
herpetic activity of chrysin can also be explained by its binding to the
thymidine kinases of viruses, such as H. simplex and V. zoster. How-
ever, a broader anti-viral activity is not obvious as Enterovirae lack
thymidine kinase [73] and studies could not show inhibitory effects
of TK-targeting drugs, such as aciclovir. Thus, the reported effects of
7 with no clear evidence for an in vivo effect [215]
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chrysin on Enterovirus [272] cannot be explained by this mechanism
and require further investigation.
Conclusively, the combination of previous knowledge on binding
of the query drug BVDU to Hsp27 and TK with the similarity assess-
ment using 3D interaction profiling workflow can not only identify
new potential binders, but also offer an explanatory component on
the background of literature reports for the activity of chrysin in
Herpes infections and tumors. Given the experimental demonstration
of binding and blockage of chemoresistance, the uncovered relation-
ship between chrysin and Hsp27 therefore serves as a powerful tool to
explore and finally validate the workflow outside the in silico envir-
onment.
3d interaction profiling for drug repositioning As in-
troduced in chapter 4, structure-invariant fingerprints are the most
recent design in interaction fingerprinting. The definition of subpat-
terns for BVDU was also done in a quasi structure-invariant manner:
Only the base aromatic ring (subpattern A) is defined as an anchor
structure in the ligand, all other subpatterns are described in relation
to this ring using relative distances and angles. With encoding into
a 10-bit vector, which records the presence of features, and a basic
similarity measure8, the presented representation for 3D interaction
profiling is a very simple fingerprinting approach. The notion of pat-
terns here is exclusively focused on interaction patterns and not on
residue arrangement, which can be searched with specialized tools
recently published such as Fit3D [120] or Geomfinder [188].
The presented 3D profiling viewpoint improves upon ligand- and
target-focused methods by enabling both ligand and target hopping:
the search is not restricted to homologous proteins or chemically si-
milar ligands since no features need to be mapped onto residues or
ligand atoms. Usage of predicted contacts, not pharmacophoric fea-
tures, captures the essence of molecular recognition and is able to
describe not only potential interactions, but binding preferences. Fi-
nally, the simple feature comparison method helps to identify which
features have actually matched. As all fingerprinting approaches (see
chapter 4), the success of the presented method strongly depends on
choice of appropriate features and associated thresholds.
One example are the characteristic π stacking interactions between
BVDU and its host proteins, which have been previously identified as
key interactions [99]. However, this interaction type is fundamental
to many supramolecular organization and molecular recognition pro-
cesses, and is present more than a quarter of all PDB small-molecule
complexes (see above). On the other hand, more specific arrange-
ments such as double π-stacking sandwiches (patterns BCD) are present
8 where the number of non-zero elements in the target vector are counted, being
loosely equivalent to Jaccard similarity
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in just 0.5% of all PDB structures. This shows that combination of
patterns separate specific binding from a random background. For
this analysis, choosing a cutoff of at least 6 matching patterns makes
sense, as a lower cutoff yields many candidates with more remote in-
teraction pattern similarity, while a higher cutoff only identifies very
similar complexes, presumably with ligands from chemically similar
classes. Finally, chrysin, selected by 6 matches from the pattern space
of BVDU, was shown to inhibit Hsp27 more effectively than the known
TK and Hsp27 binder BVDU does.
limitations in explored compound and target space Re-
cently, Heinrich et al. [100] identified and validated a series of Hsp27
inhibitors with a structural approach by exploiting similarities between
binding sites9.
Between the candidate compound set from 3D interaction profil-
ing (58 compounds) and the Heinrich series (29 inhibitor candid-
ates), eight overlapping compounds were identified. As the majority
(5) of them are nucleobase-containing compounds, it demonstrates
that both approaches are effective in recovering compounds most si-
milar to the known inhibitor BVDU. The large number of different
predictions could result from the employed datasources: while Hein-
rich et al. relied on binding databases (BindingDB, DrugBank, TTD
in addition to PDB) to collect known binders of TK as a starting point,
the current study was restricted to structural complexes from PDB.
Although the availability of BVDU structural complexes was good
(N=14), it may be problematic for other compounds of interest: while
the PDB covers just around 21,000 distinct compounds, PubChem lists
currently more than 92 million (as of October 2016). The same is true
for targets, where the number of sequences available from the public
domain is 1,000 times higher compared to the structural space [64].
To overcome the limited availability of protein-ligand complexes
for analysis, high-throughput docking is one possible solution: large
libraries of up to 106 ligands [212] can be processed effectively using
specialized docking software [265]) to produce models of the complex [1].
These newly generated models of protein-ligand complexes can be
used for the screening workflow in the same way as crystal structures.
It has to be noted here that docking has already been successfully ap-
plied standalone on large compound libraries for target prediction
[212]. While docking can be used for any compound without addi-
tional information, it is error-prone due to its complex parameter
sets and inaccurate scoring functions [212]. When additional infor-
mation on molecules is available (as for BVDU), knowledge-based
approaches such as interaction pattern matching have the potential
to identify more interesting hits, especially when dealing with un-
usual binding modes, which can be easily missed by docking [212].
9 using the identical two-step experimental setup as used here
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In most cases, using interaction pattern matching to screen for similar
complexes will possibly lead to a higher precision than docking, but
lower recall due to the strictness of the rule-based approach.
To expand the target space, protein models can be generated. This
is still a grand challenge and even the best prediction algorithms cur-
rently available can build structures with sufficient quality for this
analysis only for only 10 % of the proteins in the Critical Assessment
of protein Structure Prediction (CASP) challenge [64].
While the virtual screening is completely automated, the manual
definition of a metapattern is still a bottleneck in the workflow presen-
ted. Structure-invariant interaction fingerprints are an alternative here,
enabling the automatic encoding of patterns for any given complex.
A proof-of-concept analysis with a novel design of such a fingerprint
is presented in chapter 8. For this more sophisticated type of finger-
prints, the definition of a metapattern can be achieved by combining
several feature vectors with logical operations.
Thus, several starting points for overcoming major limitations of
the method exist and can be readily integrated, such as in the case
of docked complexes, or can be explored with advanced encoding
designs, such as the new fingerprint concept presented in chapter 8.
more drug repositioning opportunities The interaction pat-
tern matching workflow yielded a candidate set of 58 complexes and
43 drugs which show interaction patterns with a high similarity to the
known Hsp27 binder BVDU. This pattern similarity within the com-
plexes of the set leads to the hypothesis that many of the drugs might
be able to bind to one or several targets within the set. And indeed, as
the matrix in Figure 23 shows, there is already evidence of binding for
approx. 28 % of all possible drug-target combinations. This confirms
that the workflow presented herein can recover known relationships,
linked by their interaction pattern similarity. It has to be noted, how-
ever, that only 41 relations give high-confidence evidence as they stem
from crystal structures (Figure 23, green rectangles). The 81 other rela-
tions come from ChEMBL and STITCH which use data from binding
assays, text mining, and biological pathways. No activity or certainty
cutoff was used for both sources so they provide broader, but also
lower confidence on binding (Figure 23, orange rectangles) in con-
trast to the structural evidence (green rectangles).
The majority of drug-target relations from the candidate set (315
of 437, i.e. 72.1 %) has no evidence of binding (Figure 23, blank
fields). However, their shared interaction patterns make it likely that
they might be able to form a complex. While it is unrealistic to as-
sume that this is true for all unconfirmed relations, there are some
for which binding is more likely. Consider again the matrix in Fig-
ure 23: as the items on the axes are clustered by number of shared
targets (for the ligands) and shared ligands (for the targets), distinct
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clusters form where the majority of compounds is known to bind to
many of the targets in the cluster (Figure 23, marked with boxes at
the top right and bottom right corners). Combinations within these
clusters without evidence (blank fields) would be priority drug-target
combinations to test for binding. Two examples are nucleosides and
(trans)glycosidases (lower cluster) or pyrans (including chrysin) and
inosine monophosphate dehydrogenases (upper cluster). However,
further steps are necessary to investigate those relations: one possible
approach would be to perform docking simulations before experi-
mental validation to confirm these repositioning opportunities.
A last thing that the matrix shows it that the resulting candidate
set is diverse regarding its targets. As already discussed, the inter-
action pattern matching method yielded compounds with similar
interaction patterns from diverse chemical classes (ligand hopping).
The 23 target classes contain only few kinases, with a total of just 6
members of the superfamilies being kinases: deoxynucleoside kinase,
uridine-cytidine kinase 2, deoxycytidine kinase, HPPK, folic acid syn-
thesis protein (FOL1) and DNA polymerase. Considering that the
entry point of the workflow were TK complexes with BVDU, the low
amount of kinases and the broad target space, including different en-
zymes, demonstrates the target hopping ability of the method.
conclusion With the currently largest dataset on small-molecule
complexes from the PDB generated with PLIP, new general insight
on binding behaviour of small ligands were gained, including the
importance of backbone hydrogen bonding. Finally, 3D interaction
profiling was presented as a knowledge-based screening workflow
based on key interaction of a known binder to the cancer target Hsp27.
Screening a large data set of 170,219 protein-ligand complexes for
similar interaction patterns to BDVU yielded a set of just 248 com-
plexes (see Figure 14), which corresponds to 0.15 % of the screening
set size. As a result from the analysis, the natural product chrysin was
predicted as heat shock protein inhibitor and was indeed validated in
two independent assays as an inhibitor of Hsp27 function and blocker
of chemoresistance in myeloma cell lines. This finding demonstrates
the power of the presented workflow and, more general, the potential
of molecular interaction data.
7
B E Y O N D C A N C E R : M O R E A P P L I C AT I O N S W I T H
P L I P D ATA
This chapter contains material from the publications PLIP: fully
automated protein-ligand interaction profiler by Salentin et al.
[218] published 2015 in Nucleic Acids Research [218], Computational
Drug Repositioning by Target Hopping : A Use Case in Chagas
Disease Drug Repositioning by Target Hopping by Haupt et al.
[98] published 2016 in Current Pharmaceutical Design [98], and
Binding Mode Characterization of Class II Aminoacyl tRNA
Synthetases by Kaiser et al. [121] published 2016 in Proceedings of
GCB [121]. For detailed information on author contributions see the
publication list on page v
As demonstrated in chapter 6, interaction data derived with PLIP
can enable reliable screening for similar binding patterns. Going be-
yond virtual screening, this chapter shows more applications with
PLIP data, starting with evaluation of drug repositioning candidates
for Chagas disease (section 7.2): this disease caused by the protozoan
parasite Trypanosoma cruzi affects about 6 million people worldwide
[277]. The only approved anti-trypanosomal drugs (nifurtimox and
benznidazole) were developed empirically, without knowing the ex-
act mechanism of action [51, 266]. Both have limited efficiency [277]
and show severe side-effects that can compromise the treatment [20].
Thus, finding new drugs for treating Chagas disease is vital and drug
repositioning can be a valuable option [20, 21, 98].
Further applications are the analysis of binding modes in aaRS (sec-
tion 7.3), postprocessing of docking poses with PLIP (section 7.4), and
identification of key interactions for inhibitor design (section 7.5).
7.1 materials and methods
For the minor examples (docking in section 7.4 and inhibitor design
in section 7.5), description of methodology is given directly in the
corresponding sections.
Repositioning for Chagas disease
The PDB was screened with ProBiS [134] for targets and binding sites
similar to those of the known binder risedronate in the T. cruzi drug
81
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target farnesyl pyrophosphate synthase (FPPS). Results with insigni-
ficant ProBiS Z-scores were rescored using LigandRMSD [96], which
evaluates how well ligands are spatially matched in a structural bin-
ding site alignment. PLIP was then used for manual inspection to val-
idate the hypothesis generated with LigandRMSD.
Binding Mode Analysis
aars structure preparation As an initial dataset, 381 aaRS
structures were selected from the PDB using Pfam annotations. To
facilitate automatic annotation of conserved and specifically interact-
ing residues, all derived protein sequences were aligned using the
T-Coffee expresso pipeline by Notredame, Higgins and Heringa [187]
to yield a structure-guided multiple sequence alignment (MSA). Ori-
ginal PDB structures were renumbered according to the MSA with
MSA_PDB_renumber by Joachim Haupt1. With a now consistent residue
numbering, interaction patterns from the ensemble were detected and
compared with PLIP and interesting structural patterns later analyzed
with Fit3D [120].
binding mode matrix visualization Internally, interaction
data from multiple complexes (observations) is projected into a 3D
feature space created by the renumbered protein residues, interaction
types, and the enumerated observations. For each of these point, a
count of contacts is recorded and visualized in 2D space using layered
plotting and color coding: residues are plotted on the abscissa and ob-
servations on the ordinate. Contacts for each residue and observation
are shown as circles colored according to the interaction type and
sized linearly with the count number. Different points on the same
coordinates but of different types are scattered with a fixed offset to
avoid overplotting. Only data for residues with at least one contact in
one observation are shown to avoid sparsity.
testing for significant associations An automatic stat-
istical test routine is included in the module to determine which
residues are significantly positively or negatively associated with a
pre-defined group (e.g. a protein family, ligand scaffold, organism,
etc.). To perform the test, the interaction counts are aggregated and
complexes from one group are compared against the remaining ones
(as represented in a 2x2 contingency table in Table 6).
The Fisher exact test [214]2 is applied to the fourfold table (Table 6)
with counts of contacts (xA,1 and xR,1) and non-contacts (xA,2 and
xR,2) in the test group A versus all remaining groups R. For each of
the comparison, the test returns a p-value and an odds ratio to indic-
1 available at github.com/vjhaupt/MSA_PDB_renumber
2 provided by the scipy.stats module v0.13.03
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Table 6: Fourfold table (2x2 contingency table) for test group and control
groups in association test.
Group A Remaining
Contacts xA,1 xR,1
No Contacts xA,2 xR,2
ate a positive (> 1) or negative association. Significant association at
a chosen p-value in the matrix are visualized with a blue (positive
association) or red background (negative association).
7.2 repositioning drugs for chagas disease
similar binding sites From literature research, FPPS was iden-
tified as a relevant target for Chagas disease. Being a key player in
the mevalonate pathway, it is vital to the biosynthesis of isopren-
oids, including cholesterol, vitamin K, and steroid hormones [104].
The known inhibitor alendronate (AHD, see Figure 25B) acts as an
analogue the natural substrates of FPPS, leading to an inhibition of
isoprenoid biosynthesis.
From the binding site screening, one promising candidate target
is phosphonoacetate hydrolase (PhnAH) from Sinorhizobium meliloti
(3T01), which binds the anti-viral drug foscarnet (PPF) (Figure 25A).
In this case, re-scoring the binding site alignment from ProBiS with an
insignificant Z-Score of 0.71 with LigandRMSD yielded a significant
LigandRMSD of 0.64.
PhnAH is a phosphodiesterase that uses phosphonoacetate as a sub-
strate and catalyzes the conversion into acetate and phosphate. It
belongs to another family than the polyprenyl synthetase FPPS and
shows neither sequence (9 % sequence identity) nor structural simil-
arity (TM-score of 0.27, where scores ⩽0.17 are considered random).
Despite the absence of any global similarity, the binding sites align
well and so do the ligands in the binding sites with a LigandRMSD
of 0.64.
analysis of interactions An interaction analysis of the aligned
complexes with PLIP as illustrated in Figure 26 reveals similarities
and differences between functional amino acids: some residues are
well aligned and fulfill the same function, such as Arg107 (FPPS) and
His377 (PhnAH), or the water molecule adjacent to Asp254 (FPPS) and
Thr68 (PhnAH). All of them are involved in direct or water-bridged
hydrogen bonding. Asp89 (FPPS) and Asp211 (PhnAH) are spatially
close in the alignment and both coordinate a metal ion, although to
a different species: magnesium (brown) in FPPS and zinc (pink) in
PhnAH (see Figure 26B). Most interestingly, also Asp250 (FPPS) and
Asn89 (PhnAH) are well aligned, but fulfill different functions, namely
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hydrogen bonding in the former and metal coordination in the lat-
ter protein. In this case, spatial proximity in the alignment does not
relate to identical function.
The other residues are not paired in the alignment and form either
hydrogen bonds and water bridges (Tyr211, Gln247, Lys207, Ser104 in
FPPS and Asn69 in PhnAH) or help to coordinate one of the metal ions
(Asp102 in FPPS and His215 in PhnAH). Overall, the interaction pat-
terns resemble each other regarding their compositions of interaction
types and show a high similarity, given that different combinations of
substrates and ions (foscarnet and Zn, alendronate and Mg) are com-
pared. Consequently, foscarnet is predicted to bind to T. cruzi FPPS
and thus presents a promising candidate for experimental testing.
Figure 26: Structural binding site alignment between PhnAH (green) with fo-
scarnet (white) and FPPS (blue) with alendronate (black). Interac-
tions with hydrogen bonds and water bridges (A) are visualized
separately from metal coordination (B). In panel B, zinc is visual-
ized as pink and magnesium as brown spheres.
7.3 binding mode analysis in aars proteins
conserved binding motifs Preparation and renumbering was
successful for 152 aaRS class II structures. Following, the modus op-
erandi of this protein class was investigated in an integrated workflow
with PLIP and Fit3D [120] (see Figure 27). Despite of substantial di-
versity on the global sequential and structural level, an outstanding
binding motif was identified with interaction data: an orthogonally
oriented pair of structurally conserved arginine residues which fixate
adenine, coined arginine tweezers. PLIP analysis reveals that bin-
ding is mainly mediated by π-cation interactions and hydrogen bonds
to adenine by the lower tweezers tip as well as hydrogen bonds and
salt bridges to the phosphate group and the carboxylic acid of the
incorporated amino acid by the upper tip. Previously, it was shown
that both arginines of the tweezers are of utter importance for the
function of asparagine tRNA synthetase and that mutations of these
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residues will likely result in a loss of function for any other aaRS as
well [37].
The set of successfully mapped structures was partitioned into five
different modes (M1-M5) which can be distinguished by the incorpor-
ated ligands (Figure 27b): in M1, the amino acid is covalently bound
to adenosine phosphate, whereas this linking is not yet present in
M2. M3 and M4 contain just adenosine phosphate or the amino acid,
while M5 corresponds to structures with an empty binding site. For
all these groups, the distance between Cα carbon atoms of both ar-
ginines and their angle θ were measured: an average distance of
14.8 A on average, independent of presence of adenosine shows that
the particular fold region is very stable. Distributions of the angles
between modes M1-M3 and M4-M5 show a significant difference
(Mann-Whitney U test with p = 8.1× 10−5), confirming a tweezers
like behaviour of the arginines with opening and closing depending
on presence of the ligand.
Finally, PLIP interaction data from the whole PDB was screened for
pairs of arginines interacting with a phosphate group by salt bridges.
It shows that only the closed arginine tweezers conformation is in
agreement with the background distribution of 264,312 salt bridge
geometries (data not shown) while the unbound state does not re-
semble any known geometry. This shows the relevance of the tweez-
ers motion for functional binding.
binding mode discrimination Next to conserved binding mo-
tifs, specific interaction patterns used to discriminate different amino
acid ligands in aaRS can be analyzed with PLIP as well.
Figure 28 shows the resulting binding mode matrix (see section 7.1)
for class II aaRS: for each aaRS-ligand complex (ordinate) and binding
site residue (abscissa), a circle indicates the presence of a contact. Ho-
rizontal solid lines separate different amino acid ligands. The large
overview figure in Figure 28A provides information on conserved
and specific patterns and indicates significant over- or underusage
of one residue for binding a specific amino acid with blue or red
circles. Considering a small section of the plot (Figure 28B) helps
to understand key differences in binding behaviour: Alanine (top) is
recognized via hydrophobic contacts (grey) from residue 1682 and
water bridges (pale blue) from residue 1782. For both asparagine
and aspartate, residue 1684 plays a role, but using hydrogen bonds
(dark blue) in the former and salt bridges (yellow) in the latter case.
Other contacts are non-specific and generally important for binding.
This includes the arginine tweezers, represented by their lower tip on
residue 1771 with mainly π-cation interactions and hydrogen bonds.
Other examples are multiple H-Bond forming residues (1677, 1680, or
1768). Conclusively, data from PLIP in this analysis enables to identify
both structurally conserved binding motifs (arginine tweezers) as well
7.3 binding mode analysis in aars proteins 87
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Figure 28: Exemplary binding mode matrix for class 2 aaRS. For each com-
plex and residue from a multiple sequence alignment, presence
of a contact is indicated with a circle color-coded by interaction
type. While the large matrix (A) gives an overview on binding be-
haviour and shows significantly over- or underused residues (red
and blue boxes), the zoomed view provides insight on specific
interactions for each bound amino acid ligand (B).
as enables to find more conserved and specificity-conferring residues
via the binding modes analysis.
7.4 improving docking with postprocessing
In drug discovery, docking is one of the key tools to predict binding of
compounds [67, 133]. Since the reliance on energy scores can lead to
false positive results among top-scoring poses, knowledge-based ap-
proaches can be used to postprocess docking results [293]. In the fol-
lowing example, knowledge on known key interactions was used to
evaluate data from a redocking experiment of a small-molecule inhib-
itor to Cathepsin K (1VSN) using the SwissDock server3: while the top
prediction corresponds to the crystal structure pose, the one ranked
second shows a clearly different ligand conformation, but compar-
able SwissDock fitness score. PLIP was used to analyze the interaction
patterns in the complex from the crystal structure (Figure 29A) and
the complex with the alternative pose (Figure 29B) from docking.
3 swissdock.ch
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A
B
Protein Ligand H-Bond Water Bridge Hydrophobic ContactHalogen BondWater
Gln19
Figure 29: Evaluating docking results with PLIP. Natural (A) and alternat-
ive pose from redocking (B) of Cathepsin K with a small mo-
lecule inhibitor (1VSN). Shared interacting residues are labeled.
The second pose lacks characteristic halogen bonds.
For the crystal pose, a rich network of hydrogen bonds and water
bridges can only be observed (Figure 29A). In the alternative pose, the
ligand part containing the aromatic rings is flipped to the opposite
direction. Most strikingly, however, the characteristic halogen bonds
are completely missing, leaving the trifluoride group exposed. This
example shows that it is possible with a knowledge-based interaction
pattern postprocessing to reliably identify false positives poses (as
also shown in other studies [57, 59, 165, 176, 238]).
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7.5 key interactions in inhibitor design
In initial stages of inhibitor design, insights on molecular recognition
are vital for optimization of lead compounds. Here, PLIP is used to
analyze interactions in three complexes of different inhibitors (PDB:
1EIE, 1Z89, 3P2V) with aldose reductase (Figure 30).
This protein binds ligands via induced fit, leading to drastic con-
formational changes around the binding pocket [132]. The three con-
sidered inhibitors show shared key interactions but also individual
subpatterns: while both zenarastat (Figure 30A) and the benzothiazepine
inhibitor (Figure 30C) form a salt bridge to His110 and a hydrogen
bond to Trp111 via their carboxyl groups, the interaction pattern
of the sulfonyl-pyridazone inhibitor (Figure 30B) lacks this interac-
tion. Without the carboxyl group only one hydrogen bond to Tyr48
is formed. This interaction can also be observed in complex with
the benzothiazepine inhibitor. Although all inhibitors have aromatic
rings, only two of them form π-stacking interactions with Trp111. One
of the most unique interaction patterns can be seen in the complex
with zenarestat, where halogen bonds to the protein backbone are
formed from both ends of the inhibitor.
With this simple analysis using PLIP data, key and specific interac-
tions in an ensemble of inhibitors were rapidly identified. This know-
ledge can be extremely valuable for subsequent analyses, including
docking (see above) or chemical optimization of these compounds to
yield better inhibitors.
7.6 discussion
evaluation of binding site similarity In the presented Chagas
example (see section 7.2), PLIP was used in a combination with a bin-
ding site alignment method (ProBiS), and a rescoring algorithm (Lig-
andRMSD). Together with these approaches, PLIP enabled to identify
similarities in binding behaviour which were not apparent with the
alignment data alone: although spatial pairing of amino acids can
be assessed, only interaction data can explain residue functions and
elucidate binding of ion cofactors. Thus, PLIP data offers an explanat-
ory component here and identifies promising repositioning examples.
Together with the other methods, it yields a sensitive pipeline for scor-
ing local binding site similarity of unrelated targets.
repositioning of foscarnet The analysis on similar targets
to relevant targets in Chagas disease yields an example of target hop-
ping (see Figure 4): starting from risedronate, a confirmed binder to
T. cruzi FPPS, it can be postulated that the anti-viral drug and known
PhnAH binder also binds to the unrelated T. cruzi target. Hence, the
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antiviral foscarnet may modulate one of the main drug targets for
Chagas disease and is a top candidate to be tested in lab experiments.
binding mode analysis In the presented study on binding mode
analysis of aaRS class II structures, an ensemble of related proteins
with different ligands (here: amino acids) was characterized. For an
analysis of binding of one ligand to different proteins (e.g. recogni-
tion modes for ATP in the PDB), the MSA would be the limiting factor
since interactions are mapped to residues.
Other more recent studies present comprehensive analyses on bin-
ding modes in PDB complexes with graph-based approaches [222,
124]. One of them is GReMLIN by Santana et al. [222], which rep-
resents protein-ligand contacts as a bipartite graph. For the binding
mode analysis, frequent connected components (key patterns) from
these graphs are extracted and clustered [222].
While not possible with the presented workflow used in the aaRS
study, the advanced PLIP fingerprinting approach as presented in (see
chapter 8) yields structure-invariant representations of binding pat-
terns. These fingerprints can be used for clustering analyses without
further preparation, enabling proteome-wide binding mode analyses
as shown by the cited study.
aars shed light on molecular evolution aaRS are a key
component to elucidate the origins of genetic information and the
association of triplet codons to particular amino acids: each type of
aaRS protein specifically joins one tRNA molecule with a matching an-
ticodon to the corresponding amino acid. Although almost 400 struc-
tures of aaRS are available in PDB, previous studies have focused on
small subsets or single structures. The exemplary result from the on-
going study large-scale analysis of binding behaviour in aaRS can thus
help to gain a high-level view on conserved or specific interactions
and may help to shed light on some aspects of molecular evolution.
conclusion In this chapter, PLIP data was shown to be applic-
able in diverse areas: evaluation of binding site alignments (Chagas
study, see section 7.2), binding modes analysis (section 7.3), docking
postprocessing and identification of key interactions for lead optim-
ization. In all cases, interaction data helps to rapidly identify vital
residues and patterns for binding and focuses the analyses on im-
portant aspects for molecular recognition.
8
T O WA R D S A U T O M AT E D S C R E E N I N G O F T H E
P R O T E O M E
The 3D interaction profiling workflow (see chapter 6) has success-
fully predicted and validated a new inhibitor for the cancer target
Hsp27. For this approach, however, a manual definition of patterns
is needed. The PLIP Fusion Fingerprint presented in this chapter
aims to overcome this limitation by automatically encoding observed
patterns. Furthermore, its structure-invariant design allows to screen
interactions in the structural proteome to unravel hidden similarities
between unrelated targets and ligands. As a proof-of-concept ana-
lysis, the new fingerprint will be benchmarked against the state-of-
the-art design (section 8.2) and finally, advantages and limitations
discussed on a rescreening for BVDU patterns in section 8.3.
8.1 materials and methods
As already discussed in chapter 4, interaction fingerprinting requires
an algorithm for encoding of 3D patterns into features vectors and an
appropriate measure to compare the fingerprints. The PLIP Fusion
Fingerprint presented in this thesis was designed to encode interac-
tions in a structure-invariant manner, while providing a large para-
meter set for optimization (see section 8.1). Next to simple pairwise
X
1  0  1  0  1  3  0  2  0
comparison, an approximate nearest neighbor (ANN) search was im-
plemented to enable efficient screening in the structural proteome.
Fingerprint Design
Each bin in the PLIP Fusion Fingerprint corresponds to an observed
combination of features in the 3-dimensional interaction patterns from
the complex (Figure 31A). The smallest elements being encoded are
pairs of interactions which can be represented as two vectors in 3D
space (see Figure 31B). Each pair is characterized by the combination
of interaction types as well as the binned distance and angle between
the vectors (Figure 31B). In the fingerprint, each bin corresponds to
such a unique combination and counts the occurrence of the pattern
in the original complex. For a complex with n observed interactions,
n·(n−1)
2 pairings need to be encoded.
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Figure 31: Schematic for the PLIP Fusion Fingerprint. Raw interaction data
from PLIP is calculated for a complex (A). Molecular structures
are discarded. For each pair of interaction vectors, their distances
and angles are calculated (B). Finally, the geometric measures
are binned and combined with the types of the pairing into a
string representation (A). Each such combination corresponds to
a bin in the fingerprint, which is incremented for each observa-
tion of the encoded pairing. The resulting fingerprint is structure-
invariant since it only considers the interaction vectors.
features For the fingerprint, 10 interaction types t1 to t10 are en-
coded, corresponding to unmodified, pooled or split types from PLIP:
unmodified interactions comprise undirected interactions (t1: hydro-
phobic contacts and t2: π-stacking) and contacts observable only in
one direction (t3: metal coordination and t4: halogen bonds). All
other interaction types are split by directionality: hydrogen bonds
with protein (t5) or ligand (t6) as donor, salt bridges with a negative
charge in the protein (t7) or in the ligand (t8), and π-cation inter-
actions with the aromatic ring provided by the protein (t9) or the
ligand (t10). To account for replacement of hydrogen bonds by wa-
ter molecules, water bridges are pooled with hydrogen bonds of the
same directionality (t5 or t6). As for the fingerprint pairs of interac-
tions with the types T = {tn | 1 ⩽ n ⩽ 10} are considered, the space of
pairwise combinations I is defined as the set of all 2-element subsets
of T with I =
(
T
2
)
.
Observed angles between interaction vectors1 are binned to ensure
discrete values and reduce the number of possible features. With pos-
1 To measure the angles, all vectors are defined to have a directionality from the ligand
to the protein
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sible angle values aobserved = (0, 180], the set A of angle range is
defined as shown in Equation 2 where ba is a parameter for the bin-
ning size.
A =
{(
180 · n
ba
, 180 · n+ 1
ba
]
| 0 ⩽ n < ba,ba ∈ N+
}
(2)
The set of distance ranges is constructed in a similar manner. The-
oretically, the observed distances dobserved are open-ended, but are
capped for binning at a reasonable threshold dmax as shown in Equa-
tion 3 where bd determines the binning size.
D = {(bd ·n,bd · (n+ 1)] | n < bd,n ∈ N+}∪ {(dmax,∞]} (3)
encoding The complete feature space in the fingerprint is the
Cartesian product of the sets of pairings of interactions I, angle A
and distance ranges D (Equation 4).
I×A×D = {(i,a,d) | i ∈ I,a ∈ A,d ∈ D} (4)
The cardinality of the product defines the number of bins nbin =
| I×D×A |, which are enumerated with an index 1 ⩽ x ⩽ nbin. Each
bin fx in the final fingerprint F =
(
f1 f2 . . . fnbin
)
corresponds
to the feature combination with the same index x.
The fingerprint is initialized with zeros in all bins. Following, for
each feature x combination observed in a complex, a value of 1 is
added to the corresponding bin fx in the fingerprint.
Similarity Scoring and Search
pairwise similarity Interaction fingerprints can be compared
using standard similarity and distance measures (see also section 4.2).
The PLIP Fusion Fingerprint was benchmarked with cosine similarity,
Jaccard-Needham dissimilarity, and Rogers-Tanimoto dissimilarity.
approximate nearest neighbor search An ANN search was
set up to enable fast retrieval of most similar complexes. Spotify
Approximate Nearest Neighbors Oh Yeah (Annoy) v1.8.0 from PyPI2
was used to build the database index and provide core functions. A
database for the nrPSM was set up and a mapping with fast lookup
implemented in a Unix dbm[185] database3.
2 pypi.python.org/pypi/annoy/1.8.0
3 dbm uses a prefix tree for indexing to provide fast and extensible hashing.
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background distribution To provide an estimation on score
frequencies with p-values, similarities were calculated for the com-
plete nrPSM set as a background distribution. Each item from this set
was compared against all other items of the set and the resulting dis-
tribution discretized with bin sizes of 0.001 . For each score threshold
S, it was recorded how often a score ⩾ S was observed in the dataset,
generating a cumulative distribution. Division by the total number of
comparisons yields a p-value distribution: it indicates how probable
it is by random to yield a hit with or above a similarity score S.
Fingerprint Validation Set
To benchmark the new design against the state-of-the-art structure-
invariant interaction fingerprint by Desaphy et al. [59], the original
benchmark set 1 from the associated publication [59] was used (from
hereon referred to as benchmark set). It contains equally-sized sets of
each 900 similar and dissimilar protein-ligand complexes each. An-
notation files for the sc-PDB 2011 dataset used in the study[59] as
well as the list of similar and dissimilar binding sites were kindly
provided by the authors and the set reconstructed according to their
instructions: first, all 2,780 PDB files from the binding site list were
collected (2016/12/18) and ligand binding sites selected according
to the annotation file. Interactions in the complexes were analyzed
with PLIP, using the peptide mode (-peptide <chain>) for all peptide
ligands (see Table 16 in Appendix B). Modified residues were kept
in all complexes (option -keepmod) Due to ligand renaming in PDB
structures, some entries needed manual correction (see Table 15 in
Appendix B).
Screening Set
For the rescreening of BVDU complexes, the smaller non-redundant
protein-small-molecule (nrPSM) dataset (see section 6.1) was chosen.
An ANN dataset was built as described above with k=10 trees.
8.2 fingerprint optimization and benchmarking
performance The PLIP Fusion Fingerprint was tested on the De-
saphy benchmark set with a parameter space of 8,400 combinations.
For each test run, the ability to discriminate between the similar and
dissimilar complexes in the set was measured with the area under
the ROC curve (AUROC) and the F-measure, which considers preci-
sion and recall equally. The latter measure was chosen to rank the
parameter configurations. The best design showed a AUROC of 0.942
and a F-measure of 0.877 (ROC curve shown in Figure 32).
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Table 7: Performance of the PLIP Fusion Fingerprint on the Desaphy bench-
mark set in comparison to the author’s original design. The new
PLIP fingerprint performs better (AUROC and F-measure) com-
pared to the TIFP fingerprint and shows comparable performance
to the graph-based (Grim) and shape-based (IShape) approaches by
Desaphy et al. [59].
Design AUROC F-measure
Grim[59] 0.959 0.909
IShape[59] 0.954 0.892
PLIP Fusion 0.942 0.877
TIFP[59] 0.908 0.830
Figure 32: ROC characteristics for discrimination performance of the PLIP
Fusion Fingerprint on the Desaphy benchmark set (N=1,800).
Compared to state-of-the-art TIFP fingerprint by Desaphy et al.
[59], the PLIP Fusion Fingerprint shows superior performance in both
AUROC and F-measure (see Table 7). It even comes close to the graph-
and shape-based approaches Grim and IShape, which also use inter-
action data, but are much more expensive.
design The design (parameter set) with the best performance is
an integer fingerprint which has 5 distance bins with bin sizes bd of
2 A and 3 angle bins (i.e. with binning sizes ba of 60 °each). Addition-
ally, the distance calculation between lower tips of the vector (near to
the ligand) yielded better results than using the mid-distance. This
parameter set yields a fingerprint length of 825 bins. The best result
was obtained with cosine similarity as a measure for comparison.
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thresholds Figure 33 shows the distribution of similarity scores
for all 1,800 pairs in the benchmark set, color-coded by similar (blue)
and dissimilar (red) complexes. With the given distributions, a threshold
of 0.47 was determined as optimal for discrimination between si-
milar and dissimilar complexes. This value is indicated by an or-
ange dashed line, located at the meeting point of the two curves.
100 % precision regarding the positive class (similar complexes) can
be achieved by choosing a threshold of 0.85 or higher, indicated by
the red dashed line.
Figure 33: Score distribution of PLIP Fusion Fingerprint on the Desaphy
benchmark set for dissimilar (red) and similar complexes (blue).
The orange dashed line indicates the best balanced similarity
threshold for discrimination (0.47) and the red line the threshold
for 100 % precision (0.85).
8.3 automated screening
To calculate the background distribution for the nrPSM set, > 500 mil-
lion comparisons were performed (32, 0812). The p-values for each
pairwise similarity value in the nrPSM dataset is shown in Figure 34.
If a significance level of p = 0.05 is chosen (denoted with orange
dashed lines in Figure 34), hits with a fingerprint similarity of 0.54 or
more are relevant. Scores with a similarity value of 0.47 or better (op-
timal discrimination threshold from the benchmark) have a chance of
8.1 % to be observed at random. For the best cutoff at 100 % precision
(0.85), the probability decreases to just 0.2 %.
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Figure 34: Distribution of p-values for the PLIP Fusion Fingerprint similar-
ities on the nrPSM dataset. The ordinate (p-values) is shown in
logarithmic scale. The orange lines denote the fingerprint similar-
ity (0.54) at a p-value of 0.05 (significance level).
bvdu rescreening The nrPSM database was rescreened for simi-
lar patterns to BVDU (BVD and BVP). In total, 112 significant hits
(p < 0.05) were retrieved for BVD and 101 for BVP. From the 58 hit
compounds from the 3D interaction profiling workflow (see chapter 6),
almost 20 % (11/58) of them could be recovered among the top 0.3 %
ranked complexes in the dataset (112 and 101 of 32,081). Within the
top 10 hits from both screening with BVD and BVP, there are 12 lig-
ands with BVDU-like patterns which were not identified by the semi-
automatic profiling workflow. Half of them are known kinase inhib-
itors, with a total of only 32 kinases in the complete set of signific-
ant hits. Other cases include Ligase A and tRNA-guanine transglyc-
osylase, two relevant targets for antibiotics. Inspite of no global or
local structural similarities between the query (1KI8) and the hit struc-
tures (TM-scores of 0.15 and 0.14), several similarities to BVDU bin-
ding patterns are visible in both complexes (4LH7:1X8:A:401 and
4E2V:PRF:A:401).
An exemplary comparison to the a query BVDU complex to two
new hit complexes is shown in Figure 35: one is a pyrimidine com-
pound (FSK), acting as a kinase inhibitor (4JBY:FSK:B:401, Figure 35B).
Here, the interaction patterns are very similar to the query (Figure 35A),
including the single π-stacking interaction, a double water bridge and
double hydrogen bond to the central ring, as well as a couple of hy-
drogen bonds to a proximal oxygen atom.
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The other one is a structurally unrelated (TM-score 0.15) ionotropic
glutamate receptor with the ligand ZK 200775 (3KGC:ZK1:B:26). Here,
the overall binding behaviour is similar: a central π-stacking interac-
tions and hydrogen bonds at similar positions. Interestingly, one of
the two hydrogen bonds from the query is replaced with a water
bridge in the glutamate receptor complex. Since both patterns fulfill
the same function, such replacements events have been considered
in the fingerprint design (section 8.1) and are thus picked up by the
search algorithm as a signal.
8.4 discussion
The PLIP Fusion Fingerprint is a consequent step to make 3D interac-
tion profiling available on a larger scale. In this context, implications
to similarity searching, but also design challenges and limitations will
be discussed hereinafter.
signals from shared patterns Fingerprint comparison yields
similarity scores, in this case bound between 0 (no similarity) and 1
(identical). Signals may be picked up from any subpattern present in
both complexes. Judging from manually evaluated examples, values
of > 0.8 result from highly conserved patterns, with only minor differ-
ences in observed geometries. In these cases, the ligands and binding
site are often structurally related. Similarities from the PLIP Fusion
Fingerprint between 0.5 and 0.8 seem to be the most interesting re-
gion for identification of novel binders: the complexes often show
similar arrangements of key residues and share general binding char-
acteristics, e.g. a polar or hydrophobic character, while targets and
ligands can be structurally unrelated. Complexes with similarity val-
ues below 0.5 contain resemblances of single patterns, but may have
distinct binding characteristics. For examples on degrees of similarity,
see also Figure 40 in Appendix B.
comparison to 3d interaction profiling In comparison
to the 3D interaction profiling approach presented in chapter 6, the
screening with the PLIP Fusion Fingerprint data provides a slightly
different picture: although many ligands found with the previous
approach were recovered within the significant hits, a large overlap
between both methods is not observed. This does not mean that any
workflow is inferior, but rather results from different strategies to
find similar interaction patterns: while 3D interaction profiling relies
on a manual definition of patterns and strict matching, fingerprint
similarity scoring has no notion of predefined patterns but looks
for any similarity between two complexes. Interestingly, the finger-
printing approach identified complexes with ligands not retrieved by
interaction profiling: half of the new ligands in the top 10 hits are
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known kinase inhibitors (see section 8.3). Many of these complexes
show some of the key interactions as defined for BVDU, but often with
altered geometries or additional contacts. Judging from the screening
results, both methods are able to identify similar complexes, whereby
similarity in the methods has a slightly different notion. Finally, if data
on many complexes for the query is known (as in the case of BVDU),
a more knowledge-based approach such as 3D interaction profiling
may lead to more accurate matches, but automated fingerprinting
can yield similarities not easy to define a priori.
challenges in fingerprint design Constructing an algorithm
for encoding of complex 3D interaction patterns into a vector rep-
resentation is challenging since multiple factors decide if important
features are properly captured: in the detection step, only relevant
contacts need to be reported. To this end, several prioritization steps
throughout the PLIP algorithm help to reduce ambiguous contacts or
overrepresentation by frequent contact types, e.g. hydrophobic con-
tacts (see chapter 5).
The following encoding step is done in a structure-invariant man-
ner to enable comparison of complexes with structurally unrelated
proteins and ligands (section 8.1). Requirements are a fixed-length fin-
gerprints and discarding of structural information prior to encoding.
The choice of binning parameters is a tradeoff between specificity in
matching and fuzziness: large bin sizes results in more flexible match-
ing, e.g. if observed angles are divided into just 3 categories instead
of 5 or 10. Consequently, smaller binning sizes lead to shorter fin-
gerprints, but also to more false positive matches (or a higher recall).
As an additional option to introduce flexibility, fuzzy encoding can
be used, i.e. counts for patterns can also be mapped to neighbouring
bins (in terms of distances, types, etc.). A more advanced solution
is offered by graph-based comparisons (see e.g. Flexophore by Korff,
Freyss and Sander [139] or Grim by Desaphy et al. [59]).
Solvent interactions are another major challenge [221]. Although
they account for 14 % of all contacts (see section 6.2), they are of-
ten neglected. Consideration of water-bridged contacts is a novelty in
this structure-invariant fingerprint design. Water-bridged hydrogen
bonds are assigned to the group of hydrogen bonds with the same
directionality: this enables to compare high-resolution structures to
most other PDB structures, which have resolutions too low to give in-
formation on water positions. Functional replacement of sidechain or
backbone hydrogen bond hydrogen bonds by water molecules [256]
are thus considered in the fingerprint design. On example for such a
replacement has already been shown in an example from the BVDU
rescreening (Figure 35B) and demonstrates the power of the finger-
printing approach for picking up remote similarities.
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design comparison Table 8 shows key differences between the
PLIP Fusion Fingerprint and the other two structure-invariant designs
currently published. The new design improves upon the previous
ones APIF [199] and TIFP [59] by incorporating far more interaction
types and considering water molecules in complexes. Just as the APIF
approach, the new design uses duplets of interactions and not triplets
as the TIFP fingerprint by Desaphy et al. [59]. Although encoding of
triplets gives a more intuitive representation of spatial patterns, the
direct comparison in the benchmark shows that an encoding of vector
pairs as done here achieves an even better performance for discrim-
ination between similar and dissimilar protein-ligand complexes (see
section 8.2).
Table 8: Comparison of fusion-perspective interaction fingerprint designs:
APIF, TIFP and the PLIP Fusion Fingerprint. Listed are the number
of considered interactions, whether water is considered, the length
of the final fingerprint, considered geometrical elements, the units
representing interactions and which combinations of them are en-
coded.
Feature APIF[199] TIFP[59] PLIP Fusion
Interactions 2 5 8
Water no no yes
Length 294 210 825
Geometry distance distance distance & angle
Units interaction endpoints pseudoatoms interaction vectors
Combinations duplets triplets duplets
One-Step yes no yes
Additionally, the TIFP design requires a recalculation for each data-
set to remove weakly populated triplets and reduce the fingerprint
size to a reasonable size from an original length of > 12,000 bins due
to the large feature space of pseudoatom triplets. In contrast, APIF
and the PLIP Fusion Fingerprint yield the final fingerprint in just one
step (see Table 8). An important conceptual difference lies in the way
interactions are represented and encoded in the fingerprints: while
TIFP uses pseudoatoms to represent interactions, APIF and the new
PLIP design operate directly on the interacting atoms or the vector
between them. Next to a more comprehensive consideration of inter-
actions and water, another novelty of the PLIP fingerprint design is
the incorporation of the angle between interaction vectors. This fea-
ture allows to encode relative spatial orientations (as achieved with
triplets in the TIFP fingerprint), while being able to stick to duplets
for a smaller feature space. While the new fingerprint is the largest
among all design, it still has a size which is suitable for fast processing
and has a small storage footprint.
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target and scaffold hopping Since the encoding of patterns
in the PLIP Fusion Fingerprint is independent of molecular structure
and predefined fragments, screening for similar interaction patterns
can yield results with scaffold and target hopping [268], i.e. com-
plexes with unrelated ligands and targets. The chemical similarity
to BVDU in the presented examples from rescreening (section 8.3) is
low (0.16 to 0.35 with a path-based structural fingerprint4), indicating
that interaction fingerprinting enables scaffold hopping. Desaphy et
al. [59] come to the same conclusion in a larger systematic study: they
see no correlation between ligand structural similarity and shared in-
teraction patterns. It has to be noted, however, that global chemical
similarity might not give an accurate picture here since small shared
scaffolds may explain similar interaction patterns in two complexes.
Previous studies [59, 217] indicate that there is a strong link between
binding site similarity and interaction pattern similarity. Thus, finger-
print similarity can be a valuable alternative to computationally more
expensive alignment-based methods. However, despite this strong
linkage in many cases, both 3D interaction profiling chapter 6 and
fingerprinting as presented in this chapter can reach target hopping,
i.e. detection of similarities between structurally unrelated proteins:
one example is shown in Figure 35B, where highly similar interaction
patterns were discovered in targets with a TM-score of 0.15 (where ⩽
0.17 means random structural similarity). Furthermore, in the > 200
hit complexes, only 32 kinases are present. This ability to jump to
other targets results from the structure-invariant design of the fin-
gerprint, where structural data is completely discarded before the
encoding step.
limitations Major limitations of the presented method are its
performance on featureless complexes and the interpretability of re-
sults. Since the number of maximally set bins b in a fingerprint is
determined by the number of interactions n with b = n·(n−1)2 , this
number is low for a small amount of contacts and results in sparse
vectors, which can be harder to compare. The fingerprint size, set by
the feature space (here mainly by binning thresholds), mainly determ-
ines the specificity: a very short fingerprint is able to capture more
similarities between rather featureless complexes (see Figure 8B as
an example) while in general yielding a very high number of false
positives. Considering the ligands in the benchmark set, the PLIP Fu-
sion Fingerprint is expected to work best on typical small molecule
ligands, including most drugs.
The deconvolution of interpretability of results can impose a bar-
rier on using a fingerprint-based method: since the only result from
a comparison is a similarity measure, it may be difficult to see which
4 FP2 fingerprint from OpenBabel. In this context, two structures are considered struc-
turally similar with values > 0.8.
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features contributed to the measure. To this end, further analyses are
needed or the complexes have to be analyzed visually. As interac-
tion fingerprinting is a method to rapidly screen large libraries, it can
be used as a first step for filtering in combination with traditional
alignment-based to enhance confidence and be able to interpret re-
sults more easily. Another solution to this problem is provided by
the recently published PELIKAN method by Inhester et al. [109]: it
indexes spatial arrangements of interaction patterns in a relational
database and thus enables specific matching of subpatterns (similar
to 3D interaction profiling in chapter 6) for any input. The results
can be easily deconconvoluted here since it is always known which
subpatterns are shared between a hit and the query complex. Due its
long runtimes for a query, it would be a suitable setup to use finger-
prints for shrinking the search space and then use a search based on
pattern indexes such as PELIKAN for a refined matching in a second
step.
efficient searching With more than 600 new biologically rel-
evant protein-ligand complexes in PDB each week (according to Bio-
LiP [291]), the space of binding site pairs expands by several million.
As a typical problem in screening for repositioning candidates, only
the n most similar items need to be retrieved from this set for a given
query. The Annoy algorithm uses approximate nearest neighbors solve
this problem efficiently. The basic idea is to build up a tree (k-d tree)
where at each node a subset of input vectors is split up in two groups
by a hyperplane. This process is repeated until no more than a certain
number of items are unseparated. Finally, k such trees are constructed
to yield a forest for fast searching.
Since the interaction data was encoded into feature vectors (finger-
prints), it can be stored in such a tree, which can be searched for all
nearest neighbors of a query according to a similarity measure (here:
cosine similarity). The complexity of nearest neighbor algorithms has
been discussed in detail elsewhere [145, 155] and depends heavily
on the chosen algorithm. In any case, it is always a tradeoff between
database size and search time. For high-dimensional data and small
datasets, k-d trees become inefficient [85] and approximate search
algorithm implementations (such as Annoy) are a better alternative.
Here, another tradeoff can be made between database size (and con-
struction time) and a maximum error for reporting the nearest neigh-
bors.
The advantage for virtual screening is that the tree needs to be con-
structed only once for a given dataset, while further lookups are very
fast. For practical applications, space complexity is not an issue: in the
study for the PSM set, the database takes 1.2 GB of disk space, while
uncompressed flat text files with all-vs-all similarity values would
amount to > 100 GB. Finally, also new fingerprints (e.g. from docking)
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can be queried against the database without preparation in search for
the complexes with the most similar patterns, making approximate
ANN a reasonable solution for interaction fingerprint screening.
conclusion With the PLIP Fusion Fingerprint, a novel design
of a structure-invariant interaction fingerprint was presented in this
chapter. The approach was demonstrated to be superior to the cur-
rent state-of-the-art design for discrimination between similar and
dissimilar protein-ligand complexes and showed promising results
in a proof-of-concept analysis with rescreening for BVDU patterns. Fi-
nally, the method offers a transition from 3D interaction profiling to-
wards an automated screening of the structural proteome for novel
binders and repositioning opportunities with scaffold and target hop-
ping.
9
C O N C L U S I O N
a framework for systematic repositioning Due to spiral-
ing costs and high failure rates in drug development [10, 263], sys-
tematic repositioning approaches have become increasingly import-
ant. While in silico methods for drug target prediction are key to these
efforts [148], data on protein-ligand interactions still remained largely
untouched. This thesis makes a substantial contribution to structure-
based similarity searching by providing comprehensive algorithms
and workflows to understand the complex 3D interaction patterns
between proteins and ligands.
at the heart of molecular recognition With the nrPSM
dataset (see chapter 6), it is the first time that such a large ensemble
of small-molecule-protein complexes was characterized and exploited
for virtual screening with interaction patterns. This exploration on
interactions in the structural proteome is made possible with the
Protein-Ligand Interaction Profiler (PLIP), as of today the most com-
prehensive tool for rule-based detection of interactions in PDB struc-
tures. It has been developed over the last three years with 8,400 lines
of code and over 230 commits on GitHub, where it is available to
the community under the open-source Apache license. PLIP is first-in-
class to provide atom-level data for automatic processing and visual-
ization of 3D patterns. With the analysis of almost 400,000 contacts
from PDB, the vital role of backbone hydrogen bonding and water-
mediated contacts (see chapter 6) questions the long-standing focus
on amino acid properties. Furthermore, the presented findings may
lead to improvements in drug optimization, functional characteriza-
tion of proteins, and give new insights on functional building blocks
in binding site evolution. Finally, PLIP as a comprehensive and valid-
ated rule-based detection algorithm (chapter 5) enables to analyze a
broad class of input complexes and therefore poses a solution to the
Open Problem I presented at the beginning of this thesis in chapter 1.
plip as a firmly established detection tool Next to drug
target prediction (chapter 6), binding mode comparison, docking, and
lead optimization (as demonstrated in chapter 7), PLIP has been ex-
tensively used by the community: as of launch in December 2015
[218], the web service alone has seen more than 12,000 users. Several
studies have already employed PLIP data for a large range of ana-
lyses: it was the main tool for detection of interactions in crystal and
docked structures as well as Molecular Dynamics (MD) trajectories
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for the study of binding specificity of aptamers [122], evolutionary
aspects of substrate binding [27], impact of mutations [55, 299, 195],
protein isoforms [300], ligand release [63], screening and optimiza-
tion of potential inhibitors [70, 208, 156, 270, 180, 40, 223], antibody
recognition [239], and even interactions between single-walled car-
bon nanotubes (SWCNT) and biomolecules [43]. Other applications
of PLIP include visualization of biologically relevant interactions [29,
174], protein-focused fingerprinting [194], and homology modeling
[216]. Most of these studies focus on disease-relevant proteins, inclu-
ding targets for bacterial and viral infections [55, 208, 195], cancer
[270, 299, 40], pulmonary infections [156], malaria [180], adipositas
[70], and neurological diseases [300]. Thus, PLIP has already proven
to be a flexible and general-purpose tool to the scientific community.
Its open source licensing makes PLIP available to a large audience and
Pirhadi, Sunseri and Koes [202] recently listed PLIP as a quality tool
with the second-highest rating in their review paper [202]. In conclu-
sion, interaction data generated with PLIP already made substantial
contributions to research with medical relevance.
novel cancer drugs with 3d interaction profiling Ana-
lysis of interaction patterns reveals the mechanism at the heart of
molecular recognition. To identify compounds with desired binding
behaviour, these intermolecular contacts are the most detailed data-
source available and enable high-confidence predictions for binding.
In this thesis, 3D interaction profiling, a new approach to exploit this
data, was presented: while using a simple method to encode key in-
teractions from a query drug, this knowledge-based approach was
successful in predicting and validating the natural product chrysin
(see chapter 6) as a binder for Hsp27, a relevant drug target in cancer.
Additionally, with the validation of chemoresistance blocking, the hy-
pothesized function in cells was also experimentally confirmed.
The presented workflow can be applied to any query with a small
ensemble of complexes available for pattern definition. Given that
the method was successful with an input of just 14 complexes from
5 PDB structures, it is readily applicable to currently more than 1,400
ligands with the same amount of available data (according to the Bio-
LiP database, 2017/01 [291]). Furthermore, it helped to vastly reduce
the drug-target search space in a single virtual screening step from
over 170,000 complexes to 0.15 % of that size (chapter 6).
The concept of interaction profiling and comparison was further
explored with the PLIP Fusion Fingerprint as an even more flexible
solution for high-throughput screening (see chapter 8). Here, a per-
formance improvement on the current state-of-the-art fingerprint was
achieved with a new structure-invariant design. Both 3D Interaction
Profiling and the PLIP Fusion Fingerprint therefore address the Open
Problem II as defined in chapter 1: interaction patterns can be reli-
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ably exploited to detect ligands with similar binding behaviour. Con-
sideration of previously neglected aspects such as backbone hydro-
gen bonding and water-mediated interactions in combination with a
structure-invariant view on binding thus makes an important contri-
bution to structural drug target prediction in repositioning. Moreover,
interaction profiling enables to rapidly screen for more previously un-
known binders to more cancer drug targets with scaffold and target
hopping and paves way for new therapeutic applications.
outlook : a complete picture on drug binding While already
providing an comprehensive framework for interaction studies, the
presented methods offer additional entry points for further investig-
ation beyond protein-ligand binding: protein-protein, protein-DNA
and DNA-ligand interactions span a wide space of complexes where
non-covalent interactions are of equal importance (see e.g. Stasyuk et
al. [240]). A systematic exploration of this space could lead to discov-
ery of novel modulators for protein signaling or gene regulation. As
a major advantage, both 3D interaction profiling and the PLIP Fusion
Fingerprint are independent of input structures and could thus allow
functional hopping from pocket-binding compounds to inhibitors of
protein interactions or DNA regulatory sites. Such a universal profil-
ing approach can be further extended by additional interaction types
or study of contact dynamics from NMR structures. Incorporation
of genomic data could help to understand the impact of binding site
mutations for drug binding promises a new repositioning concept for
precision medicine [152].
Interaction data could also elucidate binding mode switches, which
are currently not easily detectable with any scoring method, but ap-
pear frequently [124] and often affect biologically most important mo-
lecules such as heme [160]. It is still an open question how ligands
can not only bind to different proteins with the same, but also with
different binding modes. Previously thought to occur mostly with fea-
tureless hydrophobic patterns [59], it is now clear that extreme polar
binding modes may be equally important for promiscuous ligands
[246]. Strategies such as backbone hydrogen bonding are therefore
important to investigate and understanding of interaction landscapes
are key to predict binding promiscuity.
Finally, interaction profiling can narrow the gap between computa-
tional drug target prediction and repositioning: the analysis of inter-
actions between proteins and ligands comes closest to understanding
molecular recognition of drugs at a larger scale. With the presented
algorithms and workflows, reliable hypotheses for drug repositioning
can be generated within a short timeframe and with their compatib-
ility to existing approaches and explanatory component may help to
translate hidden repositioning opportunities into working drugs.

Part III
A P P E N D I X

A
P L I P T E C H N I C A L D O C U M E N TAT I O N
license information
PLIP is published under the Apache License v2.0. More information
is provided in the LICENSE.txt file on github.com/ssalentin/plip.
Using PLIP in commercial or non-commercial projects is generally
possible when giving a proper reference to the project and the publi-
cation in Nucleic Acids Research [218]
implementation
PLIP is implemented in Python 2.7 and has the following dependen-
cies (python packages) for the latest version 1.3.3:
• lxml
• openbabel ⩾ 2.3.2
• pybel
• numpy
• pymol ⩾ 1.7
Imagemagick ⩾ 6.9.x is optional for PLIP, but is used to scale the
output images.
plip contributions
Minor code contributions were made by V. Joachim Haupt and Melissa
F. Adasme. Latest versions of PLIP contain fixes provided by GitHub
users, currently one fix by user ricrogz. An up-to-date list of contri-
butions can be viewed at github.com/ssalentin/plip/graphs/contributors.
usage
This section will provide a basic documentation on the installation
and usage of the PLIP command line tool.
Installation
The source code of PLIP is currently hosted on GitHub. To simplify in-
stallation, packages have been provided at the Python Package Index
(PyPI, pypi.python.org) and in the Ubuntu package repository.
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option 1 : github The repository can be cloned with git to the
local system using
git clone https://github.com/ssalentin/plip.git ~/pliptool
alias plip=’~/pliptool/plip/plipcmd’
which will also provide an alias to PLIP on Unix systems.
option 2 : python package manager The Python package man-
ager needs to be installed on the system. If available, PLIP and all
dependencies for python packages can be installed via
pip install plip
option 3 : ubuntu package manager In Ubuntu, PLIP is avail-
able for installation via the package manager starting from version
yakkety (16.10). PLIP and its dependencies can be installed via apt
using
apt-get install pymol openbabel python-openbabel
imagemagick
apt-get install plip
Usage of the command line tool
To run PLIP, the plipcmd script inside the PLIP folder needs to be ex-
ecuted with the desired parameters for detection, report file genera-
tion, and visualization. See Table 12 for a list of adjustable thresholds.
Additionally, a list of command line arguments can be shown directly
from the terminal using
plip -h
PLIP can be used with any structure from PDB and most files expor-
ted in PDB format with third party software. The following example
creates and opens a PyMOL visualization for the interactions between
the inhibitor NFT and its target protein in the PDB structure 1VSN.
mkdir /tmp/1vsn && cd /tmp/1vsn
plip -i 1vsn -yv
pymol 1VSN_NFT_A_283.pse
For a full description of the color coding in PLIP visualizations, see
the online documentation (DOCUMENTATION.md)at github.com/ssalentin/plip
exit codes PLIP will throw errors and exit the program if a non-
valid input leads to severe problems during the analysis. Table 11 lists
all exit codes in PLIP.
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Table 9: Elements in PLIP XML files for general information, binding sites,
and ligands.
Element Explanation
General Information
report Top-level element for a PLIP report
plipversion PLIP Version used for analysis
date_of_creation Date of report generation
citation_information How to cite PLIP
pdbid PDB structure identifier
filetype File type (e.g. .pdb)
pdbfile Input file name
pdbfixes Indicates if automatic fixes were applied
filename File used for analysis
excluded ligands List of automatically excluded ligands
Binding Site Information
bindingsite Top-level element for a bindingsite
has_interactions Indicates if there are any interactions
identifiers Collection of ligand identifiers
longname Concatenated HET IDs of (composite) ligands
ligtype PLIP Ligand type
hetid PDB HET identifier
chain Chain in PDB structure
position Assigned position in chain
composite Indicates if ligand is multi-part (composite)
members Lists all members of a (composite) ligand
smiles SMILES string of the ligand molecule
interacting_chains Lists all interacting chains
bs_residues Lists all binding site residues
Ligand information
lig_properties Top-level element for ligand information
num_heavy_atoms Number of heavy atoms
num_hbd Total number of hydrogen bond donors
num_unpaired_hbd Number of unpaired hydrogen bond donors
num_hba Total number of hydrogen bonds acceptors
num_unpaired_hba Number of unpaired hydrogen bonds acceptors
num_hal Total number of halogen atoms
num_unpaired_hal Number of unpaired halogen atoms
num_aromatic_rings Number of aromatic rings
num_rot_bonds Number of rotatable bonds
molweight Molecular weight of the ligand
logp Partition coefficient (logP)
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Table 10: Elements in PLIP XML files for general and specific contact in-
formation. The Usage indicates for which interaction types an at-
tribute is used: Hydrophobic contacts (HC), hydrogen bonds (HB),
water bridges (WB), salt bridges (SB), π-stacking (PI), π-cation in-
teractions (PC), halogen bonds (HA), metal complexes (ME).
Element Explanation Usage
General Information
resnr Residue number of interacting residue
restype Type of interacting residue
reschain Chain of interacting residue
ligcoo Coordinates of main ligand atom/centroid
protcoo Coordinates of main protein atom/centroid
dist Distance btw. interacting atoms/centroids
Type-specific
ligcarbonidx ID of ligand carbon atom HC
protcarbonidx ID of protein carbon atom HC
sidechain Indicates if contact to sidechain HB, HA
dist_X_a X ∈ {h,d}. Distance between X and acceptor HB
dist_X_w X ∈ {d,a}. Distance between X and water WB
don_angle HB,WB,HA
X_angle X ∈ {donor,water} Angle at group X WB,HA
donoridx Atom ID of donor group HB,WB, HA
donortype Type of donor group HB,WB,HA
acceptoridx Atom ID of acceptor group HB,WB,HA
acceptortype Type of acceptor group HB,WB
X_idx X ∈ {water,metal, target} Atom ID of X WB,ME
target_type Type of target group ME
coordination Coordination type of metal complex ME
watercoo Coordinates of water atom WB
lig_group Type of ligand group SB,PC
lig_idx_list Atom IDs of ligand group SB,PI,PC
centdist Distance between ring centroids PI
angle Angle between rings PI
offset Offset between ring centroids PI,PC
type Type of stacking PI
protcharged Indicates if protein is charged PC
location Location of metal complex acceptor ME
rms RMS of fit for complex geometry ME
geometry Geometry of metal complex ME
complexnum Unique ID for metal complex ME
metalcoo ID of metal atom ME
targetcoo ID of target atom ME
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Table 11: Exit codes in PLIP.
Exit code Description
1 Unspecified Error
2 Empty PDB file as input
3 Invalid PDB ID (wrong format)
4 PDB file can’t be read by OpenBabel
5 Valid PDB ID, but no PDB file on wwwPDB
Usage of the Python API
The complete PLIP functionality can be accessed in Python and added
to custom scripts. Therefor, the PLIP repository needs to be added to
the PYTHONPATH variable. For the next examples, it is assumed that
PLIP is installed in /pliptool. It is also shown how to download an
example PDB file from the RCSB server.
export PYTHONPATH=~/pliptool/plip:${PYTHONPATH}
cd /tmp && wget http://files.rcsb.org/download/1EVE.pdb
The following code chunk now demonstrates how to load a PDB
structure and run a PLIP analysis inside a Python script. Then, all
numbers of residues involved in π-stacking are printed.
from plip.modules.preparation import PDBComplex
# Load the PDB file into the PLIP class
my_mol = PDBComplex()
my_mol.load_pdb( ’/tmp/1EVE.pdb’)
# Unique binding site identifier (HetID:Chain:Position)
my_bsid = ’E20 :A:2001 ’
my_mol.analyze()
# Contains all interaction data
my_interactions = my_mol.interaction_sets[my_bsid]
# Now print numbers of all pi-stacking residues
print [pistack.resnr for pistack in s.pistacking]
# Result: [84, 129]
Analogously, all other result attributes can be accessed from the
plip.PDBComplex class.
Usage of the Python Webserver
input The user needs to provide a protein-ligand complex in PDB
format. Any structure from the PDB server can be automatically loaded
by providing a 4-letter PDB ID or via free text search in protein and
ligand names. Another option is to upload custom structures in PDB
118 plip technical documentation
Figure 36: PLIP webserver result page. An interaction diagram and a table
with interaction data is provided for each binding site. JSMol ap-
plets allows to view 3D interaction diagrams in the browser.
format (e.g. result files from docking or molecular dynamics soft-
ware).
output Figure 36 shows the result page for a typical analysis. For
each binding site with a ligand, PLIP offers 2D and 3D interaction
diagrams, a table with interaction details as well as downloadable res-
ult files (XML for automatic parsing and flat markdown-styled files)
and publication-ready visualization files (high-resolution PNG and
PyMOL session file). Details on interaction patterns can be accessed
for each binding site by clicking on the identifier in the overview
list. The results for each ligand are divided into a visualization sec-
tion and a tabular listing of interaction data below (Figure 36). A
JSMol-based 3D interaction diagram can be explored in the browser
by clicking on the preview image.
Result files
PLIP offers various output formats. Text files are designed to be
human-readable and use a markdown-style format. XML output files
can be further processed and be used to aggregate data from mul-
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tiple PLIP runs. Table 9 and Table 10 give a short description for each
value in the XML result files. PyMOL session files can be opened
with PyMOL versions equal or larger to the one used for generating
the files. A downward compatibility is not guaranteed. Ray-traced
images are provided as high-resolution PNG files for direct usage in
publications. PyMOL session files to human-readable text files and
XML files. By default, all files are deposited in the working directory
unless and output path is provided.
internal and external parameters
Most detection thresholds can be changed via the command line. For
a full list of detection thresholds in PLIP and their origin in literature,
please refer to Table 12. The following example shows how to increase
the threshold for hydrophobic contacts to 6 A in order to detect weak
interactions of this type:
plip -i 1vsn --hydroph_dist_max 5
All distance thresholds can be increased to up to 10 Angstrom.
Thresholds for angles can be set between 0 and 180 °. If two interde-
pendent thresholds have conflicting values, PLIP will show an error
message.
plip validation
All validation cases have been implemented as unit tests for Python.
Protein-ligand complexes used for validation from the original publi-
cation [218] are described in Table 13. Additional test cases for fea-
tures implemented after the publication are included in Table 14.
They include complexes of HIV proteases and inhibitors with sym-
metric binding patterns (1HII, 1HVI), one complex of a BRAF mutant
(3GO7) as well characterized complexes involving zinc (1RMD), man-
ganese (1RLA) and other ions (1HET, 1VFY, 2PVB, 2Q8Q).
plip ion selection
The following metal ions (HET IDs) are whitelisted for detection of
metal coordination:
CA, CO, MG, MN, FE, CU, ZN, FE2, FE3, FE4, LI, NA, K, RB, SR,
CS, BA, CR, NI, FE1, NI, RU, RU1, RH, RH1, PD, AG, CD, LA, W,
W1, OS, IR, PT, PT1, AU, HG, CE, PR, SM, EU, GD, TB, YB, LU, AL,
GA, IN, SB, TL, PB
This list basically includes all biologically relevant cations (posit-
ively charged ions) such as calcium, magnesium, iron, or natrium.
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materials and methods
Hardware and Software
hardware Unless specifically stated otherwise, all computations
were done on a 32 core machine with Intel® Xeon® E5-2650 v2 2.6
GHZ CPUs and 256 GB RAM as well as SSD storage.
r configuration RStudio Server v0.99.903 was used for all stat-
istical analyses. As R packages for analysis of interaction preferences
and generating figures, colorspace v1.2.6, dplyr v0.5.0, ggplot2 v2.1.0,
gplots v3.0.1, grid v3.3.2, gridExtra v2.2.1, hash 2.2.6, Heatplus v2.16.0,
knitr v1.14, RColorBrewer v1.1.2, reshape2 v1.4.1, and scales v0.4.0
were used.
python configuration Python 2.7.6 was used for all analysis
scripts. The urllib2 package was used for REST queries. SciPy[191]
(scipy package v0.13.03) was used for statistical evaluation of binding
modes.
Protocols
docking Structures of proteins were prepared with AutoDock-
Tools v1.5.4 to assign atom types and partial charges. The docking
area was defined in the respective binding pockets by a box of 60× 60× 60
A for TK and 50× 60× 50 A for Hsp27 with 0.375 A spacing. Lamar-
ckian genetic algorithm with 150 randomly placed entities, 27,000
generations, 5,000,000 energy evaluations, a mutation rate of 0.02, eli-
tism value 1, and a cross-over rate of 0.80 was used for the docking
process in a total of thirty runs per compound. The local search was
performed using the Soils and Wets algorithm with 300 iterations per
search.
experimental validation BVDU was a gift from Rudolf Fahrig,
RESprotect, Dresden (Germany). Chrysin was bought from Sigma-
Aldrich and bortezomib from Velcade.
For the aggregation assay, a 40 mmol L-HEPES buffer with 1.44
µM citrate synthase and 481 nM at 43 ◦C and pH 7.4 was used.
For the chemoresistance assay, a multiple myeloma cell line (RPMI-
8226) was obtained from the DSMZ (German Collection of Microor-
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ganisms and Cell Cultures). In the first step, the cells were cultivated
in RPMI 1640 medium supplemented with 10 % (v/v) fetal bovine
serum in a humidified atmosphere at 37 ◦C and 5 % CO2. Cells were
seeded at a density of 100,000 cells per mL in logarithmic growth
phase. Cells were passaged regularly to prevent densities of more
than 1,000,000 cells per mL. Bortezomib was added with an initial
dose of 0.1 ng/mL and increasing doses of 0.2 ng/mL (second pas-
sage) and 0.3 ng/mL (3rd passage). For the positive control, a 30
µM concentration of BVDU was chosen. For all tested compounds, the
range of functional non-toxic doses was determined before.
External Databases
pdb Files were downloaded from RCSB PDB server using the rsync_pdb.sh
script from ftp.wwpdb.org/pub/pdb/software, syncing only PDB format
coordinates.
stitch Chemical-protein links were downloaded from STITCH
v5.0 [142] (stitch.embl.de) on February 20th 2017. For each of the
compounds in the candidate set, the STITCH target IDs of all linked
proteins were extracted and filtered to consider only proteins from
the candidate set. Following, the target IDs were mapped to Uniprot
IDs using the mapping file (full_uniprot_2_string.04_2015.tsv.gz)
provided by the STRING database (string-db.org) to enable annota-
tion with the SCOPe protein superfamilies later on.
chembl The first step was a mapping from PubChem compound
IDs into ChEMBL identifiers for the 58 drugs in the candidate data
set with BVDU and BVDU-MP. The search for affinity data was per-
formed using the ChEMBL identifier for each drug, displaying all the
record for protein targets (not considering bioactivities) and finally
searching by protein name for relationships with any of the 43 pro-
teins in our data set.
pubchem The search for MeSH classifications was done via the
web API1 using the <compound ID> for each drug to retrieve the
simple (unambiguous) MeSH classification in the Chemicals and Drugs
category.
scope The Superfamily classification for proteins was retrieved
from the SCOPe database (dir.des.scope.txt, v.2.06, 2016/10/05).
It contains the description of each node in the hierarchy [157]. The
mapping to each relevant ligand-binding protein chain in the dataset
was performed using a custom Python script.
1 Query: pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/<compound
ID>/classification/XML?classification_type=simple
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pubchem score matrix service Data on chemical similarity
was retrieved from the PubChem Score Matrix Service 2 with stand-
ard settings (2D Tanimoto similarity on the PubChem Substructure
Fingerprint with result values from 0 to 100 % similarity).
Corrections for the Desaphy Benchmark Set
Table 15: Annotations for the Desaphy Benchmark Set[59]: Renaming. Listed
are complexes (with their PDB ID) for which ligands had to be
renamed manually.
PDB ID Original Updated PDB ID Original Updated
1AQX ILG:TNB:GLY GTD 2WEQ GMY GDM
1BIF ATG AGS 2WWG ATM ADP
1CYD NAP NDP 2YCK THL THG
1E3E NAD NAI 2ZRE SAP AGS
1EPO MOR:PHE:NLE:CHF:NME 2Z3 3AI2 NAP NDP
1GJV SAP AGS 3BR3 0ET ET
1GTF 00U TRP 3CKP 12 012
1GVT MOR:PHE:SMC:NOR 2ZS 3DQW SAP AGS
1H8P 0PC PC 3ENK GUD UPG
1K0D GTT GSH 3FNU 6 006
1KDO 00C C 3FR9 GSW GSH
1MG5 NAD NAI 3FUG 2E03 2E3
1O6I DPR:ARG 0HZ 3GH6 GTT GSH
1O72 0PC PC 3GUS GTT GSH
1PWL 1GL BFI 3GWS 0T3 T3
1Q5M NAP NDP 3GZ4 NAP NDP
1QOR NAP NDP 3H7W 18 018
1UH1 A2G:CH3 AMG 3H82 20 020
1VGV UD2 UD1 3HU3 ATG AGS
1WOO THL THG 3HXX ABG ACP
1X7B 41 041 3HYG 99 099
1YON APX A2R 3I6A GTT GSH
2GC2 FPC F6R 3IBH GTT GSH
2GSR ILG:OCS:GLY GTS 3IE3 GTT GSH
2H79 0T3 T3 3IR4 GTT GSH
2PIV 0T3 T3 3KDB 6 006
2PMI SAP AGS 3L3N CL LSW
2PVF ABG ACP 3LAE ILE MSE
2UUH GTT GSH 3LFL GTT GSH
2V8P CDF CDP 3MWS 17 017
2VBU CDF CDP 3MYK BL4 BIT
2W3R MPN MTE 3NJ1 P2M PYV
2W3S MPN MTE 3QJ5 22 022
4PRG 72 072
4TMN PHQ:PPH:LEU:ALA 0PK
2 pubchem.ncbi.nlm.nih.gov/score_matrix
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Table 16: Annotations for the Desaphy Benchmark Set[59]: Peptides. Listed
are complexes (with their PDB ID) for which ligands are peptides
and needed to be annotated with their chain.
PDB ID Original Chain PDB ID Original Chain
1A7C THC:VAL:ALA:SER:SET C 2Z4E GLY:HIS:ARG:PRO S
1AWU HIS:VAL:GLY:PRO:ILE:ALA B 3BS4 ASN:ILE:PHE B
1B5J LYS:GLN:LYS B 3CBP LYS:ARG:SER:LYS B
1GHA PRO:GLY:VAL:TYR P 3D9T ALA:THR:PRO:PHE:GLN:GLU D
1GHB PRO:GLY:ALA P 3DNJ TYR:LEU:PHE D
1GYB PHE:SER:PHE H 3DRH ALA:ALA:ALA:ALA:ALA:ALA B
1KUG GLU:ASN:TRP B 3DRI ALA:ALA:SER:ALA:SER:ALA B
1KUK GLU:LYS:TRP B 3FMA ILE:ALA:PRO:PRO:PRO:GLY:LEU M
1OBX ASP:SER:VAL:PHE B 3G19 LEU:LEU:LEU C
1OLC LYS:LYS:LYS:ALA B 3GCO VAL:TYR:GLN:PHE B
1SUA ALA:LEU:ALA:LEU C 3GDU TYR:ARG:PHE D
1TG4 PHE:LEU:ALA:TYR:LYS I 3GDV TYR:GLN:PHE D
1TP3 LYS:LYS:GLU:THR:PRO:VAL B 3GQ1 TRP:LEU:PHE C
1UOO GLY:PHE:ARG:PRO B 3GV4 LEU:ARG:GLY:GLY H
1UOP GLY:PHE:GLU:PRO B 3HBU ALA:LYS:ALA:ALA Z
1W9O ASN:GLU:TYR:TYR:VAL T 3HDA ALA:GLU:ALA:ALA:GLN:ALA Z
2BGR MET:ASP:PRO Y 3IQH TYR P
2FIB GLY:PRO:ARG:PRO B 3NIH ARG:ILE:ALA B
2GNS ALA:LEU:VAL:TYR:LYS P 3NII LYS:ILE:ALA B
2HPL ASP:ASP:LEU:TYR:GLY B 3OFI MET:GLN:ILE C
2HPL ASP:ASP:LEU:TYR:GLY B
2PQ2 GLY:ALA:LEU:ALA:GLY B
2Q5Y TYR:GLY:LEU D
2QL9 GLN:GLY:HIS:GLY:GLU G
additional result data
Figure 37: Molecular weight versus number of contacts (all PLIP interaction
types). Density lines are shown in blue color.
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Figure 38: Covariance of interaction types in the nrPSM set. Positive correla-
tion is indicated by red color and negative correlation with blue
color.
Figure 39: Distribution of the share of backbone hydrogen bonds in the
nrPSM set. The value on the abscissa indicates the share of back-
bone hydrogen bonds on all hydrogen bonds.
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